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Carbohydrates are the most abundant type of biomolecules. However, relatively little 
is known about the relation between the molecular structure of carbohydrates and their 
macroscopic properties. In order to shed light on this structure-properties correlation, the 
method that would enable an access to a variety of carbohydrate structures has to be 
developed. One of the most promising approaches to achieve this goal is automated solid-
phase synthesis. 
Chapter 2 of this dissertation covers the in-depth analysis and optimization of all the 
steps of automated glycan assembly, including resin functionalization, elongation cycle and 
photocleavage process. Several resin loading determination methods have been tested and the 
method with the best applicability has been chosen. New photo cleavable linkers have been 
designed and their potential applicability in automated glycan assembly has been investigated.  
The optimization of the elongation cycle (acidic wash, glycosylation, deprotection 
steps) in automated glycan assembly has been performed. The time required for the cycle has 
been significantly reduced (from 170 min to 60 min), the amount of solvents and building 
blocks used has been decreased that made the overall automated process greener.  
 
The scheme of automated glycan assembly. Time required for an elongation cycle 
before (in brackets) and after optimization. 
Chapter 3 describes the application of the optimized conditions to the synthesis of a 




to different building blocks and can enable a modular and rapid access to a variety of 
structures (mannosides, glucosides, glucosaminosides).  
Molecular modelling studies of the synthesized structures have been performed. It was 
revealed that hexamers  of mannose, glucose and glucosamine have different molecular shape 
that can lead to differences in their macroscopic properties.  
Synthesis of oligosaccharides for structural investigations. 
Chapter 4 describes the investigation of potential strategies to synthesize 
glycosaminoglycans. The synthesis of building blocks needed for the synthesis of dermatan 
and chondroitin sulfate oligosaccharides has been performed. Several strategies for the 
synthesis of fully deprotected dermatan sulfate oligosaccharides have been tested. The 
automated synthesis of several dermatan sulfate oligosaccharides has been conducted. The 
synthesis of several iduronic acid derivatives has been performed. The optimal synthesis 
conditions for the disulfated iduronic acid, previously found to be a potential inhibitor for 
CCL20 – heparin sulfate interaction, have been chosen.  
In conclusion, it is shown that automated glycan assembly enables an access to the 





Kohlenhydrate sind die häufigste Art von Biomolekülen. Über die Korrelation 
zwischen der Molekülstruktur von Kohlenhydraten und ihren makroskopischen Eigenschaften 
ist jedoch relativ wenig bekannt. Um dieses Verhältnis aufzuklären, muss eine Methode 
entwickelt werden, die Zugang zu einer Vielzahl von Kohlenhydratstrukturen ermöglicht. 
Einer der vielversprechendsten Ansätze zur Erreichung dieses Ziels ist die automatisierte 
Festphasensynthese. 
Kapitel 2 dieser Dissertation behandelt die detaillierte Analyse und Optimierung 
aller Schritte der automatisierten Festphasensynthese von Oligosacchariden, einschließlich der 
Funktionalisierung von Harzen, des Elongationszyklus und des Photospaltungsprozesses. 
Mehrere Bestimmungsverfahren der Harzbeladung wurden getestet und das Verfahren mit der 
besten Anwendbarkeit wurde ausgewählt. Neue photospaltbare Linker wurden entwickelt und 
ihre mögliche Anwendbarkeit im Automated Glycan Assembly wurde untersucht. 
Die Optimierung des Elongationszyklus (saure Wasch-, Glykosylierungs-, 
Entschützungsschritte) beim Automated Glycan Assembly wurde durchgeführt. Die für den 
Zyklus benötigte Zeit wurde signifikant verkürzt (von 170 min auf 60 min), die Menge an 
verwendeten Lösungsmitteln und Bausteinen wurde verringert, wodurch der gesamte 
automatisierte Prozess umweltfreundlicher wurde. 
 
Das Schema des Automated Glycan Assembly. Zeit, die für einen Elongationszyklus vor (in 
Klammern) und nach der Optimierung benötigt wird 
Kapitel 3 beschreibt die Anwendung der optimierten Bedingungen für die Synthese 
einer Bibliothek von Oligo- und Polysacchariden für Strukturuntersuchungen. Es wurde 




einen modularen und schnellen Zugang zu einer Vielzahl von Strukturen (Mannoside, 
Glucoside, Glucosaminoside) ermöglichen. 
Molekülmodellierungsstudien der synthetisierten Kohlenhydrate wurden 
durchgeführt. Es wurde gezeigt, dass Hexamere von Mannose, Glucose und Glucosamin 
unterschiedliche molekulare Formen haben, die zu Unterschieden in ihren makroskopischen 
Eigenschaften führen können. 
 
Synthese von Oligosacchariden für Strukturuntersuchungen 
Kapitel 4 beschreibt die Untersuchung möglicher Strategien zur Synthese von 
Glykosaminoglykanen. Die Synthese von Bausteinen, die für die Synthese von Dermatan- und 
Chondroitinsulfat-Oligosacchariden benötigt werden, wurde durchgeführt. Mehrere Strategien 
für die Synthese von vollständig entschützten Dermatansulfat-Oligosacchariden wurden 
getestet. Die automatisierte Synthese von mehreren Dermatansulfat-Oligosacchariden wurde 
durchgeführt. Die Synthese von mehreren Iduronsäure-Derivaten wurde durchgeführt. Die 




Inhibitor für die CCL20 - Heparinsulfat - Wechselwirkung identifiziert wurde, wurden 
ausgewählt.  
Zusammenfassend wird gezeigt, dass die automatisierte Festphasensynthese einen 
Zugang zu der Bibliothek von Oligosacchariden ermöglicht, die für weitere 







1.1 General introduction 
Carbohydrates are the most abundant type of biological molecules.1 They are used by 
organisms as energy storage materials (like starch2-3 and glycogen4), as structural components 
(like cellulose5 and chitin6-7), they play an important role in cell-cell adhesion (like 
glycosaminoglycans)8-10 and are a part of glycoproteins11 and glycolipids12 that have various 
biological functions. It is also notable how small differences in structure of polysaccharides 
can lead to substantial differences in their macroscopic properties. For example, cellulose 
forms flexible structure of cotton,5 whereas chitin is a major component of a robust 
exoskeleton of crabs.7  
Nevertheless, relatively little is known about the correlation between the molecular 
structure and macroscopic properties of carbohydrates.13-14 That is why the development of 
methods that enable fast and modular access to various carbohydrate structures is of a big 
importance. 
1.2  Structure of carbohydrates 
Polysaccharides are comprised of monosaccharides units connected together to form a 
chain. Therefore, the structure of polysaccharides is determined by the conformation of 
monosaccharides and by the geometry of glycosidic linkages. Some aspects of 
monosaccharides’ conformations as well as the geometry of glycosidic linkages are discussed 
below.  
1.2.1 Conformations of monosaccharides 
Most of the monosaccharides have a rigid ring structure: they exist either as pyranoses 
(6-membered ring) or furanoses (5-membered ring).  The 6-membered ring of 
monosaccharides can exist in different conformations (Figure 1).15-16 There are two chair 
conformations (1C4 and 
4C1), two boat conformations (B1,4) and 
1,4B), one twisted boat (5So) 
and one half-chair conformation (oH5). For most of the pyranoses 
4C1 chair conformation is 
the most favorable. For furanoses there are five possible conformations (three envelope 4E, 1E 






Figure 1. Possible conformations of monosaccharides. 
There are several factors that determine monosaccharide conformation. As in the case 
with other cyclic molecules, equatorial substituents are favored in comparison with axial ones. 
The other aspect is the anomeric effect. It is a stereoelectronic phenomenon that describes the 
tendency of an anomeric substituent to prefer an axial orientation.17 
This effect can be represented in two ways. In the first representation (Figure 2) partial 
dipole moments of the O-5 lone pairs and the bond between C-5 and an anomeric substituent 
are considered. In the equatorial anomer these dipoles are partially aligned and therefore 
repelling each other. In the axial anomer, on contrary, they are roughly opposing representing 
a more stable anomer. The other explanation of the anomeric effect (Figure 3) is following: an 
electron withdrawing axial substituent is stabilized via hyperconjugation owing to the 
periplanar orientation of both nonbonding orbital of O-5 and antibonding orbital of C-1. This 
does not occur with the other anomer, as the nonbonding orbital of O-5 and antibonding 
orbital of C-1 are in different planes and therefore are not able to interact.  
 





Figure 3. Orbital representation of the anomeric effect. 
1.2.2 Oligosaccharide conformations 
While monosaccharides generally represent a rigid ring structure, most of the 
glycosidic linkages are not rigid but flexible. For a characterization of a glycosidic linkage 
two or three torsion angles have to be determined (Figure 4).  
The flexibility of glycosidic linkages makes the conformation characterization very 
difficult in case of oligosaccharides. Complete characterization of a glycosidic linkage 
requires knowledge of the number of conformers adopted by the linkage, the time spent in 
each conformer and the flexibility of each conformer.13  
The torsion angle Φ is determined largely by the exo-anomeric effect.18 This is a 
stereoelectronic effect involving the lone pairs of the linkage oxygen. The torsion angle ψ is 
determined largely by the steric interactions and hydrogen bonding between residues and the 
solvent. The torsion angle ω exists only for 1-6 linkages and can adopt three staggered 
rotamers based on steric interactions.  
 
Figure 4. Angles determining conformations of glycosidic linkages. 
There are several methods that can be used for characterization of the molecular shape 
of oligo- and polysaccharides: X-Ray crystallography, nuclear magnetic resonance (NMR) 
spectroscopy and molecular modelling. Although X-Ray crystallography is a powerful 
method for structural analysis of biomolecules, it has limited applicability in case of highly 
flexible oligosaccharide structures. NMR provides only time-averaged conformation data. 




conformations. However, theoretical calculations are limited by the accuracy of the theory 
used. 
1.3 Approaches to the synthesis of carbohydrates 
Extraction of carbohydrates from natural sources allows the access to relatively large 
variety of structures (like glycosaminoglycans,19-24 plant carbohydrates,25 capsular 
polysaccahrides26-28 etc.), but it has a disadvantage: most of the polysaccharides obtained by 
this method are heterogeneous and this heterogeneity complicates to the large extent the 
further biological investigation and potential application of these molecules. Hence it is 
important to develop methods that will enable fast and modular synthesis of structurally-
defined oligosaccharides. However, there are several challenges in the synthesis of 
carbohydrates. Unlike proteins and nucleic acids, carbohydrate molecules are often branched, 
monosaccharides units can be connected in different ways (for hexoses, for example, there are 
5 possible connection points). Additionally, there are two types of linkages (α and β linkages) 
between monosaccharide units. From the nine monosaccharides found in humans more than 
15 million tetrasaccharides can be assembled.29  
Glycan assembly can be performed using following approaches: enzymatic synthesis, 
chemical synthesis (manual or automated, solution-phase or on the solid support) or the 
combination of these methods.  
1.3.1 Enzymatic synthesis of carbohydrates 
The usage of enzymes for oligosaccharide synthesis enables relatively simple control 
of glycosylation stereo- and regioselectivity and makes it possible to perform reaction in mild 
conditions. Two types of enzymes can be used for the synthesis of carbohydrates: 
glycosyltransferases (enzymes that establish natural glycosidic linkages) and glycosidases 
(enzymes that hydrolyze glycosidic bonds).  
Glycosyltransferases used in glycan synthesis generally catalyze the transfer of a 
glycosidic donor (in most of the cases nucleotide diphosphate) to a glycosyl acceptor. A 
representative example of the enzymatic synthesis using glycosyltransferases is the synthesis 
of LewisX derivative (LeX-OBn) (Scheme 1).30 Initially, benzyl glucosaminoside was 
glycosylated by uridine 5’-diphosphate-galactose (UDP-Gal) in the presence of β1,4-
galactosyltransferase from bovine milk (B4GALT1). Then, the resulting disaccharide was 




amino acids truncate α1,3-fucosyltransferase from Helicobacter pylori (Hpα1,3FT), giving 
LeX-OBn. 
 
Scheme 1. Enzymatic synthesis of LeX-OBn. Modified from ref. 30 
  Enzymatic synthesis using glycosyltransferases has several limitations.  Firstly, 
glycosyltransferases are not readily available (they have to be cloned or overexpressed) and 
can be used for only a limited scope of substrates. Secondly, nucleotide glycosidic donors are 
often unstable and/or very expensive.31 
Glycosidases are the other enzyme type that can be applied for the enzymatic synthesis 
of glycans. In nature glycosidases hydrolyze glycosidic bonds, therefore, in order to use them 
for synthetic purposes, their normal function must be reversed. As long as enzymatic reactions 
are (formally) equilibrium processes, it is possible to force a glycosidase to run in reverse by 
exposing the enzyme to a large excess of the reaction products and allowing the system to 
reach equilibrium. Replacing the anomeric hydroxyl group of the glycosyl donor fragment 
with a good leaving group, such as para-nitrophenol (PNP), shifts the equilibrium toward the 
glycosylation product. 
Synthesis of 6’-sulfated disaccharides is an example of glucosidase-catalyzed process 
(Scheme 2). It was found out that when 4-methylumbelliferyl 6-sulfo β-D-galactopyranoside 
was used as a glycosylating agent, the enzyme (β-D-galactosidase from B. circulans) induced 
the transfer of 6-sulfo galactosyl residue to a GlcNAc acceptor, giving the mixture of isomers 
6’-Sulfo N-acetyllactosamine (S6Galβ1-4GlcNAc) and 6’-Sulfo N-acetylisolactosamine 
(S6Galβ1-6GlcNAc), in a molar ratio 1:4.32 
 
Scheme 2. One of the examples of the enzymatic synthesis of oligosaccharides. 




Glycosidases are more stable and more readily accessible than glycosyltrasferases. 
Glycosidase-based transformations can use much broader scope of potential substrates, but 
they result in lower yields, than glycosyltransferase-catalyzed processes.  
 
 
Scheme 3. A representative example of the OPME (One-pot multienzyme synthesis). 
Modified from ref. 33. 
One-pot multienzyme synthesis (OPME) is an interesting modification of the 
enzymatic approach.33-35 In this method, simple monosaccharides or derivatives can be 
activated by one or more enzymes to form desired sugar nucleotides for glycosyltransferase-
catalyzed formation of target elongated glycans in one pot. Each OPME process adds one 
monosaccharide or derivative with a desired glycosidic linkage defined by the 
glycosyltransferase used. Multiple OPME reactions can be carried out to build up more 
complex glycan targets.36 One of the representative examples of this approach is the synthesis 
of Lacto-N-neotetraose from lactoside, N-acetylglucosamine (GlcNAc) and 5’-diphosphate-
glucose (Scheme 3).33 GlcNAc was activated to form UDP-GlcNAc in the presence of 
adenosine 5’-triphosphate (ATP), uridine 5’-triphosphate (UTP) and a fusion enzyme NahK-
Glmu. The resulting UDP-GlcNAc was utilized by a Helicobacter pylori β1–3-N-acetyl-
glucosaminyltransferase (HpLgtA) to form trisaccharide. At the next step, uridine 5’-
diphosphate-galactose (UDP-Gal) was generated in situ from uridine 5’-diphosphate-glucose 




Neisseria meningitides β1–4-galactosyltransferase (NmLgtB) for β1–4-galactosylation of 
trisaccharide giving Lacto-N-neotetraose. 
Overall, the usage of enzymes makes it possible to achieve excellent regio- and 
stereoselectivities in glycosylation transformations without extensive protecting group 
manipulation. Nevertheless, applicability of enzymatic oligosaccharide synthesis is limited by 
enzyme availability and the scope of possible enzymatic substrates. 
1.3.2 Chemical synthesis of oligosaccharides 
There are two approaches for chemical synthesis of oligosaccharides: linear synthesis 
(Scheme 4) and convergent (blockwise) synthesis (Scheme 5). In the linear approach (Scheme 
4) oligosaccharide chain is step-by-step elongated by one unit using monosaccharide building 
blocks (that have protecting groups (PG) and a leaving group (LG)). In the convergent 
approach (Scheme 5), several oligosaccharide “blocks” are initially synthesized. Then, they 
are coupled together giving the desired oligosaccharide. 
 






Scheme 5. Convergent approach to oligosaccharide synthesis. 
 
The key step of chemical oligosaccharide synthesis are glycosylation reactions 
(Scheme 6). Glycosidic donor is generally activated by promoter forming a reactive 
intermediate (oxonium ion) that reacts further with a glycosidic acceptor (a molecule with a 
nucleophilic center, generally, free hydroxide group).  
 
Scheme 6. General scheme of glycosylation reaction. 
 
A lot of glycosylation donor types were developed (Figure 5). The first example was 
Koenigs-Knorr method, in which glycosyl halide are used as glycosylation donors. They are 
activated by silver or heavy metal salts.37-38 Among glycosylation donors that are used 
nowadays are phosphites,39-40 phosphates,41 trichloroacetimidates,42 thioimidates,43  
sulfoxides,44 thioglycosides,45 disulfides,46 selenium glycosides,47 thiocyanates,48 
pentenylglycosides,49 glycosyl acetates,50 silyl ethers,51 orthoesters,52 carbonates,53 





Figure 5. Glycosyl donors that are used in chemical synthesis of oligosaccharides. 
The control of glycosylation stereoselectivity is a very important issue in the chemical 
synthesis of carbohydrates. There are several factors that influence stereoselectivity of 
glycosylations: structure of the glycosyl donor (protecting groups and the leaving group), 
structure of the glycosyl acceptor (protecting groups and position of the hydroxyl) and 
reaction conditions.  
Neighboring-group participation is one of the most powerful tools to direct 
stereoselectivity toward the formation of a 1,2-trans-linked product.58 In this case 
acyloxonium ion is formed and the further attack by a nucleophile is possible only from the 
trans-face (Scheme 7). Apart from neighboring-group participation, remote-group 
participation can influence glycosylation stereoselectivity (Scheme 8). Several examples of C-
3, C-4 and C-6 participations are described in literature.59-60 
 





Scheme 8. An example of remote-group (C-4) participation (NPG – non-participating 
group). 
Stereoselectivity of glycosylation reactions can be regulated by the solvent effect 
(Scheme 9).61 One of the common examples of this effect is in using acetonitrile as a solvent. 
Acetonitrile can act as a nucleophile forming an intermediate that hinders the α-face and leads 
mainly to the β-product. The usage of diethyl ether, on contrary, results in α-product: it is 
assumed that equatorially-oriented oxonium ion is formed and subsequently attacked by 
glycosidic acceptor in SN2-type manner.
62  
 
Scheme 9. Solvent effects in glycosylation reactions. 
1.3.3 One-pot synthesis of oligosaccharides  
The reactivity-based one-pot glycosylation is an interesting approach for the solution-
phase synthesis of oligosaccharides. This method utilizes building blocks (glycosylation 
donors) with different reactivity that are allowed to react sequentially in a single reaction 
vessel. Varying electron-donating and electron-withdrawing protecting groups in 
glycosylation donors makes it possible to tune the reactivity of building blocks (within a 
specific glycosylation donor type, for example, phosphates).63 The synthesis is planned so that 




donor with the lowest reactivity is used for the non-reducing end of the target 
oligosaccharide.64 
This method has been applied to the synthesis of various glycans.65-71 However, 
obtaining building blocks with different anomeric reactivities is in a lot of cases difficult and 
might require excessive synthetic manipulations. 
The modification of this approach is iterative one-pot synthesis of oligosaccharides 
(Scheme 11).72 This method doesn’t require the synthesis of glycosylation donors with 
different reactivities. It is based on the pre-activation procedure: glycosylation donor and a 
promoter are mixed together resulting in the formation of a reactive intermediate. Afterwards, 
glycosylation acceptor is added to the reaction mixture. This procedure can be repeated 
sequentially, resulting in the desired oligosaccharide.  
 
Scheme 10. Iterative one-pot synthesis of oligosaccharides. Modified from ref. 72. 
A variety of examples of utilization of this approach has been reported.73-76 It was also 
recently utilized for the synthesis of the longest oligosaccharide – arabino-galactan containing 
92 monosaccharide units.77 Despite the advantages that this method provides, it also has some 
limitations: this method is not automated, the variety of glycosylation donors that can be used 
for the synthesis is rather limited (even though several new glycosyl-donors have been 
developed for this synthetic method),78-79 it also lacks modularity.  
1.3.4 Automated solution-phase synthesis of oligosaccharides 
One-pot sequential glycosylation was used to develop an automated platform for 




several examples of biologically relevant molecules.81 Similar approaches have been used for 
the synthesis of oligomannosides82-84 as well as olimannuronates.82  
One of the modifications of iterative one-pot oligosaccharide synthesis is automated 
electrochemical assembly of thioglycosides (Scheme 12).85 This method involves 
preactivation of glycosylation donors via electrochemical oxidation following by the addition 
of a glycosylation acceptor. In this way, oligosaccharide chain is built from the non-reducing 
to reducing end. This approach has been successfully applied to the synthesis of several 
glycans,86-87 including oligoglucosamines having 1,4-β-glycosidic linkages.88  
 
 
Scheme 11. General scheme of the automated solution-phase synthesis with 
electrochemical preactivation. 
1.3.5 Automated solid-phase synthesis of carbohydrates 
Automated glycan assembly (AGA) is a powerful method that was applied to the 
synthesis of a large variety of carbohydrate structures including glycosaminoglycans,89-91 
plant cell wall oligosaccharides92-94, glycans related to blood group determinants95-96, and 
tumor-associated glycans95, 97 among others.  





Scheme 12. General scheme of automated glycan assembly (AGA). Reprinted 
(adapted) with permission from Seeberger, P. H., The logic of automated glycan assembly. 
Acc Chem Res 2015, 48 (5), 1450-63. Copyright (2015) American Chemical Society  
Merrifield resin functionalized with a linker (metathesis99, base100, or photo labile91, 
101) is used as a solid support for automated glycan assembly. Free hydroxide groups of the 
linker are glycosylated with a building block (different types of glycosyl-donors can be used, 
Scheme 13). Building blocks have permanent protecting groups (PG, ex: benzyl (Bn), benzoyl 
(Bz), acetyl (Ac)) as well as temporary protecting groups (tPG, ex: 9-
fluorenylmethyloxycarbonyl (Fmoc), levunoyl (Lev), 2-naphthyl (Nap)). The next step after 
glycosylation is a capping reaction, acetylation of the unreacted hydroxide groups, followed 
by deprotection of temporary protecting groups and further glycosylation with the next 
building block. This procedure is repeated several times before the synthesized 
oligosaccharide is cleaved from the solid support. The cleavage method depends on the linker 
that is used. Several important aspects of automated glycan assembly that will be discussed in 
the following sections include: 1) solid support; 2) linkers; 3) building blocks. 
1.3.5.1 Solid support 
Several properties of the resin are important for automated synthesis including: 1) type 
of the reactive groups on the surface on the resin; 2) resin loading capacity (the number of 




The type of reactive groups on the surface of the resin determines to a large extent the 
methods of resin functionalization as well as resin stability under storage conditions. The 
most common resin types used in automated synthesis have chloride groups on their surface 
that allows easy functionalization with nucleophiles. 
 
Figure 6. Structure of Merrifield resin.  
Resin loading capacity is also an important consideration for automated synthesis. 
Low resin loading capacity may result in low synthesis productivity (the amount of produced 
material per gram of resin).  With high resin loading some of the reaction sites may not be 
accessible for functionalization. Another factor that has to be considered when choosing the 
resin loading is the reaction concentration during automated glycan assembly (AGA). Low 
resin loading can require a very small reaction volume, which might be difficult to practically 
achieve. Conversely, high resin loading necessitates large reaction volumes that might require 
a more intense mixing or exceed the defined volume of the reaction vessel. 
When choosing the resin, solvent compatibility and swelling properties of resins also 
have to be considered. Solvent absorption influences the reactivity of functional groups on the 
resin surface. Resin swelling also influences diffusion of reagents to the reactive sites. If resin 
swelling in a given solvent is not sufficient, the diffusion of reagents will also not be 
sufficient, possibly leading to poor reaction outcomes. Resin swelling properties also have to 
be considered while performing consecutive processes in different solvents. To completely 
remove solvent absorbed by the resin additional washing steps are required.  
The most common resins for automated solid-phase synthesis are Merrifield resin and 
controlled pore glass (CPG).98  For AGA, Merrifield resin (Figure 6) is the most commonly 
used solid support. As a cross-linked polymer resin, it is compatible with diverse solvents 
including DCM, THF, DMF, and dioxane. It also possesses good swelling properties. It 
allows for easy functionalization and has an optimal loading capacity for AGA as well.  
Controlled pore glass is used frequently for oligonucleotide solid-phase synthesis. It is 




synthesis. However, there are several aspects  of CPG that complicate its use for AGA: 1) 
handling of CPG beads may be difficult because of their mechanical instability (it is more 
fragile than Merrifield resin); 2) relatively low resin loading capacity compared to Merrifield 
resin; 3) incompatibility with silyl ether protecting groups that can be used as temporary 
protecting group in AGA.102 
1.3.5.2  AGA Linkers  
There are several types of linkers that can be used in automated glycan assembly: 
metathesis labile linker;99 base labile linker;100 and photo labile linkers91, 101 (Scheme 14).98 
Metathesis labile linkers were used for the synthesis of a broad range of structures.95, 
97, 99, 103-105 The advantages of these linkers are orthogonal cleavage conditions to many 
common AGA synthesis conditions and the possibility to get the oligosaccharide coupled to 
alkyl moiety that can be used as a glycosylation donor. The major disadvantage is that the 
linker is not stable in the presence of electrophiles, therefore it will react with NIS/TfOH, is 
the promotor for thioglycoside glycosylations.  
Base-labile linkers are stable in the broad range of glycosylation conditions and can be 
used with most known glycosylation donors.100, 106 Another advantage of this linker is the 
possibility to obtain conjugation-ready oligosaccharides. Free amino-group of the linker can 
be used for immobilization of oligosaccharide on the surface (that enables applications in 
glycan arrays)107 or for a coupling to a protein (forming glycoconjugates that can be used, for 
example, in vaccine development).108-111 The major disadvantage are the harsh cleavage 
conditions. This linker cannot be used for the synthesis of compounds that are not stable 
under strongly basic conditions (for example, sulfated oligosaccharides). 
Another type of linker that is used for AGA are photo cleavable linkers.91 These 
linkers were used mostly in recent years for the synthesis of large variety of glycans.91-94, 98, 
112-116 One of the major advantages of these linkers, compared to base- or metathesis labile 
ones, is the possibility for orthogonal cleavage in mild conditions. The most commonly used 
photo cleavable linker also allows the synthesis of conjugation-ready oligosaccharides. 
Recently, a traceless photo cleavable linker has also been developed that allows the synthesis 
of oligosaccharides with free reducing ends.101  
The major difficulty with them is achieving high efficiency in the photo cleavage 










1.3.5.3 Building blocks for AGA 
Three types of glycosyl-donors have been used in AGA: glycosyl thioglycosides, 
glycosyl trichloroimidates, and phosphates. There are several aspects that determine the 
building block choice for a synthesis: 1) reactivity; 2) stability under synthesis conditions; 3) 
selectivity of glycosylation; 4) solubility.  
 
Scheme 14. Types of glycosylation donors used in AGA and promoters for their 
activation.  
For the activation of the three glycosylation donors, different conditions are required. 
The reagents used for the activation of the above glycosylation donors are well-established 
(Scheme 15). But the exact conditions (reaction temperature and time) vary from building 
block to building block. Many factors determine the reactivity of glycosylation donor. The 
reactivity of the respective the glycosylating agent is determined predominantly by the 
stability of the carbocation that is formed during glycosylation process. In this regard, electron 
donating protecting groups, like benzyl ethers, increase reactivity, whereas electron 
withdrawing protecting groups, such as –OAc, -OBz, -OLev, decrease the reactivity of 
building blocks.  
Another important aspect is the stereoselectivity of the glycosylation reaction. In most 
cases, building blocks contain participating group in the C-2 position of a building block to 
achieve anti-selectivity of glycosylation. Recently, remote participating groups were 
successfully used for the synthesis of several biologically important oligosaccharides 
containing multiple cis-glycosidic linkages.117 The usage of solvent effect61 for controlling 
glycosylation stereoselectivity may be difficult to apply in the solid-phase synthesis 





One more important property of the building blocks is their solubility. Most of the 
glycosylation reactions in AGA are performed in a DCM/Dioxane mixture or pure DCM. As 
glycosylation efficiency depends on the concentration of the building block, it is important 
that glycosylation donors are soluble to some degree in DCM or the DCM/Dioxane mixture.   
1.4 Aim of the thesis 
The overall goal of this work is to contribute to the development of rapid and modular 
approach that would enable the access to an oligosaccharide library for structural 
investigations. Even though carbohydrates are a widespread type of biomolecules, the lack of 
homogeneous oligo- and polysaccharides in a lot of cases hinders structural and biological 
investigations of these molecules.   
The first objective of this work is to optimize all the steps of automated glycan 
assembly (AGA). In order to develop standardized conditions that can be applied for the 
various building blocks, the analysis and optimization of all the steps of AGA has to be 
performed. The possibility to improve the efficiency of the synthesis (increase the yield, 
reduce reaction time, decrease the amount of building blocks and solvents used) has to be 
investigated. 
Standardized conditions will make it possible to synthesize a collection of natural and 
unnatural oligo- and polysaccharides, structures of which can be afterwards studied using 
molecular dynamics.  
Another objective of this dissertation is the development of synthetic strategies for 
homogeneous fully-deprotected glycosaminoglycans (GAGs). These molecules attract a lot of 
interest because their biological importance (they play a role in cell-cell adhesion, cell 
differentiation and proliferation), but the investigations and medical application of these 
compounds is complicated by their heterogeneity. Synthesis of homogeneous GAGs is 
challenging: these sulfated molecules are not stable in both acidic and basic media and, 
therefore, require mild synthetic conditions. Hence it is importance to develop new 
approaches to access GAGs. 
 Monosaccharide building blocks required for the synthesis of dermatan and 
chondroitin sulfate oligosaccharides have to be prepared. Dermatan sulfate oligosaccharides 
have to be assembled in solution phase in order to test potential synthetic strategies. Then, 





2  Automated Solid-Phase Oligosaccharide Synthesis 
Optimization 
2.1 Introduction 
N. Kottari et. al. recently made a major achievement in AGA, having synthesized a 
50-mer mannoside, the longest oligosaccharide synthesized via automated synthesis112 (the 
previous longest sugar was a 30-mer, synthesized by O. Calin et. al. in 2012)118. His work 
illuminated several important issues: 
1) The yield of automated solid-phase synthesis of mannoside trimer is 56%, 
while the yield of 50-mer is 5%. Figure 2 shows that the yield of the synthesis decreases very 
drastically for the first few saccharide units and then decreases at a slower, gradual rate until 
the 50-mer. This pattern means that the chain elongation step during automated solid-phase 
synthesis proceeds with quite high yield (average yield of one elongation cycle is 95%), while 
the major loss of yield occurs either during the first glycosylation or the photocleavage. 
2)  The time required for one chain elongation in AGA is relatively high, when 
compared to peptide synthesis. One elongation cycle takes approximately 180 minutes such 
that the synthesis of hexamer takes approximately 18 hours and the synthesis of a 50-mer 
takes approximately ten days.  
3) The amount of building block used for automated synthesis is relatively high. 
For the synthesis of 0.4 mg of fully unprotected 50-mer 2.74 g of building block is needed.  
4) The quantity of solvents used during the synthesis is high (see Table 1). 
 
 


















Table 1. Amount of solvent used for the synthesis of a 50-mer. 
Solvent Amount, L 
DCM 2.5 
DMF 1.5  
Dioxane 0.1  
DCE 0.12  
THF 0.30  
 
The aim of the following optimization is to understand these four issues and to 
develop a faster elongation cycle that uses less building blocks and solvents. To optimize 
automated solid-phase synthesis, every step was analyzed in detail. 
2.2 Photo cleavable Linker and Solid Support 
2.2.1 Existing synthesis of photo cleavable linker and resin preparation 
For AGA, Merrifield resin modified with a photo cleavable linker is frequently used. 
This resin is prepared by a method previously developed in Seeberger group (Scheme 9).91 In 
the first step, 5-hydroxy-2-nitrobenzaldehyde (1) forms an imine with 5-aminopentanol, then 
this imine is reduced using sodium borohydride to complete the reductive amination reaction. 
Then, the product is treated with CbzCl, to protect the resultant secondary amine, and after 





Scheme 15. Synthesis of photo cleavable linker. 
2.2.2 Investigation of resin loading and photo cleavage  
The first step of automated solid-phase synthesis is the functionalization of the 
Merrifield resin with the photocleavable linker. The process is shown in Scheme 10.   
 
Scheme 16. Modification of the Merrifield resin with the photo cleavable linker.   
The process of resin functionalization was developed in the Seeberger laboratory.91 In 
the first step, photo cleavable linker, Cs2CO3 (base) and TBAI (promotor) are added to 
Merrifield resin swollen in DMF. Then, the reaction mixture is left rotating on the rotorvap at 
60˚C overnight. 
The resin is subsequently washed with various solvents (THF/water (1/1), THF, DMF, 
MeOH, DCM, and MeOH) and is swollen again in DMF. Then, the resin is treated with CsOAc 
at 60˚C overnight to acetylate all potential active electrophilic sites on the resin. 
There are several methods to determine the resin loading developed in our laboratory: 
 1) determination of the number of free hydroxyl-groups on the surface of the resin;  
2) gravimetric quantification of monosaccharide after photo cleavage;  
3) determination of Fmoc-groups on the resin after the first glycosylation. 




1) In the first method, Merrifield resin modified by the linker is treated with an excess 
of FmocCl in pyridine in order to protect all of the free hydroxyl groups on the resin. The 
subsequent treatment of the resin with triethylamine makes it possible to remove all the 
Fmoc-protecting groups and by spectrophotometry, quantify the loading of the resin. The 
resulting quantification represents the number of hydroxyl groups on the surface of the solid-
support before performing glycosylation reactions. 
2) The second method utilizes glycosylation of the resin with an excess of the building 
block (most commonly mannose). Subsequent to photo cleavage the mass of the product is 
measured.  
3) The third method uses the following procedure: Merrifield resin is glycosylated 
with an excess of the building block containing Fmoc-protecting group. The resin is 
subsequently treated with DBU (1,8-diazabicycloundec-7-ene) and the amount of Fmoc-
derivative released is measured by spectrophotometry. This method is similar to one that is 




To understand which of these three methods should be applied for the resin loading 
quantification further investigations were performed.  
 
Scheme 17. Methods of loading determination 
The resin loading determination results differed significantly between methods. For 
example, for one of the resin batches, the resin loading was determined as follows for the 
three methods: 1) 0.36 mmol/g, 2) 0.18 mmol/g, 3) 0.25 mmol/g. 
Several explanations for the differences in resin loading determination results are 
possible. The likely reason why the first method gives higher results than the subsequent 
methods is the fact that not all hydroxyl-groups of the linker on the surface are available for 
the glycosylation reaction. Therefore, this method shows the amount of linker that is attached 
to the surface of the resin.  
The difference in the second and the third method of loading determination is likely 
because the monosaccharide does not get completely cleaved from the resin. The failing to 
cleave completely could be due to two factors. The first potential reason is that some 
oligosaccharide molecules are coupled directly to the Merrifield resin, without the linker in 




second potential reason is that the photo cleavage itself doesn’t proceed effectively. Both of 
these hypotheses had to be tested. 
In the first hypothesis, oligosaccharide molecules could be directly coupled to the 
surface of the resin. This could be possible when some reactive nucleophilic centers are still 
present on the surface of the resin. One potential nucleophilic center could be hydroxyl 
groups, that could be then glycosylated. How then could hydroxyl groups potentially be on 
the surface of the resin?  During the resin functionalization process the active electrophile 
(with a C-I bond) are formed. One of the steps of resin functionalization is washing of the 
resin with the THF-water mixture (1:1). As long as there is excess base in the system, in the 
water-containing mixture would form OH- anions that can nucleophilically attack the C-I 
bond, forming hydroxyl groups directly on the surface of the resin. Similar processes can also 
happen during the resin capping step. In that step, an excess of cesium acetate is used and the 
resin is washed with the THF-water mixture (1:1). The partial hydrolysis of cesium acetate in 
water-containing media can also lead to the formation of hydroxide anion and cause the 
formation of hydroxyl groups on the surface of the resin.   
In order to test these hypotheses, the following experiments have been carried out 
(Scheme 12). Merrifield resin was functionalized with para-nitrophenol in the same 
conditions as is normally done for photo cleavable linker. In this case, if it is possible to 
couple a monosaccharide donor to the surface of the resin, it means that the presence of 
hydroxyl groups directly on the surface of the resin is proved. To test whether the 
glycosylation reaction does proceed, Fmoc-quantification of the resin after glycosylation can 
be performed. In this experiment it was determined that the resin does not have 
monosaccharide molecules attached to it, meaning that hydroxyl groups are not forming on it 





Scheme 18. Testing the efficiency of resin functionalization.  
These results indicate that the difference in loading determination may originate from 
inefficiencies associated with photo cleavage process. 
The first step of analyzing the photo cleavage reaction, was an investigation of how 
the photo cleavable linker behaves under the reaction conditions. I found that mainly product 
6 was formed (Scheme 14). The photocleavage of the linker itself night, however, differ from 
the photocleavage process of the linker coupled to Merrifield resin.  
 
 




To mimic the conditions of the photo cleavage on the resin, several molecules were 
prepared and their reactivities studied. Surprisingly, it was found that the photo cleavable 
linker undergoes a rearrangement to give unusual product. Increasing acidity of the reaction 
resulted in increasing amount of rearrangement product. 
 
 
Scheme 20. The reactivity of different photo cleavable linker derivatives. 
Based on this information, studies of the photo cleavage of resin, modified with the 
photo cleavable linker and monosaccharide were performed. Resin with a loading of 0.25 
mmol/g was subjected to photo cleavage conditions at different pH. Different numbers of 
injections in the photo reactor represents different reaction times (each injection is 10 min). 










Table 2. The influence of acidity on the photo cleavage reaction.  


































The standard conditions of photo cleavage (Table 2, entries 1 and 2) result in 44-52% 
yield, depending on the number of injections. Since acidic conditions promote linker 
rearrangement, experiments with catalytic amounts of the strong base lutidine were carried 
out. However, the yield of these reactions was even lower than in case of standard photo 
cleavage conditions. One of the reasons for this outcome could be that lutidine can absorb 
light energy, act as a scavenger and inhibit the photo cleavage reaction. When the reaction 
was performed in DCM washed with a saturated solution of NaHCO3. It was possible to 




strongly acidic media results in very low yield (only 16%) of photo cleavage. These results 
prove that the photo cleavage process is strongly pH-dependent.  
To improve the outcome of the photo cleavage reaction, the mechanism behind 
byproduct formation during photo cleavage should be understood. In the literature, several 
similar processes are described.120-121 
During the first possible mechanism a reactive intermediate is formed first which can 
undergo two different conversions (see Scheme 16).120  
 
Scheme 21. One possible mechanism of the photo cleavage process.  
The other possible process that can explain the decrease in yield of photo cleavage 
(Scheme 17). In this case, nitroso-aldehyde as a reactive intermediate is formed. This 
molecule is not stable in acidic media and can undergo a disproportionation reaction, giving a 
diaso-compound. This diaso-compound stays on the resin and can absorb light, thereby 





Scheme 11. Formation of diaso-compounds during photocleavage. 
Both mechanisms involve the abstraction of the hydrogen atom from the CHNHR- 
group. Therefore, introduction of a methyl-group to this position should avoid formation of 
these byproducts, improving the overall yield of photo cleavage reaction. 
 




2.2.3 The development of a new photo cleavable linker 
Several photo cleavable linkers (see Scheme 12) were chosen as potential linkers for 
AGA. Similar linkers have been used in oligonucleotide synthesis. Some of them have either 
Me- or Ph-groups instead of hydrogen that might help in avoiding the a forementioned side 
products. Apart from this, some of the molecules carry MeO-groups on the phenyl ring. 





Scheme 22. Structures of potential functionalized resins that can be used for photo 
cleavage. 
Before the synthesis of a photo cleavable linker that can be attached to the surface of 
the resin, model studies of reactivity were performed. To perform these experiments, two 
model compounds were synthesized (see the Scheme 13) 
 





Compounds 25 and 28 were subjected to the photocleavage process at different pH 
(Figure 4 and 5). Photocleavage of the compounds gives the mixture of nitroso-aldehyde and 
amine. Notably the amount of aldehyde present in the mixture decreases with increasing 
acidity of the reaction media. It can explained by the fact that acidic condtions promote 
disproportionation of nitroso-aldehyde. 
 
 
Figure 4. Investigation of the reactivity of model compound. 
In case of compound 19 another reaction pattern is observed, as a mixture of two 
compounds is obtained (Figure 5). Since disproportion of the ketone is not possible, this 






Figure 5. Investigation of the reactivity of model compound. 
At the next step, the new photo cleavable linker was synthesized (Scheme 14). This 
compound was attached to Merrifield resin using the standard conditions and the loading 
determination measurements for this resin were performed (using method 3). The loading was 
determined to be 0.29 mmol/g, which is comparable to the loading of the original linker.  
 
Scheme 24. Synthesis of new photocleavable linker.  
 
Scheme 25. Functionalization of the resin with the new linker. 
The resin modified with the new linker was glycosylated (Scheme 20), to test the 




nitroso-group in its structure (Scheme 21). The residual loading of the resin was determined to 
be 0.15 mmol/g, meaning that the yield of photocleavage was 50%.  
In order to gain a better understanding of the photocleavage process, the 
photocleavage of the new linker itself was performed. The linker itself does not undergo any 
reaction even after several injections. One probable explanation for this result could be 
different stability of the radicals that are formed during photocleavage process. For the new 
linker, proton abstraction from the CH2 group of Merrifield resin leads to the formation of a 
more stable radical, in comparison to the tertiary radical, •C(Me)NCbzR (Scheme 22).  
 
 
Scheme 26. Photocleavage of the resin fuctionalized with the new photocleavable 
linker. 
 
Scheme 27. Possible explanation for the unexpected result with the new photo 
cleavable linker. 
Considering these results, the further investigations are required to find a linker and 




2.3 Resin loading determination using different building blocks  
A very important issue in automated solid-phase synthesis is the determination of resin 
loading. As discussed above, three methods of resin loading determination can be used: 1) the 
method based on the determination of the number of free hydroxyl-groups on the surface of 
the resin; 2) gravimetrical quantification of the amount of monosaccharide after photo 
cleavage; 3) the method that is based on the determination of Fmoc-groups on the resin after 
the first glycosylation. Method 3 proved most suitable since it provides the information about 
the number of reactive sides on the surface of the resin that are accessible for glycosylation. 
 
Scheme 28. Resin loading determination using two different types of building blocks.  
There is one very important aspect about this loading determination method: generally, 
mannose building block is used to determine resin loading. However, when different 
monosaccharides are used for the first glycosylation the result might be different. In order to 
investigate this aspect, the following experiment has been performed: Merrifield resin 
functionalized with linker was glycosylated using two building blocks 37 and 38, and the 
loading was measured (Scheme 23). No significant difference between loadings obtained was 
observed.  
2.4 Optimization of automated solid-phase synthesis 
In order to accelerate automated solid-phase synthesis, improve yields and reduce the 
amount of reagents and solvents used, the stepwise optimization of the synthesis was 




deprotection. Initially I analyzed how much time it takes to perform each step of the synthetic 




Table 3. Time required for different steps in standard AGA 
Cycle Time, min 
Acidic wash 30 
Glycosylation 70 
Deprotection 60 
Total time  160 
 
 
2.4.1 Acidic wash optimization 
The initial step of each elongation cycle in AGA is the acidic wash. During acidic 
wash any base that might have been left on the resin from the previous steps (generally, after 
deprotection step that is done in highly basic conditions) is neutralized. As long as the 
following glycosylation step acid is performed under acidic conditions it is important to make 
sure that no traces of base left on the resin.  
The acidic wash includes several steps (Table 4): the reaction vessel with resin is 
cooled down to -30°C, TMSOTf solution in DCM is delivered and left bubbling for 2 min. 
Then, the resin is washed with DCM. Overall, it takes 25 minutes to perform the whole 
process of acidic wash. 
The slowest step of the process is cooling the reaction vessel to -30°C. The acidic 
wash procedure should be performed at low temperature to ensure that the compound on the 
surface of the resin is not affected by highly acidic media. The solution that is used for the 
acidic wash (TMSOTf in DCM) was also used as an activator solution for phosphate 
glycosylation donors in AGA90 and is generally applied at temperatures from -40°C to -20°C. 
In this regard, the temperature for acidic wash was chosen to be -20°C that helped to reduce 






Table 4. Optimization of acidic wash cycle. 
Step Standard Cycle Optimized Cycle 
Chiller to (-30°C) 1140 
 
Wash lines 120 120 
Chiller to (-20°C) 
 
900 
TMSOTf Delivery 120 120 
Wash lines 60 60 
Bubbling with TMSOTf 120 120 
Wash with DCM 30 30 
Total time (s) 1470 1230 
Total time (min) 24.5 20.5 
  
2.4.2 Glycosylation cycle 
The glycosylation cycle is the most important step of automated solid-phase synthesis 
of oligosaccharides and it is important to optimize the conditions of performing it. Generally, 
it is necessary to optimize the reaction conditions, such as glycosylation temperature, reaction 
time as well as the amount of building block used, for each building block: different 
monosaccharides have different reactivity and glycosylation conditions may vary from one 
glycosylating agent to another. But there are several aspects that are common for most of the 
building blocks and that have to be optimized:  
1) The standard glycosylation cycle includes several steps. First, the reaction 
vessel is cooled down to the temperature T1 that is by 20°C lower than the actual reaction 
temperature T2. At the temperature T1 the building block solution as well as the activator 
solution are added to the resin. Then, the temperature is set to increase gradually to T2. The 




exothermic and the addition of reagents results in local overheating of the reaction mixture. 
This might lead to the formation of byproducts. The pre-cooling process, however, takes 
substantial time that slows down the overall synthesis.  
2) The amount of building blocks used for one glycosylation step is quite high, as 
overall 10 eq. of building block are used for one elongation step.  
3) One elongation step involves two glycosylation cycles. This leads to long time 
of elongation not only because of overall long reaction time, but also because of the time 
between glycosylation cycles when the temperature is brought down to T1 again. 
4) The number of washing steps is excessive and results in long time and high 
DCM usage per elongation cycle.  
In order to optimize glycosylation cycle, the glycosylation reaction of the mannose 
building block 37 was used as a model process. It was shown by N. Kottari et. al. that this 
building block is highly reactive and allows for good separation of deletion sequences.112 
 
 
Scheme 29. Synthesis of mannoside dimer used as a model reaction for glycosylation 
cycle optimization. 
Initially, I investigated the optimal temperature for performing glycosylation reaction 
for building block 37. Therefore, the model process (shown on Scheme 23) was performed at 
different conditions (Table 5). 
The glycosylation was most efficient at T1=-20˚C and T2=0˚C as at these conditions a 
single glycosylation using 5.0 eq. of building block 37 gives very good results: the ratio of 
monosaccharide: disaccharide is 7:93. In order to achieve the full conversion during 
glycosylation process, the number of equivalents of building blocks was increased. It was 






Table 5. Optimization of glycosylation conditions 
T (˚C) Glyc. / min 
mono : di 
(30 : 31) 
-40 to -20 70 10 : 90 
-20  10 28:72 
-20  20 17:83 
-20 30 15:85 
-20 to 0 20 7:93 
 
The necessity of performing the washing procedures was analyzed. There are several 
washing steps that are crucial in the glycosylation cycle: it is important to wash away all the 
activator solution from the resin and it can be done with the subsequent washing of the 
reaction mixture with dioxane and then with DCM (twice). The washing with dioxane is 
necessary for the reason that NIS that is used as an activator in the glycosylation reaction is 
poorly soluble in DCM, but has good solubility in dioxane. As the following test show this 
washing steps were sufficient to achieve good glycosylation results. 
Overall, as a result of the optimization of the glycosylation step, several improvements 
have been achieved: 
1) The glycosylation cycle time was substantially reduced. 
2) One glycosylation cycle is enough to achieve full conversion using 6.5 eq. of 
building block 37. 
3) The amount of building block and solvents used was significantly reduced. 
The overview of the glycosylation cycle optimization and solvent usage is shown in 
Table 6 and Table 7 respectively.  
Even though the described glycosylation cycle was optimized using mannose building 
block 37, it can be also applied for different monosaccharides (as shown in Chapter 3). It can 
be also modified for the glycosylation donors with low reactivity (the number of equivalents 
that are used can be increased, two cycles of glycosylation can be performed, reaction time 




Table 6. Optimization of glycosylation cycle 
 
Standard Cycle (s) Optimized Cycle (s) 
Chiller to (T1) From prev. From prev. 
Wash lines 70 70 
Delivery of BB 90 90 
Push back BB 60 60 
Wash Activator line 270 
 
Prime Activator line 60 
 
Wait for T1 
  
Delivery of activator 210 210 
Push back activator 120 120 
Bubble at T1 300 300 
Wait for T2 120 
 
Bubble at T2 1800 300 
Chiller to T3 (Fmoc) 
 
(25°C) 
Wash with Dioxane 90 90 
Wash with DCM (x6) 180 50 (25 x 2) 
Wait for 25°C 480 
 
Wash BB lines 150 
 
Wash with DCM (x6) 180 
 
Total time (s) 4180 1290 
Total time (min) 70.0 21.5 
 
Table 7. Total amount of solvents used in the glycosylation cycle 
Solvent Standard Cycle Optimized Cycle 
DCM 28 mL 4 mL 





2.4.3 Deprotection cycle 
In AGA, several methods of Fmoc-deprotection cycles have been used. The most 
common cycle utilizes excess of a 20% solution of Et3N in DMF. This method allows for 
effective removal of Fmoc-protecting group, but requires a lot of time: as it takes almost one 
hour to perform the whole cycle. In order accelerate the process, the cycle has to be 
optimized. 
There are several important considerations that have to be kept in mind concerning the 
optimization of the deprotection step: 
1) The conditions used for the reaction should not affect protecting groups that are 
generally used for the AGA (OBz, OLev, etc.), as some of the protecting groups 
can be labile in highly basic conditions.  
2) The procedure should be fast and, ideally, should not require a large amount of 
solvents used. 
Several aspects of Fmoc-deprotection process have to be discussed: solvent and base 
that is used for the reaction, as well as reaction temperature and time. 
Most of the reported methods of Fmoc-deprotection utilize strong base in the solution 
of DMF or DCM. Considering the fact that glycosylation cycle is performed mainly in DCM 
or DCM/dioxane mixture, it is desirable, that Fmoc-deprotection cycle is also performed in 
DCM (in this case it will be not necessary to perform the additional washing of resin because 
of the change of the solvent). It was however shown in Seeberger group that the Fmoc-
deprotection reaction is slower in DCM than in DMF and might take up to four hours 
depending on the carbohydrate, so the usage of DCM as a solvent for the deprotection 
reaction in automation is not efficient. 
 





Table 8. Optimization of the Fmoc-deprotection cycle  
Base  
(solution in DMF) 
Reaction time 
(min) 
mono : di 
(30 : 31) 
Et3N (20%) 15 (x2)  0 : 100 
Et3N (20%) 15 15 : 85 
Et3N (50%) 15 10 : 90 
Piperidine (20%) 15 0 : 100 
Piperidine (20%) 10 0 : 100 
Piperidine (20%) 5 0 : 100 
 
Mindful of these considerations, several reaction conditions for deprotection were 
selected (see Table 8). The synthesis of mannose dimer with an optimized glycosylation cycle 
was used as a model process (Scheme 25). The best conditions for Fmoc-group deprotection 
in AGA are a piperidine solution in DMF. The reaction is completed within 5 minutes and 
only one cycle is necessary to achieve full conversion. 
Washing procedures that were used during the cycle have been also analyzed. There 
are several washing steps that are indispensable for performing this cycle: in the beginning of 
the cycle the resin has to be washed three times with DMF (because all the previous steps 
were done in DCM); after the deprotection reaction, washing with DMF is required to remove 
any traces of base that are left on the resin; at the end of the cycle the resin should be washed 
with DCM, because the next step, generally the glycosylation, is performed in DCM. All the 
other washing procedures were found to be not necessary and were removed from the cycle. It 
was possible to reduce the time required for the deprotection cycle from 55 min to 22 min and 
significantly reduce the amount of solvents used (Tables 9 and 10). 
Table 9. Optimization of Fmoc-deprotection cycle 
 
Standard Cycle Optimized Cycle 
Wash DMF  30x3 30x3 
Delivery of DMF 5 
 
Wash dep. lines 270 
 





DMF to waste 150 150 
Dep 1 750 0 
Dep 2 750 0 
Dep 3  750 750  
Wash with DMF 60 60 
Wash  dep. lines 150 150 
Wash with DCM 15 0 
Wash with DMF x3 30x3 0 
Wash with THF x3 30x3 0 
Wash with DCM  30x3 30x2 
Total time (s) 3320 1300 
Total time (min) 55 22 
Table 10. Total amount of solvents used in the deprotection cycle 
Solvent Standard Cycle Optimized Cycle 
DCM 14 mL 10 mL 
DMF 20 mL 14 mL 
THF 6 mL 0 
2.5 Conclusions and perspectives 
The described experiments made it possible to improve several aspects of automated 
solid-phase synthesis of oligosaccharides: 
1) The overall cycle time has been significantly reduced: in the optimized version one 
elongation cycle takes one hour (in comparison with previous standard cycle – three 
hours). 
2) The amount of building block used for one elongation cycle has been notably reduced: 
it is required 6.5 equivalents of building block 37 per elongation cycle to ensure the 




3) Total amount of solvents used was lowered.  
The next step is testing of the optimized conditions on various building blocks and 
application of the new cycles to the synthesis of a library of compounds. 
2.6 Experimental part 
2.6.1 Synthesis of photo cleavable linkers and their derivatives 
Synthesis of compound 3 
 
 
5-Hydroxy-2-nitrobenzaldehyde 1 (0.5 g, 3.0 mmol) and 5-aminopentanol (0.31 g, 3.0 
mmol) were stirred in anhydrous methanol (10 mL) at room temperature for 2.5 h under argon 
atmosphere. Then, the reaction mixture was cooled to 0˚C and NaBH4 (0.12 g, 3.0 mmol) was 
added a portionwise and allowed to warm to room temperature. After 1h, excess NaBH4 was 
quenched by the addition of acetone (15 mL) and the solvents were evaporated to furnish the 
secondary amine 2. Secondary amine 2 was re-dissolved and stirred in MeOH (80 mL) 
followed by the addition of triethylamine (1.25 mL, 8.9 mmol) and Cbz-Cl (1.68 mL, 7.48 
mmol) at room temperature. After 1 h, K2CO3 (2.0 g) was added to the reaction mixture and 
stirred for an hour. The reaction mixture was then filtered through celite and the solvents were 
evaporated to dryness. The crude product was dissolved in DCM and washed with 0.1 M HCl 




flash chromatography (Silica/ EtOAc:Hexane) to obtain photo-cleavable linker 3 in 85% yield 
(0.98 g)91. 
Analytical data for linker 3: 1H NMR (400 MHz, CDCl3) δ (ppm) 8.19 - 8.07 (m, 1H), 
7.38 - 7.24 (m, 5H), 6.85 - 6.71 (m, 2H), 5.17 - 5.05 (m, 2H), 4.91 (s, 2H), 3.63 - 3.60 (m, 
2H), 3.38 - 3.35 (m), 1.57 - 1.41 (m, 6H); 13C NMR (101 MHz, Chloroform-d) δ (ppm) 162.7, 
162.1, 157.1, 157.1, 139.6, 137.5, 135.7, 128.8, 128.8, 128.4, 128.3, 128.2, 128.2, 128.2, 
128.2, 128.1, 128.0, 127.9, 127.4, 114.8, 114.8, 114.6, 113.8, 113.8, 113.0, 67.6, 62.2, 49.9, 
49.9, 49.8, 49.6, 48.8, 48.7, 48.46 48.4, 48.4, 31.8, 28.1, 27.6, 22.8. Analytical data in 
accordance with previously reported data.91  
 
 
Synthesis of compound 7 
 
To a solution of building block 37 (120 mg, 0.16 mmol) and linker 3 (191 mg, 0.493 
mmol) in anhydrous DCM (10 mL) molecular sieves (4 Å, powder) were added. The mixture 
was stirred for 10 minutes before NIS (55 mg, 0.25 mmol) was added. After stirring for 20 
minutes the reaction mixture was cooled down to -20°C before TfOH (0.015 mL, 0.16 mmol) 
was added dropwise to the reaction mixture. The reaction mixture was stirred for 20 minutes 
and allowed to warm to room temperature. The reaction was successively quenched by 
saturated NaHCO3 solution (15 mL) and saturated Na2S2O3 solution. The organic layer was 
washed with brine (3x 15 mL), dried over Na2SO4 and concentrated in vacuum. The crude 
product was purified by column chromatography (silica gel, hexane – EtOAc, 1:3 to 1:1), 
giving product 7 (145 mg, 0.137 mmol, 84%) as yellow syrup.  
Analytical data for compound 6: 1H NMR 1H NMR (400 MHz, CDCl3) δ 8.19 – 8.05 
(m, 3H), 7.78 (d, J = 7.5 Hz, 2H), 7.62 – 7.58 (m, 2H), 7.53 (t, J = 7.6 Hz, 1H), 7.40 (q, J = 
7.7 Hz, 4H), 7.38 – 7.24 (m, 17H), 6.85 – 6.71 (m, 2H), 5.71 (s, 1H), 5.42 (s, 1H), 5.17 – 5.05 
(m, 2H), 4.94 – 4.89 (m, 3H), 4.80 – 4.75 (m, 1H), 4.61 – 4.58 (m, 2H), 4.47 (s, 2H), 4.39 (d, 
J = 7.7 Hz, 2H), 4.35 – 4.23 (m, 2H), 4.07 – 3.94 (m, 2H), 3.39 - 3.35 (m, 2H), 2.67 – 2.62 




Chloroform-d) δ 165.65, 162.72, 162.08, 157.12, 156.82, 139.62, 138.10, 137.56, 137.51, 
135.65, 133.26, 129.42, 129.12, 128.76, 128.35, 128.15, 128.01, 127.95, 127.92, 127.76, 
127.68, 114.78, 114.72, 114.61, 113.82, 113.02, 82.45, 78.42, 75.12, 74.04, 72.20, 71.51, 
70.89, 67.64, 62.20, 61.94, 49.91, 48.75, 48.72, 48.65, 48.46, 31.82, 28.14, 27.65, 25.56, 
22.82, 14.83. MS (ESI) m/z calcd for C62H60N2O14 [M+Na]
+ 1080.5. Found 1080.7. 
 
Synthesis of benzyl (5-(benzyloxy)-2-nitrobenzyl)(5-hydroxypentyl)carbamate 9 
 
The solution of the compound 3 (320 mg, 0.82 mmol) and benzyl bromide (0.14 mL, 
1.1 mmol) in 10 mL DMF was cooled down to 0°C before NaH (40 mg, 1.1 mmol) was added 
dropwise. The reaction mixture was allowed to warm up to RT and was stirred for three hours 
before being quenched by saturated solution of NH4Cl. The reaction mixture was diluted with 
EtOAc and washed with brine. Volatiles were removed under vacuum, the crude product was 
purified by column chromatography (silica gel, hexane – EtOAc, 1:4 to 1:1), giving product 9 
(315 mg, 0.66 mmol, 80%) as yellow syrup. 
Analytical data for compound 10: 1H NMR (400 MHz, CDCl3) δ 8.13 (d, J = 9.1 Hz, 
1H), 7.42 – 7.29 (m, 7H), 7.28 – 7.11 (m, 3H), 6.90 (d, J = 9.1 Hz, 1H), 6.74 (d, J = 32.3 Hz, 
1H), 5.22 (d, J = 35.9 Hz, 1H), 5.04 (d, J = 17.0 Hz, 2H), 4.89 (d, J = 24.3 Hz, 3H), 3.56 (dt, J 
= 19.5, 6.5 Hz, 3H), 3.18 (dt, J = 20.8, 7.5 Hz, 3H), 1.64 – 1.45 (m, 4H), 1.37 – 1.29 (m, 2H). 
13C NMR (101 MHz, Chloroform-d) δ 153.25, 135.99, 130.48, 128.53, 127.26, 117.09, 97.04, 
69.18, 67.33, 65.47, 48.59, 41.28, 31.99, 26.81, 23.05, 21.78. MS (ESI) m/z calcd for 
C27H30N2O6 [M+Na]
+ 500.5. Found 500.9. 
 






To a solution of building block 37 (180 mg, 0.24 mmol) and linker 10 (360 mg, 0.75 
mmol) in anhydrous DCM (15 mL) molecular sieves (4 Å, powder) were added. The mixture 
was stirred for 10 minutes before NIS (83 mg, 0.37 mmol) was added. After stirring for 20 
minutes the reaction mixture was cooled down to -20°C before TfOH (0.023 mL, 0.24 mmol) 
was added dropwise to the reaction mixture. The reaction mixture was stirred for 20 minutes 
and allowed to warm to room temperature. The reaction was successively quenched by 
saturated NaHCO3 solution (15 mL) and saturated Na2S2O3 solution. The organic layer was 
washed with brine (3x 15 mL), dried over Na2SO4 and concentrated in vacuum. The crude 
product was purified by column chromatography (silica gel, hexane – EtOAc, 1:3 to 1:1), 
giving product 11 (198 mg, 0.173 mmol, 72%) as yellow syrup.  
Analytical data for compound 12: 1H NMR (400 MHz, Chloroform-d) δ 8.17 (d, J = 
9.1 Hz, 1H), 8.10 (d, J = 7.7 Hz, 2H), 7.60 (t, J = 7.4 Hz, 1H), 7.48 (t, J = 7.7 Hz, 2H), 7.45 – 
7.29 (m, 11H), 7.29 – 7.15 (m, 6H), 6.93 (d, J = 9.2 Hz, 1H), 6.79 (d, J = 32.8 Hz, 1H), 5.61 
(s, 1H), 5.25 (d, J = 16.7 Hz, 1H), 5.07 (d, J = 22.4 Hz, 2H), 4.93 (dd, J = 16.0, 5.3 Hz, 5H), 
4.81 (d, J = 11.4 Hz, 1H), 4.68 (d, J = 10.9 Hz, 1H), 4.60 (d, J = 11.3 Hz, 1H), 4.18 – 4.07 (m, 
2H), 3.98 (t, J = 9.6 Hz, 1H), 3.94 – 3.79 (m, 2H), 3.79 – 3.59 (m, 2H), 3.41 (dq, J = 14.6, 
8.1, 7.4 Hz, 1H), 3.22 (dt, J = 16.7, 7.7 Hz, 2H), 1.60 (dp, J = 15.3, 7.6 Hz, 4H), 1.35 (dq, J = 
14.6, 6.6 Hz, 2H). MS (ESI) m/z calcd for C69H66N2O14 [M+Na]
+ 1170.2. Found 1169.9. 
 
Synthesis of benzyl (2-nitrobenzyl)(propyl)carbamate 16 
 
Starting material 23 (1 g, 6.6 mmol) and propylamine (0.60 mL, 7.3 mmol) were 
dissolved in 10 mL anhydrous THF. The reaction was stirred for two hours at RT. The 




Then, the reaction mixture was cooled down to 0°C and NaBH4 (249 mg, 6.6 mmol) was 
added portionwise. The reaction was stirred for two hours before being quenched by acetone. 
All volatile products were removed under vacuum. The crude product was subjected to the 
next step without purification. 
Crude product was dissolved in anhydrous MeOH and CbzCl (1.1 mL, 7.9 mmol) was 
added. Triethylamine (1.9 mL, 13 mmol) was added and the reaction mixture was stirred for 
four hours at RT. Afterwards all the volatile products were removed under vacuum, the solid 
material was dissolved in DCM, washed by HCl (twice), NaHCO3 (twice), dried over MgSO4 
and concentrated under vacuum. Purification by column chromatography gave 1.82 g (3.8 
mmol, 84% yield) of compound 25.  
Analytical data for compound 25: 1H NMR (400 MHz, Chloroform-d) δ 8.09 – 7.99 
(m, 1H), 7.54 (p, J = 7.8 Hz, 1H), 7.43 – 7.27 (m, 6H), 7.14 (s, 1H), 5.17 (d, J = 15.9 Hz, 2H), 
5.08 (s, 1H), 4.92 – 4.79 (m, 2H), 3.26 (p, J = 7.5 Hz, 2H), 1.58 (q, J = 7.9 Hz, 2H), 0.87 (dt, 
J = 14.0, 7.5 Hz, 3H). MS (ESI) m/z calcd for C18H20N2O4 [M+Na]
+ 351.1. Found 351.4. 
Synthesis of benzyl (1-(2-nitrophenyl)ethyl)(propyl)carbamate 19  
 
Starting material 26 (1 g, 6.1 mmol) and  propylamine (0.55 mL, 6.7 mmol) were 
dissolved in 10 mL anhydrous THF. The reaction was stirred for two hours at RT. The 
reaction mixture was concentrated in vacuum and dissolved in anhydrous MeOH (10 mL). 
Then, the reaction mixture was cooled down to 0°C and NaBH4 (230 mg, 6.1 mmol) was 
added portionwise. The reaction was stirred for two hours before being quenched by acetone. 
All the volatile products were removed under vacuum. The crude product was subjected to the 
next step without purification. 
Crude product was dissolved in anhydrous MeOH and CbzCl (1.02 mL, 7.2 mmol) 
was added. Triethylamine (1.7 mL, 12 mmol) was added and the reaction mixture was stirred 
for four hours at RT. Afterwards all the volatile products were removed under vacuum, the 
solid material was dissolved in DCM, washed by HCl (twice), NaHCO3 (twice), dried over 
MgSO4 and concentrated under vacuum. Purification by column chromatography gave 1.29 g 




Analytical data for compound 28: 1H NMR (400 MHz, Chloroform-d) δ 7.73 (dd, J = 
8.1, 1.3 Hz, 1H), 7.50 (q, J = 7.8 Hz, 2H), 7.36 (td, J = 7.7, 7.2, 3.4 Hz, 1H), 7.33 – 7.16 (m, 
5H), 5.72 (q, J = 7.0 Hz, 1H), 5.05 (s, 2H), 3.29 – 3.06 (m, 2H), 1.59 (d, J = 7.1 Hz, 3H), 1.55 
– 1.36 (m, 2H), 0.77 (t, J = 7.4 Hz, 3H). MS (ESI) m/z calcd for C19H22N2O4 [M+Na]+ 365.3. 
Found 365.5. 
 
Synthesis of benzyl (1-(5-hydroxy-2-nitrophenyl)ethyl)(5-hydroxypentyl)carbamate 25 
 
 
Starting material (500 mg, 2.8 mmol) and propylamine (0.25 mL, 3.1 mmol) were 
dissolved in 10 mL anhydrous THF. The reaction was stirred overnight at RT. The reaction 
mixture was concentrated in vacuum and dissolved in anhydrous MeOH (10 mL). Then the 
reaction mixture was cooled down to 0°C and NaBH4 (106 mg, 2.8 mmol) was added 
portionwise. The reaction was stirred for two hours before being quenched by acetone. All the 
volatile products were removed under vacuum. The crude product was subjected to the next 
step without purification. 
Crude product was dissolved in anhydrous MeOH and CbzCl (0.50 mL, 3.5 mmol) 
was added. Triethylamine (0.85 mL, 6.0 mmol) was added and the reaction mixture was 
stirred for four hours at RT. Afterwards all the volatile products were removed under vacuum, 
the solid material was dissolved in DCM, washed by HCl (twice), NaHCO3 (twice), dried over 
MgSO4 and concentrated under vacuum. Purification by column chromatography gave 0.340 
g (3.8 mmol, 30% yield) of compound 25.  
Analytical data for compound 25: 1H NMR (400 MHz, Chloroform-d) δ 8.07 (d, J = 
9.1 Hz, 1H)7.70 (dd, J = 8.0, 1.5 Hz, 1H), 7.55 – 7.49 (m, 2H), 7.41 – 7.34 (m, 1H), 7.32 – 
7.10 (m, 4H), 5.70 (q, J = 7.0 Hz, 1H), 5.08 (s, 2H), 3.27 – 3.06 (m, 2H), 1.56 (d, J = 7.1 Hz, 
3H), 1.53 – 1.34 (m, 2H), 0.80 (t, J = 7.3 Hz, 3H). MS (ESI) m/z calcd for C21H26N2O6 
[M+Na]+ 425.4. Found 452.1. 






Resin functionalization. Merrifield resin (0.50 mmol/g, 8.0 g, 4.0 mmol, 1.0 eq.) and 
linker 3 or 31 (6.21 g, 16 mmol, 4.0 eq.) were taken up in a minimal amount of anhydrous 
DMF (~4 mL DMF/g resin) to completely swell the resin and solubilize the linker. The 
suspension was then degassed by placing the flask under high vacuum for a couple of 
minutes, followed by refilling the evacuated flask with Argon. After repeating this degassing 
procedure two more times, Cs2CO3 (5.21 g, 16 mmol, 4.0 eq.) and TBAI (1.48 g, 4.0 mmol, 
1.0 eq.) were added to the flask and the entire suspension rotated on a rotovap at 60 °C and 
atmospheric pressure overnight. The next morning, water was added to the resin to dissolve 
all solids and the resin was subsequently washed with THF/water (1/1), THF, DMF, MeOH, 
DCM, MeOH, and finally DCM (six times each) to remove the yellow color. The resin was 
transferred again to a round bottom flask, swollen in a minimal amount of DMF (4 mL 
DMF/g resin) and the flask degassed as above. Afterwards, CsOAc (1.54 g, 8.0 mmol) was 
added and the entire suspension rotated on a rotovap at 60 °C and atmospheric pressure 
overnight. The next morning, the resin was washed with THF/water (1/1), THF, DMF, 
MeOH, DCM, MeOH, and finally DCM (six times each) to remove the yellow color. It was 












Resin loading determination methods. 
Method 1.   
 
An aliquot of the resin (20-30 mg) is swollen in DCM (1 mL) for 1 hour. To this 
suspension was subsequently added FmocCl (100 mg) and pyridine (100 μL) and shaken 
overnight at room temperature. The next morning, the resin was drained and washed with 
MeOH and DCM (six alternating washes). A solution of 20% triethylamine in DMF (6 mL) 
was then added to the resin and shaken at RT for 4 hours. After draining the resin, a 100 μL 
aliquot of the solution was taken and diluted to 10 mL using 20% triethylamine in DMF and 
the absorbance at 301 nm (ε = 7800 L/mol*cm) measured. 
Method 2. 
 
An aliquot of the resin (40 mg) is subjected to the glycosylation cycle (Module C) 
with 10 equiv. of building block 37 followed by the photo cleavage, HPLC purification and 
measurement of the mass of the resulting compound. 
Method 3. 
 
An aliquot of the resin (40 mg) is subjected to the glycosylation cycle (Module C) 
with 10 equiv. of building block 37 followed by DBU promoted Fmoc-cleavage and 




2.6.2 Photo cleavage of linkers and functionalized resin 
2.6.2.1 General procedure for photo cleavage of the resin 
The resin is suspended in 20 mL of DCM is pumped through the Vaportec E-Series 
UV-150 photo reactor Flow Chemistry System at a flow rate of 0.8 mL/min. After passing the 
resulting solution through the filter, all the volatiles are removed under under vacuum and the 
crude products are subjected to purification. 
2.6.2.2 General procedure for photo cleavage of the compounds:  
The solution of the compound in DCM is pumped through the Vaportec E-Series UV-
150 photo reactor Flow Chemistry System at a flow rate of 0.8 mL/min. The resulting solution 
was concentrated under vacuum and the crude mixture was analyzed by NMR. 
 
Photo cleavage of benzyl (5-hydroxy-2-nitrobenzyl)(5-hydroxypentyl)carbamate 3 
 
Linker 3 (25 mg, 0.071 mmol) was dissolved in 20 mL of anhydrous DCM and the 
solution was subjected to the photo cleavage procedure as described above. 
Analytical data for rearrangement product 5: 1H NMR (400 MHz, CDCl3) δ 7.40 – 
7.24 (m, 6H), 6.99 (dt, J = 9.6, 2.0 Hz, 1H), 6.38 (s, 1H), 5.19 (s, 2H), 3.83 (t, J = 7.0 Hz, 
2H), 3.58 (t, J = 6.2 Hz, 2H), 1.68 – 1.56 (m, 2H), 1.56 – 1.47 (m, 2H), 1.43 – 1.32 (m, 2H). 
MS (ESI) m/z calcd for C20H22N2O5 [M+Na]
+ 393.4. Found 393.7. 
Analytical data for linker 6: 1H NMR (400 MHz, CDCl3) δ 7.38 – 7.22 (m, 5H), 5.09 
(s, 2H), 3.63 (t, J = 6.5 Hz, 2H), 3.23 – 3.15 (m, 2H), 1.68 – 1.49 (m, 4H), 1.44 – 1.36 (m, 
2H). Analytical data in accordance with previously reported data.123 





Linker 7 (26 mg, 0.025 mmol) was dissolved in 20 mL anhydrous DCM and the 
solution was subjected to the photo cleavage procedure as described above. 
Analytical data for compound 8: 1H NMR (400 MHz, CDCl3) δ 8.10 (d, J = 7.8 Hz, 
2H), 7.74 (d, J = 7.6 Hz, 2H), 7.61 (dd, J = 13.5, 7.8 Hz, 2H), 7.56 – 7.52 (m, 1H), 7.43 – 7.24 
(m, 22H), 6.99 (dt, J = 9.6, 2.0 Hz, 1H), 6.38 (s, 1H), 5.73 (s, 1H), 5.44 (s, 1H), 5.19 (s, 2H), 
4.92 (d, J = 11.0 Hz, 1H), 4.83 – 4.75 (m, 1H), 4.65 – 4.52 (m, 2H), 4.47 (s, 2H), 4.41 (d, J = 7.8 
Hz, 2H), 4.38 – 4.23 (m, 2H), 4.07 – 3.94 (m, 2H), 3.81 (t, J = 7.1 Hz, 2H), 3.56 (t, J = 6.2 Hz, 
2H), 1.69 – 1.58 (m, 2H), 1.57 – 1.47 (m, 2H), 1.41 – 1.32 (m, 2H). MS (ESI) m/z calcd for 
C62H58N2O13 [M+Na]
+ 1062.1. Found 1062.3. 
 
Photo cleavage of benzyl (5-(benzyloxy)-2-nitrobenzyl)(5-hydroxypentyl)carbamate 10 
 
Linker 9 (25 mg, 0.055 mmol) was dissolved in 20 mL anhydrous DCM and the 
solution was subjected to the photo cleavage procedure as described above. 
Analytical data for rearrangement product 10: 1H NMR (400 MHz, CDCl3) δ 7.40 – 
7.24 (m, 11H), 7.02 – 6.98 (m, 1H), 6.35 (s, 1H), 5.21 (s, 2H), 5.21 (s, 2H), 5.05 (s, 2H), 3.88 
(t, J = 6.8 Hz, 2H), 3.56 – 3.50 (m, 2H), 1.66 – 1.53 (m, 2H), 1.52 – 1.46 (m, 2H), 1.44 – 1.33 
(m, 2H). MS (ESI) m/z calcd for C27H28N2O5 [M+Na]
+ 483.5. Found 483.2. 
Analytical data for the linker 6: 1H NMR (400 MHz, CDCl3) δ 7.38-7.27 (m, 5H), 5.09 
(s, 2H), 4.82 (s, 1H), 3.63 (t, 2H, J = 6.5 Hz), 3.20 (q, 2H, J = 6.5Hz), 1.62 (s, 1H), 1.61-1.53 






Photo cleavage of benzyl (5-(benzyloxy)-2-nitrobenzyl)(5-hydroxypentyl)carbamate 10 in 
acidic media 
 
Compound 9 (25 mg, 0.055 mmol) was dissolved in 20 mL the mixture of DCM: 
AcOH (100:1) and the solution was subjected to the photo cleavage procedure as described 
above. 
Analytical data for rearrangement product 10: 1H NMR (400 MHz, CDCl3) δ 7.40 – 
7.24 (m, 11H), 7.02 – 6.98 (m, 1H), 6.35 (s, 1H), 5.21 (s, 2H), 5.21 (s, 2H), 5.05 (s, 2H), 3.88 
(t, J = 6.8 Hz, 2H), 3.56 – 3.50 (m, 2H), 1.66 – 1.53 (m, 2H), 1.52 – 1.46 (m, 2H), 1.44 – 1.33 
(m, 2H). MS (ESI) m/z calcd for C27H28N2O5 [M+Na]
+ 483.5. Found 483.2. 
Analytical data for the linker 6: 1H NMR (400 MHz, CDCl3) δ 7.38-7.27 (m, 5H), 5.09 
(s, 2H), 4.82 (s, 1H), 3.63 (t, 2H, J = 6.5 Hz), 3.20 (q, 2H, J = 6.5Hz), 1.62 (s, 1H), 1.61-1.53 
(m, 6H). Analytical data in accordance with previously reported data.123 
 
Photo cleavage of compound 12 
 
 
Compound 11 (26 mg, 0.025 mmol) was dissolved in 20 mL anhydrous DCM and the 
solution was subjected to the photo cleavage procedure as described above. 
Analytical data for compound 12: 1H NMR (400 MHz, CDCl3) δ 8.12 (d, J = 7.7 Hz, 
2H), 7.73 (d, J = 7.6 Hz, 2H), 7.60 (dd, J = 13.3, 7.7 Hz, 2H), 7.55 (t, J = 7.7 Hz, 1H), 7.41 
(q, J = 7.7 Hz, 4H), 7.38-7.23 (m, 17H), 5.73 (s, 1H), 5.42 (s, 1H), 4.92 (d, J = 11.4 Hz, 1H), 
4.82 – 4.75 (m, 2H), 4.62 (dd, J = 21.3, 11.1 Hz, 2H), 4.49 (s, 2H), 4.39 (d, J = 7.7 Hz, 2H), 
4.35 – 4.21 (m, 2H), 4.07 – 3.96 (m, 2H) ), 3.62 (t, 2H, J = 6.2 Hz), 3.22 – 3.16 (m, 2H), 1.64 – 
1.56 (m, 2H), 1.55 – 1.44 (m, 2H), 1.42 – 1.33 (m, 2H). MS (ESI) m/z calcd for C55H55NO11 





Photo cleavage of benzyl (2-nitrobenzyl)(propyl)carbamate 16 
 
Compound 25 (25 mg, 0.076 mmol) was dissolved in 20 mL anhydrous DCM and the 
solution was subjected to the photo cleavage procedure as described above. 
Analytical data for the aldehyde 25a: 1H NMR (400 MHz, CDCl3) δ 12.03 (s, 1H), 
8.19 (d, J = 7.7 Hz, 1H), 7.88 (t, J = 7.6 Hz, 1H), 7.69 – 7.62 (m, 1H), 7.27 – 7.22 (m, 1H). 
Analytical data for the linker 25b: 1H NMR (400 MHz, CDCl3) δ 7.38–7.32 (m, 5H), 
5.09 (s, 2H), 4.78 (s, 1H), 3.20–3.10 (m, 2H), 1.57–1.44 (m, 2H), 0.92 (t, J=7.5 Hz, 3H). 
Analytical data in accordance with previously reported data.124 
 
Photo cleavage of benzyl (1-(2-nitrophenyl)ethyl)(propyl)carbamate 19 
 
Compound 28 (25 mg, 0.076 mmol) was dissolved in 20 mL anhydrous DCM and the 
solution was subjected to the photo cleavage procedure as described above. 
Analytical data for the ketone 28a: 1H NMR (400 MHz, CDCl3) δ 8.22 – 8.16 (m, 1H), 
7.90 – 7.84 (m, 1H), 7.72 – 7.67 (m, 1H), 7.27 – 7.22 (m, 1H), 2.73 (s, 3H). 
Analytical data for the linker 28b: 1H NMR (400 MHz, CDCl3) δ 7.38–7.32 (m, 5H), 
5.09 (s, 2H), 4.78 (s, 1H), 3.20–3.10 (m, 2H), 1.57–1.44 (m, 2H), 0.92 (t, J=7.5 Hz, 3H). 





2.6.3 Automated glycan assembly 
2.6.3.1 General materials and methods 
All solvents used were HPLC-grade. The solvents used for the building block, 
activator, TMSOTf and capping solutions were taken from an anhydrous solvent system 
(jcmeyer-solvent systems). The building blocks were co-evaporated three times with 
chloroform and dried for 1 h on high vacuum before use. Activator, deprotection, acidic wash 
and building block solutions were freshly prepared and kept under argon during the 
automation run. All yields of products obtained by AGA were calculated on the basis of resin 
loading. 
2.6.3.2  Preparation of stock solutions 
 
• Building Blocks: between 0.062 and 0.080 mmol of the building block 28 was 
dissolved in 1 mL of DCM. 
• Activator solution: 1.35 g of NIS was dissolved in 40 mL of a 2:1 mixture of 
anhydrous DCM and anhydrous dioxane. Then triflic acid (55 μL) was added. The 
solution is kept at 0°C for the duration of the automation run. 
• Fmoc deprotection solution 1: A solution of 20% Et3N in DMF (v/v) was prepared. 
• Fmoc deprotection solution 2: A solution of 20% piperidine in DMF (v/v) was 
prepared. 
• TMSOTf Solution: TMSOTf (0.45 mL) was added to DCM (40 mL). 
2.6.3.3 Optimized modules for automated synthesis 
Module A: Resin Preparation for Synthesis (20 min) 
All automated syntheses were performed on 0.0125 mmol scale. Resin was placed in 
the reaction vessel and swollen in DCM for 20 min at room temperature prior to synthesis. 
During this time, all reagent lines needed for the synthesis were washed and primed. Before 
the first glycosylation, the resin was washed with the DMF, THF, and DCM (three times each 
with 2 mL for 25 s).  
Module B: Acidic Wash with TMSOTf Solution (20 min) 
The resin was swollen in 2 mL DCM and the temperature of the reaction vessel was 




drop wise to the reaction vessel. After bubbling for 3 min, the acidic solution was drained and 
the resin was washed with 2 mL DCM for 25 s. 
Action Cycles Solution Amount T (°C) 
Incubation 
time 
Cooling - - - -20 (15 min)* 
Deliver 1 DCM 2 mL -20 - 
Deliver 1 TMSOTf solution 1 mL -20 3 min 
Wash 1 DCM 2 mL -20 25 s 
*Time required to reach the desired temperature. 
Module C: Thioglycoside Glycosylation (35 min) 
The building block solution (0.08 mmol of BB in 1 mL DCM per glycosylation) was 
delivered to the reaction vessel. After the set temperature was reached, the reaction was 
started by drop wise addition of the activator solution (1.0 mL, excess). The glycosylation 
conditions are building block dependent (we report the most common set of conditions). After 
completion of the reaction, the solution is drained and the resin was washed with DCM, 
DCM:dioxane (1:2, 3 mL for 20 s) and DCM (two times, each with 2 mL for 25 s). The 
temperature of the reaction vessel is increased to 25 °C for the next module. 
Action Cycles Solution Amount T (°C) 
Incubation 
time 
Cooling - - - -20 - 
Deliver 1 BB solution 1 mL -20 - 
Deliver 1 Activator solution 1 mL -20 - 
Reaction time 1  




Wash 1 DCM 2 mL 0 5 s 
Wash 1 
DCM : Dioxane 
(1:2) 
2 mL 0 20 s 
Heating - - - 25 - 
Wash 2 DCM 2 mL > 0 25 s 
 
Module D: Fmoc Deprotection (14 min) 
The resin was washed with DMF (three times with 2 mL for 25 s) and the temperature 
of the reaction vessel was adjusted to 25 °C. Fmoc deprotection solution (2 mL) was delivered 




with DMF (three times with 3 mL for 25 s) and DCM (five times each with 2 mL for 25 s). 
The temperature of the reaction vessel is decreased to -20 °C for the next module. 
Action Cycles Solution Amount T (°C) 
Incubation 
time 
Heating - - - 25 (5 min) 
Wash 3 DMF 2 mL 25 25 s 
Deliver 1 Fmoc depr. solution 2 mL 25 5 min 
Wash 1 DMF 2 mL   
Cooling - - - -20 - 
Wash 3 DMF 2 mL < 25 25 s 
Wash 5 DCM 2 mL < 25 25 s 
2.6.3.4 Post-synthesizer manipulations 
Cleavage from Solid Support  
After automated synthesis, the oligosaccharides were cleaved from the solid support 
using a continuous-flow photoreactor as described previously.91  
Purification 
Solvent is evaporated in vacuo and the crude products were analyzed and purified 
using analytical and preparative HPLC (Agilent 1200 Series spectrometer). 
Synthesis of dimer 31 
 
 
 Module Conditions 
 A: Resin Preparation for Synthesis   
2 { 
B: Acidic Wash with TMSOTf Solution  
C: Thioglycoside Glycosylation BB 37, 10 eq (-20° for 5 min, 0° for 20 min) 




Cleavage from the solid support as described in Post-synthesizer manipulation 
followed by purification using preparative HPLC afforded compound 31 (9.2 mg, 62%)  
Analytical data for 40: 1H NMR (400 MHz, Chloroform-d) δ 8.10 (dd, J = 19.2, 7.5 
Hz, 4H), 7.59 (t, J = 7.6 Hz, 1H), 7.52 – 7.44 (m, 5H), 7.36 – 7.09 (m, 25H), 5.73 (s, 1H), 
5.63 (s, 1H), 5.09 (s, 3H), 4.92 – 4.86 (m, 3H), 4.83 (d, J = 11.4 Hz, 1H), 4.74 (d, J = 11.7 Hz, 
1H), 4.63 (d, J = 10.9 Hz, 1H), 4.57 (d, J = 11.0 Hz, 1H), 4.52 – 4.45 (m, 2H), 4.09 (d, J = 8.6 
Hz, 2H), 4.01 – 3.92 (m, 2H), 3.87 (d, J = 8.7 Hz, 2H), 3.76 (q, J = 10.5, 10.0 Hz, 4H), 3.67 
(d, J = 8.9 Hz, 1H), 3.43 (q, J = 7.4 Hz, 1H), 3.18 (q, J = 7.0 Hz, 2H), 1.56 (dt, J = 32.2, 7.5 
Hz, 4H), 1.38 (q, J = 7.9 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 165.82, 165.52, 156.40, 
138.28, 138.23, 137.90, 137.69, 133.26, 129.94, 129.89, 129.84, 129.80, 128.56, 128.48, 
128.34, 128.30, 128.13, 128.08, 128.01, 127.94, 127.76, 127.68, 127.65, 127.61, 97.83, 78.54, 
77.87, 75.18, 74.26, 73.85, 72.14, 71.62, 71.31, 70.57, 69.03, 68.78, 67.81, 66.56, 66.22, 





3 Synthesis of oligosaccharides for structural investigations 
Carbohydrates are the most abundant type of organic materials.1 However, relatively 
little is known about the correlation between the molecular structure and macroscopic 
properties of polysaccharides. Establishing this correlation requires chemically well-defined 
oligosaccharides.  
Carbohydrates can be accessed from natural sources or via enzymatic and/or chemical 
synthesis. A large variety of carbohydrates (like glycosaminoglycans,19-24 plant 
carbohydrates,25 capsular polysaccahrides26-28 etc.) can be extracted from natural sources, but 
these results in heterogeneous samples making  structural investigations very challenging. 
Enzymatic synthesis, on contrary, permits the synthesis of homogeneous oligosaccharides,32, 
125-126 But the scope of molecules that could be accessed by this approach is limited by the 
number of available enzymes and substrates. This limitation could be overcome by solution-
phase synthesis of oligosaccharides.127-128 The main difficulty here is the fact that this method 
relies on multiple protecting group manipulations and often requires many synthetic steps. 
Hence, solution-phase synthesis often does not allow for the rapid access to the desired 
compounds.  
 





Automated glycan assembly can enable the preparation of well-defined oligo- and 
polysaccharides. In order to shed light on the correlation between polymer composition, three-
dimensional structure and macroscopic properties of carbohydrates, several natural (cellulose 
and chitin) and unnatural oligosaccharides (1→6 mannosides and 1→6 glucosides) were 
chosen as synthetic targets (Scheme 31).  
3.1 Synthesis of building blocks  
For the synthesis of the oligosaccharide collection building blocks 37, 41- 45 were 
used (Scheme 32). Benzyl ethers served as non-participating permanent protecting groups for 
alcohols while benzoyl or acetyl esters as well as trichloroacetyl (TCA) were used as 
permanent participating protecting groups ensuring selective trans-glycoside formation. The 
fluorenylmethyloxycarbonyl (Fmoc) temporary protecting group is removed following each 
elongation cycle. 
 
Scheme 32. Retrosynthetic analysis of the building blocks  
Mannose BB 37 was synthesized from commercially available precursor 46 via an 
established protocol.112 Glucose BBs 41a,bi were obtained from precursors 47a,b 
respectively, that were obtained from the compound 47 using the described procedures.129-130 
                                                 




Glucosamine BB 42 was synthesized from commercially available precursor 48 via an 
established protocol (Scheme 33).131 Glucose BB 43ii was obtained from 47 using a described 
methodology.131 Mannose BB 44 iiiused for 1→2 linkages was synthesized from compound 
50. Building block 45iv for the synthesis of oligosaccharides with carboxylic group 
functionalities was synthesized from precursor 51 using a described synthetic route.112 
 
Scheme 33. Synthesis of glucosamine building block. 
3.2 Synthesis of an oligosaccharide library 
Automated glycan assembly was performed for thioglycoside building blocks 37, 41 – 
45 using optimized conditions. Glycosylation cycles were performed using 6.5 equiv. of BBs 
(5.0 equiv. for BB 41b because of its high reactivity) in the presence of NIS/TfOH at -20°C (5 
min) – 0°C (20 min). The removal of Fmoc protecting group was performed using 20% 
piperidine in DMF and a TMSOTf (63mM in DCM) solution was used for acidic wash prior 
to the next glycosylation. 
Mannose BB 37 for the synthesis of 6-mer 52a, 12-mer 52b and 20-mer of mannose 
52c (Scheme 34, Table 11). In all the cases, it was possible to achieve a high yield of the 
synthesis and access the desired oligosaccharides in less than one day.  
Table 11. AGA of mannose oligosaccharides 
Oligosaccharide Synthesis (h) Yield, % 
6-mer, 52a 7  51 
12-mer, 52b 14  29 
20-mer, 52c 23  19 
 
                                                 
iiBuilding block 43 was synthesized by Mr. Yu 
iiiBuilding block 44 was provided by Mr. Pardo 




Assembly of 1→6 glucosides was initially performed using building block 41b. This 
building block exhibits a very high reactivity and gives excellent results in automated 
synthesis. However, the global deprotection of oligosaccharides obtained from BB 41b was 
hindered by insolubility of oligosaccharides formed.  Glucose BB 41a is less reactive (it 
contains an additional electron withdrawing protecting group OBz, instead of the OBn in 
building block 41b), but it helped to overcome the solubility issues during the global 
deprotection step and made it possible to synthesize glucose oligosaccharides 53a and 53b. 
 
Scheme 34. Scheme of oligosaccharide synthesis for compounds 52a-c  
Glucosamine building block 42 has lower reactivity as a glycosidic donor, therefore a 
capping step was performed. A capping step is used to block the unreacted hydroxyl groups 
after each glycosylation preventing any unreacted chains from growing to form internal 
deletion sequences. Recently, a new capping procedure utilizing Ac2O (10%) and 
methanesulfonic acid (2%) in DCM was developed in Seeberger group.132 This procedure was 
implemented in the synthesis of chitin and cellulose oligomers. (Scheme 35). Analogous 
method was used for the synthesis of 1→4 hexaglucoside 55 from building block 43.v  
 
                                                 





Scheme 35. Scheme of AGA for chitin hexasaccharide 54 (with capping). 
Oligosaccharides 52 - 55 were purified using HPLC and subjected to the deprotection 
procedure (methanolysis and hydrogenation).vi As a result, target oligosaccharides d-52 – d-
55 were obtained. Interestingly, the glucose oligosaccharides were obtained in much lower 
yields (2% for d-53b), in comparison to the other synthesized compounds. The reason for this 
is insolubility of these oligosaccharides in most solvents.   
One of the major advantages of automated synthesis technology is its modularity: it 
allows introduction of modifications at any position in the sequence of the desired 
oligosaccharide. This advantage was utilized in the synthesis of heteropolymers 56 – 59. In an 
attempt to disrupt the 3D structure of glucose oligomers, mixed oligomers containing one 
mannose unit 56a,b were prepared. It was found that the introduction of a mannose unit was 
indeed beneficial. The more soluble 12-mer (56b) containing one mannoside unit in position 7 
was isolated in 20% yield.  
The introduction of different linkages was also explored where building block 50 was 
used for the installation of the (1→2) linkage (58). Using building blocks 37 and 45 
oligosaccharides 59a and 59b, bearing a carboxylic acid group allowing for further block-
coupling, were synthesized. 
                                                 





Figure 8. Overview of the oligosaccharides prepared by AGA. 
3.3 AGA of a mannose 50-mer 
The longest oligosaccharide synthesized via AGA was a mannose 50-mer.112 However, 
the synthesis of this compound was performed within 10 days and the poly-mannoside was 
obtained only in 5% yield.112 In order to improve this result, the applicability of the optimized 
AGA conditions for the synthesis of mannoside 50-mer was investigated. 
The optimized elongation cycle, including the new capping procedure was used for the 
synthesis of 50-mer 60. Several advantages of the newly developed synthetic procedure, in 
comparison to previously reported,112 can be pointed out. First of all, the overall synthesis was 
much faster: 80 hours in comparison with 250 hours reported before. The yield improvement 
was also significant: 22% instead of 5%. That means that the average yield of the elongation 
cycle is 98% and making AGA comparable to oligopeptide or oligonucleotide synthesis. Also, 
the usage of solvents has been reduced drastically (Table 12). Optimization helped to reduce 












DCM 2.5  1.2  
DMF 1.5 0.7  
Dioxane 0.1  0.1  
DCE 0.12  0.06  
THF 0.30  0 
 
In addition to the mannose 50-mer (60), mannose 49-mer both uncapped (60a) and 
acetylated (60b) were prepared. For acetylation of the 49-mer the conditions, analogous to the 
capping procedure were utilized (Ac2O (10%) and methanesulfonic acid (2%) in DCM).
 vii 
These three compounds were used for the evaluation of the HPLC resolution power in the 
separation of long polysaccharides. Uncapped 50-mer 60, that represents the desired final 
product of AGA, and the potential deletion sequence, the uncapped 49-mer 60a are eluted 
with virtually the same retention time, while capped 49-mer 60b is eluted more than one 
minute before either of the other two compounds and can be readily separated from the final 
product (Figure 9). This finding demonstrates that capping not only improves the yield, but 
also generates more readily separable side-products, even when polysaccharides are prepared. 
                                                 





Figure 9. HPLC trace of the crude 50-mer 60 compared with the potential deletion 
sequence 60a and uncapped 49-mer 60b.  
3.4 Molecular dynamics investigationsviii 
With this collection of oligo- and polysaccharides in hand, we began to investigate the 
3D structure of such materials in order to correlate glycan sequence with macroscopic 
properties. Ideally, we would be able to understand how modifications such as the insertion of 
a different monosaccharide affect the overall molecular geometry. 
Long molecular dynamics (MD) simulations (between 500 ns and 5.5 μs) using the 
AMBER12 package133 with ff12SB,133 GAFF,134 and GLYCAM06j135 force fields provided 
conformational and dynamic information and revealed significant structural differences 
between the different polymers (Figure 10). The geometries of different hexamers were 
compared by analyzing different parameters, including the radius of gyration (RoG), the 
RMSD values (root-mean square deviation of atomic positions), the distances between the 
non-reducing end moiety with all other residues, the torsion angles around the glycosidic 
linkages (Figure 11), and the shape of the six-membered rings. The RoG describes the overall 
extension of the molecule and is defined as the root mean square distance of the collection of 
atoms from their common center of gravity.  
                                                 






Figure 10. The global minima conformations of oligosaccharides obtained by 
molecular dynamics simulations. 
In particular, the major conformer of the β1,6-Glc hexasaccharide d-53a adopts a 
helical structure with an internal cavity (Figure 10, d-53a). The cavity resembles a crown 
ether, with the oxygens presenting the same spatial orientation while the non-polar faces of 
the Glc rings point the opposite direction. The exo-anomeric Φ value (ca. 42º)136 is kept 
throughout the simulation, while Ψ varies from to 80º to 180º. Analysis of the Cremer-Pople 
parameters137 showed some chair-to-chair interconversions where the 4C1 chair always 
dominates (85 - 96%), while alternative boats and skew boat conformers are observed for less 
than 1.5% of all pyranose rings. The populations of the alternative 1C4 conformers reach 12-
15% for the glucose residues 2 and 5.138 The relatively small RoG (ca. 5.6 Å) and the distance 
between both ends, that rarely extended beyond 20 Å, indicate that the molecule adopts bent 





Figure 11. Definition of the torsion angles for every type of linkage 
The MD simulations suggest a significantly more rigid structure for the α1,6 
hexamannoside (Figure 10, d-52a) The calculated mean RoG for this molecule is now 
significantly larger (7.5 Å), albeit with values ranging from 5 to 9 Å and a maximum between 
8-9 Å. Most of the time the molecule adopts extended shapes (RoG closer to 9 Å) but bent 
conformations are also observed for a period of time. The distance between both ends usually 
remained between 20-25 Å. For the major conformer, the hydroxyl groups on the periphery of 
the chain are available to interact with polar groups. Chair-to-chair interconversions are rare 
(< 1%) as the 4C1 chair is always favored from both stereoelectronic and steric perspectives. 
The insertion of mannose in position 3 of the β1,6-Glc hexamer (d-56a) indeed 
distorts the chain and results in a less defined helical structure (Figure 10, d-56a). A larger 
RoG than for the β1,6-Glc hexasaccharide d-53a is predicted. In this particular case, there is 
not any clear preference for a given shape. A single chain of cellulose, represented by the β1,4 
hexaglucoside d-55 adopts a twisted ribbon-like structure with no cavity where the C3 
hydroxyl of one residue hydrogen bonds with the O5 of the preceding moiety.139 The C2 and 
C6 hydroxyl groups that are not engaged in the intramolecular hydrogen bonds are oriented 
outside the major axis of the ribbon, ready to interact with other polar donors.139 The β1,4-Glc 
hexamer (d-55) displays the largest RoG (>9 Å), and the highest mean distances between the 
two remote ends (>25 Å).  
Chitin d-54, where the C2-hydroxyl groups present in cellulose are replaced by C2-N-
acetlyls adopts a structure similar to that of cellulose. The chair-to-chair interconversions of 
the six-membered rings are even smaller than those for the cellulose hexamer as the bulkier 
C2 NHAc substituents prevent the transitions to this geometry. The molecule adopts a helix-
like structure with no internal cavity. The acetamide moieties, like the C6 hydroxyls, adorn 
the periphery of the main axis, displaying the NH and CO hydrogen bond donor and 
acceptors. The methyl groups can be engaged in van der Waals interactions with other 
partners.140 
3.5 Toward tailor-made carbohydrate-based materialsix 
Oligomers of different conformation are ideal “bricks” to create novel carbohydrate-
based synthetic materials. To combine these “bricks”, connection points at either side of the 
                                                 




oligomer are required. The reducing terminus of all synthetic oligomers prepared by AGA 
carries a unique primary amine group. Placement of a BB containing a C6 carboxymethyl 
group (45) during the last cycle of the assembly resulted in carbohydrate oligomers where an 
amine and a carboxylic acid can be exploited for conjugation (d-59a,b).  
 
 
Scheme 36. An example of block-coupling procedure 
Three block couplings based on PyBOP/DIPEA mediated amide bond formation were 
explored (Scheme 36). After simply connecting oligo-mannose blocks, oligo-mannose and 
oligo-glucose blocks of different geometries and solubility were combined. All the coupling 
products were isolated in high yields and easily purified using RP-HPLC.  
3.6 Conclusions and perspectives 
Automated glycan assembly enables the preparation of well-defined oligo- and 
polysaccharides resembling natural as well as unnatural structures. It has been shown that the 
optimized glycosylation cycle can be used for various thioglycoside building blocks 
(mannose, glucose, glucosamine) and for different types of glycosidic linkages (1→2, 1→4, 




The structure of the synthesized hexasaccharides was investigated using molecular 
dynamics. It was found that mannosides (1→6), glucosides (1→4 and 1→6) and 
glucosaminosides (1→4) present different geometries and flexibility that can lead to 
differences in the macroscopic properties of polysaccharides (for example, solubility). AGA 
modularity allowed for specific modifications, permitting the fine tuning of the polymer shape 
and conformation. Oligomers of different conformation are ideal “bricks” to create novel 
carbohydrate-based synthetic materials.  
Optimized AGA procedures can be applied for the synthesis of a larger collection of 
oligo- and polysaccharides. The synthesized glycans can be used for further structural 
investigations. 
3.7 Experimental part 
3.7.1 Automated glycan assembly 
3.7.1.1 General materials and methods 
All solvents used were HPLC-grade. The solvents used for the building block, 
activator, TMSOTf and capping solutions were taken from an anhydrous solvent system 
(jcmeyer-solvent systems). The building blocks were co-evaporated three times with 
chloroform and dried for 1 h on high vacuum before use. Activator, deprotection, acidic wash 
and building block solutions were freshly prepared and kept under argon during the 
automation run. All yields of products obtained by AGA were calculated on the basis of resin 
loading. 
3.7.1.2  Preparation of stock solutions 
 
• Building Blocks: between 0.062 and 0.080 mmol of the building block 28  was 
dissolved in 1 mL of DCM. 
• Activator solution: 1.35 g of NIS was dissolved in 40 mL of a 2:1 mixture of 
anhydrous DCM and anhydrous dioxane. Then triflic acid (55 μL) was added. The 
solution is kept at 0°C for the duration of the automation run. 




• Fmoc deprotection solution 2: A solution of 20% piperidine in DMF (v/v) was 
prepared. 
• TMSOTf Solution: TMSOTf (0.45 mL) was added to DCM (40 mL). 
3.7.1.3 Optimized modules for automated synthesis 
Module A: Resin Preparation for Synthesis (20 min) 
All automated syntheses were performed on 0.0125 mmol scale. Resin was placed in 
the reaction vessel and swollen in DCM for 20 min at room temperature prior to synthesis. 
During this time, all reagent lines needed for the synthesis were washed and primed. Before 
the first glycosylation, the resin was washed with the DMF, THF, and DCM (three times each 
with 2 mL for 25 s).  
Module B: Acidic Wash with TMSOTf Solution (20 min) 
The resin was swollen in 2 mL DCM and the temperature of the reaction vessel was 
adjusted to -20 °C. Upon reaching the low temperature, TMSOTf solution (1 mL) was added 
drop wise to the reaction vessel. After bubbling for 3 min, the acidic solution was drained and 
the resin was washed with 2 mL DCM for 25 s. 
Action Cycles Solution Amount T (°C) 
Incubation 
time 
Cooling - - - -20 (15 min) 
Deliver 1 DCM 2 mL -20 - 
Deliver 1 TMSOTf solution 1 mL -20 3 min 
Wash 1 DCM 2 mL -20 25 s 
Module C: Thioglycoside Glycosylation (35 min) 
The building block solution (0.08 mmol of BB in 1 mL of DCM per glycosylation) 
was delivered to the reaction vessel. After the set temperature was reached, the reaction was 
started by drop wise addition of the activator solution (1.0 mL, excess). The glycosylation 
conditions are building block dependent (we report the most common set of conditions). After 
completion of the reaction, the solution is drained and the resin was washed with DCM, 
DCM:dioxane (1:2, 3 mL for 20 s) and DCM (two times, each with 2 mL for 25 s). The 
temperature of the reaction vessel is increased to 25 °C for the next module. 
Action Cycles Solution Amount T (°C) 
Incubation 
time 




Deliver 1 BB solution 1 mL -20 - 
Deliver 1 Activator solution 1 mL -20 - 
Reaction time 1  




Wash 1 DCM 2 mL 0 5 s 
Wash 1 
DCM : Dioxane 
(1:2) 
2 mL 0 20 s 
Heating - - - 25 - 
Wash 2 DCM 2 mL > 0 25 s 
 
Module D: Fmoc Deprotection (14 min) 
The resin was washed with DMF (three times with 2 mL for 25 s) and the temperature 
of the reaction vessel was adjusted to 25 °C. 2 mL of Fmoc deprotection solution was 
delivered into the reaction vessel. After 5 min, the reaction solution was drained and the resin 
washed with DMF (three times with 3 mL for 25 s) and DCM (five times each with 2 mL for 
25 s). The temperature of the reaction vessel is decreased to -20 °C for the next module. 
Action Cycles Solution Amount T (°C) 
Incubation 
time 
Heating - - - 25 (5 min) 
Wash 3 DMF 2 mL 25 25 s 
Deliver 1 Fmoc depr. solution 2 mL 25 5 min 
Wash 1 DMF 2 mL   
Cooling - - - -20 - 
Wash 3 DMF 2 mL < 25 25 s 
Wash 5 DCM 2 mL < 25 25 s 
3.7.1.4 Post-synthesizer manipulations 
Cleavage from Solid Support  
After automated synthesis, the oligosaccharides were cleaved from the solid support 
using a continuous-flow photoreactor as described previously.91  
Purification 
Solvent is evaporated in vacuo and the crude products were analyzed and purified 
using analytical and preparative HPLC (Agilent 1200 Series spectrometer). 




The resin was washed with DMF (two times with 2 mL for 25 s) and the temperature 
of the reaction vessel was adjusted to 25 °C. 2 mL of Pyridine solution (10% in DMF) was 
delivered into the reaction vessel. After 1 min, the reaction solution was drained and the resin 
washed with DCM (three times with 3 mL for 25 s). 4 mL of capping solution was delivered 
into the reaction vessel. After 20 min, the reaction solution was drained and the resin washed 
with DCM (three times with 3 mL for 25 s). 
Action Cycles Solution Amount T (°C) 
Incubation 
time 
Heating - - - 25 (5 min) 
Wash  2 DMF 2 mL 25 25 s 
Deliver 1 
 10% Pyridine in 
DMF 
2 mL 25 1 min 
Wash  3 DCM 2 mL 25 25 s 
Deliver 1 Capping Solution 4 mL 25 20 min 
Wash  3 DCM 2 mL 25 25 s 
 
3.7.2 Synthesis of homopolymers 




 Module Conditions 
 A: Resin Preparation for Synthesis   
6 { 
B: Acidic Wash with TMSOTf Solution  




D: Fmoc Deprotection  
 
Cleavage from the solid support as described in Post-synthesizer manipulation 
followed by purification using preparative HPLC afforded compound 52a (21.3 mg, 58%). 
Analytical data for 52a: 1H NMR (400 MHz, Chloroform-d) δ 8.24 – 8.13  (m, J = 
10H), 8.11 (d, J = 7.7 Hz, 2H), 7.62 (t, J = 7.5 Hz, 2H), 7.59 – 7.47 (m, 18H), 7.39 – 7.30  (m, 
7H), 7.30 – 7.23 (m, 18H), 7.23 – 7.07 (m, 38H), 5.88 – 5.82   (m, 3H), 5.80 (s, 1H), 5.66 (s, 
1H), 5.14 (s, 1H), 5.12 – 5.04 (m, 5H), 4.92 (d, J = 11.7 Hz, 4H), 4.86 – 4.79  (m, 7H), 4.75 
(d, J = 11.4 Hz, 2H), 4.61 (dd, J = 15.6, 11.0 Hz, 3H), 4.52 (d, J = 3.6 Hz, 1H), 4.50 – 4.40 
(m, 6H), 4.40 – 4.34  (m, 3H), 4.12 (dt, J = 9.0, 4.1 Hz, 2H), 4.09 – 3.93 (m, 10H), 3.92 – 
3.88  (m, 3H), 3.85 – 3.75  (m, 6H), 3.74 – 3.59 (m, 9H), 3.55 (t, J = 9.8 Hz, 3H), 3.50 – 3.37 
(m, 4H), 3.20 (q, J = 6.9 Hz, 2H), 1.65 – 1.56 (m, 2H), 1.56 – 1.45 (m, 2H), 1.43 – 1.32 (m, 
2H); 13C NMR (101 MHz, Chloroform-d) δ 165.87, 165.63, 165.55, 165.43, 156.40, 138.53, 
138.47, 138.31, 138.26, 137.94, 137.63, 137.57, 137.54, 136.67, 133.34, 133.30, 129.98, 
129.93, 129.88, 128.67, 128.60, 128.51, 128.37, 128.33, 128.24, 128.19, 128.16, 128.07, 
128.03, 127.72, 127.68, 127.65, 127.43, 127.38, 127.33, 127.24, 127.14, 127.11, 98.47, 98.41, 
98.14, 97.89, 77.68, 77.26, 75.20, 75.11, 75.05, 75.02, 74.19, 73.90, 73.80, 73.74, 73.68, 
72.10, 71.65, 71.42, 71.32, 71.20, 70.99, 70.91, 70.73, 69.05, 68.54, 68.42, 68.36, 67.79, 
66.57, 66.09, 65.81, 65.72, 65.43, 61.83, 40.97, 29.79, 29.05, 23.45; m/z (HRMS+) 2937.160 





Deprotection of 52a (18.0 mg, 6.2 µmol) as reported is Section 3.5 (Module F and G) 
followed by purification using preparative HPLC afforded compound d-52a (5.8 mg, 88%). 
Analytical data for d-52a: 1H NMR (400 MHz, Deuterium Oxide) δ 4.80 (d, J = 1.8 
Hz, 1H), 4.80 – 4.77 (m, 4H), 4.75 (d, J = 1.7 Hz, 1H), 3.90 – 3.86 (m, 5H), 3.86 – 3.79 (m, 
6H), 3.77 (d, J = 1.7 Hz, 2H), 3.76 – 3.68 (m, 11H), 3.68 – 3.60 (m, 10H), 3.60 – 3.57 (m, 
2H), 3.55 (d, J = 9.3 Hz, 1H), 3.46 (dt, J = 9.9, 6.1 Hz, 1H), 2.93 – 2.85 (m, 2H), 1.63 – 1.50 
(m, 4H), 1.35 (hept, J = 6.8 Hz, 2H). 13C NMR (176 MHz, Deuterium Oxide) δ 99.89, 99.42, 
99.32, 99.29, 72.72, 70.92, 70.84, 70.80, 70.77, 70.72, 70.69, 70.55, 70.07, 69.99, 69.94, 
67.63, 66.75, 66.61, 66.57, 65.62, 65.58, 65.53, 61.32, 60.94, 39.38, 30.65, 28.04, 27.99, 











 Module Conditions 
 A: Resin Preparation for Synthesis   
12 { 
B: Acidic Wash with TMSOTf Solution  
C: Thioglycoside Glycosylation BB 37, 6.5 eq (-20° for 5 min, 0° for 20 min) 
D: Fmoc Deprotection  
 
Cleavage from the solid support as described in Post-synthesizer manipulation 
followed by purification using preparative HPLC afforded compound 52b (26.5 mg, 38%). 
Analytical data for 52b: 1H NMR (600 MHz, Chloroform-d) δ 8.19 – 8.11 (m, 19H), 
8.10 (d, J = 7.3 Hz, 2H), 8.07 (d, J = 7.8 Hz, 2H), 7.57 (t, J = 7.5 Hz, 2H), 7.53 – 7.42 (m, 
35H), 7.35 – 7.25 (m, 11H), 7.25 – 7.20 (m, 12H), 7.20 – 7.13 (m, 55H), 7.13 – 7.09 (m, 
24H), 7.09 – 7.02 (m, 23H), 5.85 – 5.80 (m, 8H), 5.80 – 5.77 (m, 2H), 5.76 (s, 1H), 5.61 (d, J 
= 3.0 Hz, 1H), 5.09 (s, 1H), 5.07 – 5.01 (m, 11H), 4.90 – 4.83 (m, 12H), 4.83 – 4.81 (m, 2H), 
4.81 – 4.73 (m, 10H)   4.71 (d, J = 11.3 Hz, 2H), 4.58 (d, J = 11.1 Hz, 2H), 4.54 (d, J = 11.0 
Hz, 2H), 4.48 – 4.43 (m, 3H), 4.40 (d, J = 10.9 Hz, 10H), 4.36 – 4.30 (m, 8H), 4.07 (td, J = 
8.2, 7.5, 3.0 Hz, 2H), 4.04 – 3.99 (m, 8H), 3.98 – 3.92 (m, 12H), 3.92 – 3.86 (m, 3H), 3.86 – 
3.80 (m, 3H), 3.80 – 3.75 (m, 4H), 3.75 – 3.67 (m, 10H), 3.67 – 3.61 (m, 4H) , 3.61 – 3.37 (m, 
9H), 3.54 – 3.47 (m, 2H), 3.18 – 3.12 (m, 2H), 1.61 – 1.52 (m, 2H), 1.52 – 1.44 (m, 2H), 1.38 
– 1.30 (m, 2H); 13C NMR (151 MHz, Chloroform-d) δ 165.81, 165.58, 165.48, 165.37, 
156.34, 138.50, 138.44, 138.40, 138.27, 138.22, 137.91, 137.62, 137.54, 137.51, 137.48, 
136.66, 133.27, 133.22, 129.97, 129.92, 129.87, 129.82, 128.61, 128.53, 128.45, 128.33, 




127.33, 127.31, 127.26, 127.20, 127.07, 127.04, 127.00, 126.82, 98.51, 98.46, 98.37, 98.13, 
98.09, 97.84, 78.56, 78.27, 78.17, 77.66, 77.25, 77.20, 77.04, 76.99, 76.83, 76.78, 75.14, 
75.06, 75.01, 74.96, 74.18, 73.88, 73.77, 73.69, 73.53, 73.49, 72.07, 71.61, 71.38, 71.30, 
71.26, 71.16, 70.96, 70.87, 70.71, 69.04, 68.54, 68.42, 68.34, 68.14, 67.74, 66.51, 66.08, 
65.77, 65.70, 65.52, 65.41, 61.81, 40.92, 29.74, 29.01, 23.40; m/z (HRMS+) 2817.099 [M + 
H + K]2+ (C337H332NO75K requires 2817.096). 
 
 
Deprotection of 52b (22.2 mg, 4.0 µmol) as reported is Section 3.5 (Module F and G) 
followed by purification using preparative HPLC afforded the compound d-52b (6.3 mg, 
77%). 
Analytical data for d-52b: 1H NMR (700 MHz, Deuterium Oxide) δ 4.84 (d, J = 1.5 
Hz, 1H), 4.83 (d, J = 1.7 Hz, 10H), 4.79 (d, J = 1.7 Hz, 1H), 3.93 – 3.90 (m, 10H), 3.90 – 3.84 
(m, 12H), 3.82 (dd, J = 12.2, 2.1 Hz, 1H), 3.80 – 3.74 (m, 20H), 3.74 – 3.68 (m, 14H), 3.68 – 
3.62 (m, 14H), 3.58 (t, J = 9.7 Hz, 2H), 3.49 (dt, J = 10.0, 6.1 Hz, 1H), 2.93 (t, J = 7.7 Hz, 
2H), 1.65 – 1.56 (m, 4H), 1.38 (dh, J = 29.2, 7.3 Hz, 2H); 13C NMR (176 MHz, Deuterium 
Oxide) δ 99.90, 99.35, 72.72, 70.84, 70.70, 70.55, 69.99, 67.63, 66.76, 66.60, 65.52, 60.94, 







Synthesis of α(1-6) icosamannoside, 52c 
 
 
 Module Conditions 
 A: Resin Preparation for Synthesis   
20 { 
B: Acidic Wash with TMSOTf Solution  
C: Thioglycoside Glycosylation BB 37, 6.5 eq (-20° for 5 min, 0° for 20 min) 
D: Fmoc Deprotection  
 
Cleavage from the solid support as described in Post-synthesizer manipulation 
followed by purification using preparative HPLC afforded compound 52c (38 mg, 33%). 
Analytical data for 52c: 1H NMR (600 MHz, Chloroform-d) δ 8.22 – 8.20 (m, 2H), 
8.20 – 8.12 (m, 32H), 8.12 – 8.09 (m, 3H), 8.08 – 8.04 (m, 5H), 8.01 – 7.97 (m, 4H), 7.60 – 
7.55 (m, 4H), 7.55 – 7.41 (m, 56H), 7.39 – 7.26 (m, 26H), 7.26 – 7.20 (m, 24H), 7.20 – 7.09 
(m, 109H), 7.09 – 7.00 (m, 40H),  5.86 – 5.81 (m, 12H), 5.81 – 5.77 (m, 3H), 5.76 (t, J = 2.4 
Hz, 1H), 5.65 (d, J = 8.2 Hz, 2H), 5.63 – 5.60 (m, 6H), 5.51 (t, J = 9.6 Hz, 2H), 5.47 (d, J = 
5.5 Hz, 1H), 5.35 – 5.29 (m, 2H), 5.20 – 5.13 (m, 3H), 5.11 – 5.04 (m, 6H), 5.03 (s, 6H), 4.90 
– 4.84 (m, 14H), 4.81 – 4.76 (m, 14H), 4.71 (d, J = 11.5 Hz, 3H), 4.68 – 4.64 (m, 2H), 4.64 – 
4.58 (m, 7H), 4.58 – 4.53 (m, 4H), 4.49 – 4.43 (m, 5H), 4.43 – 4.37 (m, 14H), 4.37 – 4.26 (m, 
17H), 4.21 (td, J = 12.6, 4.7 Hz, 5H), 4.18 – 4.13 (m, 2H), 4.13 – 4.05 (m, 7H), 4.05 – 3.91 
(m, 30H), 3.91 – 3.87 (m, 3H), 3.86 – 3.80 (m, 5H), 3.80 – 3.63 (m, 24H), 3.62 – 3.51 (m, 
15H), 3.41 (t, J = 9.7 Hz, 14H), 3.17 – 3.13 (m, 2H), 1.60 – 1.52 (m, 2H), 1.49 (p, J = 7.5 Hz, 
2H), 1.37 – 1.31 (m, 2H); 13C NMR (151 MHz, Chloroform-d) δ 170.77, 170.74, 170.66, 
170.63, 169.56, 169.32, 169.27, 169.26, 169.25, 169.07, 168.98, 168.75, 165.83, 165.50, 




133.30, 133.24, 129.96, 129.88, 129.83, 128.62, 128.48, 128.46, 128.43, 128.34, 128.31, 
128.27, 128.19, 128.10, 128.02, 127.98, 127.95, 127.82, 127.78, 127.66, 127.60, 127.48, 
127.39, 127.33, 127.26, 127.20, 127.05, 126.97, 99.30, 98.50, 98.37, 98.21, 98.12, 97.84, 
91.97, 91.74, 91.56, 89.49, 89.24, 82.87, 80.82, 79.95, 78.57, 78.47, 78.16, 77.81, 77.65, 
77.22, 77.01, 76.80, 75.15, 74.96, 74.76, 74.18, 73.87, 73.67, 73.46, 73.35, 73.19, 72.99, 
72.89, 72.80, 72.15, 72.07, 71.76, 71.61, 71.51, 71.26, 71.16, 70.85, 70.70, 70.31, 70.25, 
70.15, 70.03, 69.27, 69.10, 69.01, 68.53, 68.34, 67.74, 67.66, 66.52, 66.07, 65.68, 65.40, 
63.07, 61.77, 61.46, 40.93, 29.74, 29.01, 23.41, 20.87, 20.75, 20.73, 20.69, 20.59, 20.50; m/z 
(MALDI-TOF) 9201.212 [M + Na]+ (C553H539N1O124Na requires 9199.579). 
 
Deprotection of 52c (15.1 mg, 1.6 µmol) as reported is Section 3.5 (Module F and G) 
followed by purification using preparative HPLC afforded compound d-52c (3.1 mg, 57%). 
Analytical data for d-52c: 1H NMR (700 MHz, Deuterium Oxide) δ 4.83 (d, J = 1.6 
Hz, 19H), 4.79 (d, J = 1.6 Hz, 1H), 3.94 – 3.90 (m, 18H), 3.87 (m, 20H), 3.82 (dd, J = 12.2, 
2.1 Hz, 2H), 3.77 (m, 36H), 3.70 (m, 20H), 3.68 – 3.62 (m, 23H), 3.59 (d, J = 9.7 Hz, 1H), 
3.58 – 3.55 (m, 1H), 3.52 – 3.46 (m, 1H), 2.95 – 2.89 (m, 2H), 1.65 – 1.56 (m, 4H), 1.38 (dh, 
J = 28.4, 7.3 Hz, 2H). 13C NMR (176 MHz, Deuterium Oxide) δ 171.02, 99.90, 99.35, 70.84, 
70.70, 69.98, 66.60, 65.51, 60.94; m/z (HRMS+) 1673.588 [M + 2H]2+ (C125H215NO101 
requires 1673.587). 






 Module Conditions 
 A: Resin Preparation for Synthesis   
50 { 
B: Acidic Wash with TMSOTf Solution  
C: Thioglycoside Glycosylation BB 37, 6.5 eq (-20° for 5 min, 0° for 20 min) 
E: Capping  
D: Fmoc Deprotection  
 
Cleavage from the solid support as described in Post-synthesizer manipulation 
followed by purification using preparative HPLC afforded compound 60 (64 mg, 22%). 
Analytical data for 37: 1H NMR (700 MHz, Chloroform-d) δ 8.21 – 8.17 (m, 100H), 
7.54 – 7.48 (m, 125H), 7.25 – 7.06 (m, 530), 5.87 – 5.84 (m, 50H), 5.06 (s, 50H), 4.89 (d, J = 
11.5 Hz, 50H), 4.80 (d, J = 10.9 Hz, 50H), 4.44 (d, J = 10.9 Hz, 50H), 4.36 (t, J = 11.2 Hz, 
50H), 4.04 (dd, J = 9.3, 3.1 Hz, 50H), 3.99 (t, J = 9.5 Hz, 50H), 3.75 (d, J = 10.6 Hz, 50H), 
3.60 (d, J = 9.7 Hz, 50H), 3.45 (d, J = 11.1 Hz, 50H), 3.15 – 3.13 (m, 2H), 1.58 – 1.52 (m, 
2H), 1.49 (m, 2H), 1.35 – 1.31 (m, 2H). 13C NMR (176 MHz, CDCl3) δ 165.54, 138.53, 
138.48, 137.51, 133.31, 130.01, 129.86, 128.65, 128.49, 128.36, 128.34, 128.14, 128.01, 
127.68, 127.64, 127.37, 127.30, 127.24, 127.09, 127.01, 98.55, 78.20, 77.21, 77.02, 76.84, 
75.18, 75.00, 73.71, 71.30, 70.90, 68.39, 65.73, 29.72. 




 Module Conditions 
 A: Resin Preparation for Synthesis   
6 { 
B: Acidic Wash with TMSOTf Solution  





D: Fmoc Deprotection  
 
Cleavage from the solid support as described in Post-synthesizer manipulation 
followed by purification using preparative HPLC afforded 53a (17.2 mg, 45%). 
Analytical data for 53a: 1H NMR (600 MHz, Chloroform-d) δ 8.29 – 8.22 (m, 6H), 
8.20 (d, J = 7.7 Hz, 2H), 8.14 – 8.08 (m, 4H), 8.07 (d, J = 7.9 Hz, 2H), 8.03 (d, J = 8.0 Hz, 
1H), 8.01 – 7.92 (m, 6H), 7.90 – 7.86 (m, 2H), 7.53 – 7.43 (m, 4H), 7.42 – 7.20 (m, 22H), 
7.20 – 6.99 (m, 21H), 6.99 – 6.94 (m, 2H), 6.93 – 6.85 (m, 5H), 6.85 – 6.73 (m, 4H), 6.73 – 
6.64 (m, 5H), 6.61 (t, J = 7.4 Hz, 1H), 6.53 (t, J = 7.5 Hz, 2H), 6.50 – 6.44 (m, 4H), 6.41 (t, J 
= 7.5 Hz, 2H), 6.02 (t, J = 9.6 Hz, 2H), 5.95 (td, J = 9.6, 7.1 Hz, 2H), 5.89 – 5.78 (m, 4H), 
5.72 – 5.60 (m, 3H), 5.53 – 5.43 (m, 3H), 5.31 (d, J = 8.0 Hz, 1H), 5.27 (d, J = 8.1 Hz, 1H), 
5.11 (t, J = 10.5 Hz, 1H), 5.07 – 4.95 (m, 3H), 4.95 – 4.88 (m, 1H), 4.78 (br, 1H), 4.69 – 4.60 
(m, 4H), 4.42 – 4.22 (m, 11H), 4.22 – 4.12 (m, 4H), 4.09 – 3.92 (m, 7H), 3.85 – 3.72 (m, 3H), 
3.71 – 3.65 (m, 2H), 3.63 (d, J = 9.6 Hz, 1H), 3.59 – 3.53 (m, 2H), 3.51 (t, J = 9.5 Hz, 1H), 
3.28 – 3.24 (m, 1H), 3.21 (dd, J = 13.4, 2.6 Hz, 1H), 2.93 (dq, J = 12.5, 6.3 Hz, 2H), 1.68 – 
1.59 (m, 2H), 1.47 – 1.35 (m, 2H), 1.34 – 1.27 (m, 2H); 13C NMR (151 MHz, Chloroform-d) 
δ 165.74, 165.58, 164.95, 164.83, 164.51, 164.30, 156.35, 138.02, 137.52, 137.30, 136.77, 
136.49, 133.04, 132.81, 132.69, 132.51, 132.41, 132.25, 130.45, 130.20, 129.97, 129.92, 
129.78, 129.67, 129.58, 128.96, 128.91, 128.87, 128.47, 128.36, 128.32, 128.24, 128.18, 
128.15, 128.09, 128.04, 127.93, 127.86, 127.82, 127.66, 127.55, 127.40, 104.29, 103.75, 
103.14, 102.55, 101.84, 100.38, 79.75, 79.36, 78.76, 78.57, 76.25, 76.15, 75.86, 75.75, 75.64, 
75.29, 75.16, 75.07, 74.04, 73.61, 73.38, 73.03, 72.89, 72.65, 72.54, 72.39, 69.80, 66.17, 




Deprotection of 37 (7.0 mg, 2.3 µmol) as reported is Section 3.5 (Module F and G) 




Analytical data for 37d: 1H NMR (600 MHz, Deuterium Oxide) δ 4.42 – 4.35 (m, 5H), 
4.33 (d, J = 8.0 Hz, 1H), 4.08 (ddd, J = 11.7, 6.7, 2.1 Hz, 5H), 3.83 – 3.66 (m, 7H), 3.62 – 
3.52 (m, 2H), 3.52 – 3.44 (m, 6H), 3.35 (dq, J = 14.0, 10.4, 9.7 Hz, 11H), 3.26 (t, J = 9.4 Hz, 
1H), 3.18 (t, J = 8.4 Hz, 5H), 3.13 (t, J = 8.5 Hz, 1H), 2.87 (t, J = 7.5 Hz, 2H), 1.54 (dq, J = 
14.1, 7.3, 6.8 Hz, 4H), 1.32 (t, J = 7.8 Hz, 2H); 13C NMR (151 MHz, Deuterium Oxide) δ 
102.93, 102.90, 102.82, 102.14, 75.84, 75.65, 75.59, 75.50, 74.82, 73.00, 72.96, 70.11, 69.54, 
69.38, 68.71, 68.53, 60.64, 39.29, 28.11, 26.34, 22.02; m/z (HRMS+) 1076.427 [M + H]+ 
(C41H74NO31 requires 1076.424). 
 




 Module Conditions 
 A: Resin Preparation for Synthesis   
12 { 
B: Acidic Wash with TMSOTf Solution  
C: Thioglycoside Glycosylation BB 41b, 6.5 eq (-20° for 5 min, 0° for 20 
min) 
D: Fmoc Deprotection  
 
Cleavage from the solid support as described in Post-synthesizer manipulation 
followed by purification using preparative HPLC afforded 53b.  
Analytical data for 53b: 1H NMR (700 MHz, Chloroform-d) δ 8.49 – 8.27 (m, 26H), 
8.27 – 8.19 (m, 13H), 8.14 (d, J = 8.0 Hz, 2H), 8.09 – 7.96 (m, 6H), 7.60 (t, J = 7.4 Hz, 1H), 
7.51 (tq, J = 13.5, 7.1, 6.4 Hz, 11H), 7.46 – 7.29 (m, 35H), 7.28 – 7.12 (m, 18H), 7.08 (dq, J = 
16.0, 7.6 Hz, 12H), 7.02 (d, J = 6.9 Hz, 2H), 6.94 (dt, J = 22.2, 8.7 Hz, 9H), 6.88 (t, J = 7.7 




Hz, 25H), 6.39 (q, J = 7.7 Hz, 4H), 6.20 – 5.79 (m, 22H), 5.75 (t, J = 8.6 Hz, 1H), 5.69 (dt, J 
= 17.6, 8.2 Hz, 3H), 5.62 (d, J = 7.9 Hz, 1H), 5.58 (t, J = 9.0 Hz, 1H), 5.47 (d, J = 8.0 Hz, 
1H), 5.43 (t, J = 8.9 Hz, 2H), 5.39 (dd, J = 8.1, 5.0 Hz, 2H), 5.35 (d, J = 7.9 Hz, 1H), 5.31 (d, 
J = 8.3 Hz, 2H), 5.28 (d, J = 7.7 Hz, 1H), 5.25 – 4.94 (m, 8H), 4.90 – 4.84 (m, 2H), 4.76 – 
4.67 (m, 4H), 4.67 – 4.60 (m, 1H), 4.54 (d, J = 8.7 Hz, 1H), 4.53 – 4.30 (m, 10H), 4.28 (d, J = 
8.8 Hz, 1H), 4.26 – 3.91 (m, 23H), 3.88 (dd, J = 12.4, 6.4 Hz, 3H), 3.76 – 3.66 (m, 4H), 3.67 
– 3.53 (m, 5H), 3.53 – 3.39 (m, 6H), 3.36 (t, J = 7.9 Hz, 3H), 3.28 (dt, J = 22.4, 8.4 Hz, 3H), 
3.18 (d, J = 13.4 Hz, 1H), 3.04 – 2.92 (m, 2H), 1.68 – 1.59 (m, 2H), 1.47 – 1.35 (m, 2H), 1.34 
– 1.27 (m, 2H); 13C NMR (151 MHz, Chloroform-d) δ 165.74, 165.54, 165.42, 165.14, 
164.20, 138.12, 137.56, 137.21, 136.39, 133.02, 132.78, 132.52, 132.19, 130.52, 130.27, 
130.10, 129.80, 129.60, 129.46, 129.31, 129.06, 128.92, 128.86, 128.37, 128.25, 128.17, 
128.13, 128.06, 127.83, 127.78, 127.61, 127.53, 127.46, 104.20, 103.26, 102.75, 101.96, 
100.41, 79.71, 78.77, 76.01, 75.70, 75.41, 75.16, 75.02, 73.51, 73.41, 72.64, 72.45, 72.15, 
69.81, 66.17, 61.74, 41.10, 29.67, 28.72, 23.16; m/z (HRMS+) 2900.971 [M + H + K]2+ 
(C337H308NO87K requires 2900.972). 
 
 
Deprotection of 53b (5.2 mg, 0.9 µmol) as reported is Section 3.5 (Module F and G) 
followed by purification using preparative HPLC afforded the d-53b (0.3 mg, 16%). 
Analytical data for d-53b: 1H NMR (600 MHz, Deuterium Oxide) δ 4.38 (t, J = 8.5 
Hz, 11H), 4.33 (d, J = 8.0 Hz, 1H), 4.09 (d, J = 11.2 Hz, 11H), 3.78 (d, J = 11.8 Hz, 2H), 3.72 
(dd, J = 11.9, 6.0 Hz, 12H), 3.52 – 3.45 (m, 14H), 3.41 (dd, J = 11.8, 6.5 Hz, 3H), 3.35 (p, J = 
9.3 Hz, 20H), 3.27 (d, J = 9.5 Hz, 1H), 3.19 (t, J = 8.4 Hz, 10H), 3.13 (t, J = 8.4 Hz, 1H), 2.87 
(t, J = 7.6 Hz, 2H), 1.61 – 1.43 (m, 4H), 1.33 (d, J = 7.8 Hz, 2H); m/z (HRMS+) 2048.739 [M 
+ H]+ (C77H134NO61 requires 2048.741). 







 Module Conditions 
 A: Resin Preparation for Synthesis   
6 { 
B: Acidic Wash with TMSOTf Solution  
C: Thioglycoside Glycosylation BB 42, 6.5 eq (-20° for 5 min, 0° for 20 min) 
E: Capping  
D: Fmoc Deprotection  
 
Cleavage from the solid support as described in Post-synthesizer manipulation 
followed by purification using preparative HPLC afforded 54 (11.5 mg, 45%). 
Analytical data for 54 (1-4): 1H NMR (600 MHz, Chloroform-d) δ 7.36 – 7.25 (m, 
35H), 7.24 – 7.15 (m, 30H), 6.20 (d, J = 8.5 Hz, 2H), 6.10 (d, J = 9.0 Hz, 1H), 6.06 – 6.00 (m, 
1H), 5.06 (s, 2H), 5.00 (dd, J = 11.8, 5.4 Hz, 2H), 4.95 (d, J = 11.5 Hz, 1H), 4.82 (d, J = 11.1 
Hz, 1H), 4.78 (d, J = 11.4 Hz, 1H), 4.77 – 4.66 (m, 4H), 4.61 – 4.55   (m, 2H), 4.54 – 4.45  
(m, 5H), 4.43 – 4.38 (m, 3H), 4.38 – 4.31 (m, 5H), 4.24 (d, J = 8.2 Hz, 1H), 4.20 (dd, J = 14.4, 
8.3 Hz, 2H), 4.14 – 4.03 (m, 4H), 4.02 – 3.92 (m, 5H), 3.92 – 3.86 (m, 2H), 3.85 – 3.75  (m, 
5H), 3.74 – 3.61 (m, 6H), 3.60 – 3.52 (m, 5H), 3.52 – 3.47  (m, 3H), 3.47– 3.37  (m, 5H), 3.32 
(dd, J = 9.7, 6.6 Hz, 1H), 3.31 – 3.23 (m, 2H), 3.23 – 3.18  (m, 1H), 3.16 – 2.98  (m, 6H), 1.68 
– 1.59 (m, 2H), 1.47 – 1.35 (m, 2H), 1.34 – 1.27 (m, 2H). 13C NMR (151 MHz, cdcl3) δ 
161.59, 156.34, 138.60, 138.34, 137.96, 137.61, 137.51, 137.33, 137.21, 136.61, 128.97, 
128.92, 128.85, 128.70, 128.52, 128.47, 128.29, 128.23, 128.07, 128.03, 127.94, 127.88, 
127.73, 127.68, 127.58, 127.51, 127.41, 127.31, 99.59, 99.43, 98.98, 92.58, 92.58, 92.49, 
80.05, 79.16, 79.06, 78.92, 78.77, 77.99, 77.19, 76.98, 76.77, 75.88, 75.67, 74.94, 74.59, 
74.32, 74.20, 74.11, 74.04, 73.77, 73.59, 73.49, 73.38, 72.51, 71.27, 69.53, 68.14, 67.85, 
66.54, 57.10, 56.88, 40.89, 31.90, 29.67, 29.53, 28.92, 23.18, 22.66; m/z (HRMS+) 3170.578 





Deprotection of 54 (9.0 mg, 2.9 µmol) as reported is Section 3.5 (Module F and G) 
followed by purification using preparative HPLC afforded the d-54 (1.8 mg, 48 %). 
Analytical data for d-54: 1H NMR (600 MHz, Deuterium Oxide) δ 4.46 – 4.40 (m, 
5H), 4.35 (d, J = 7.6 Hz, 1H), 3.80 – 3.76 (m, 3H), 3.76 – 3.66 (m, 5H), 3.66 – 3.47 (m, 19H), 
3.47 – 3.38 (m, 7H), 3.38 – 3.30 (m, 4H), 2.84 (t, J = 7.7 Hz, 2H), 1.97 – 1.88 (m, 18H), 1.53 
(p, J = 7.7 Hz, 2H), 1.50 – 1.42 (m, 2H), 1.26 (d, J = 9.0 Hz, 2H). 13C NMR (151 MHz, 
Deuterium Oxide) δ 174.51, 101.16, 78.84, 74.45, 71.97, 70.03, 60.45, 59.85, 54.96, 39.26, 
27.98, 26.29, 22.03; m/z (HRMS+) 1322.584 [M + H]+ (C53H92N7O31requires 1322.583). 
3.7.3 Synthesis of heteropolymers 




 Module Conditions 
 A: Resin Preparation for Synthesis   
2 { 
B: Acidic Wash with TMSOTf Solution  
C: Thioglycoside Glycosylation BB 41b, 6.5 eq (-20° for 5 min, 0° for 20 min) 
D: Fmoc Deprotection  
 B: Acidic Wash with TMSOTf Solution  
 C: Thioglycoside Glycosylation BB 37, 6.5 eq (-20° for 5 min, 0° for 20 min) 





B: Acidic Wash with TMSOTf Solution  
C: Thioglycoside Glycosylation BB 41b, 6.5 eq (-20° for 5 min, 0° for 20 min) 
D: Fmoc Deprotection  
 
Cleavage from the solid support as described in Post-synthesizer manipulation 
followed by purification using preparative HPLC afforded 56a (15.6 mg, 43%). 
Analytical data for 56a: 1H NMR (400 MHz, Chloroform-d) δ 8.31 – 8.21 (m, 2H), 
8.03 – 7.93 (m, 7H), 7.89 – 7.82 (m, 4H), 7.69 – 7.59 (m, 3H), 7.57 – 7.02 (m, 75H), 6.97 (dd, 
J = 7.2, 2.2 Hz, 2H), 6.86 (dd, J = 7.3, 2.3 Hz, 2H), 5.65 – 5.58 (m, 1H), 5.45 – 5.23 (m, 4H), 
5.18 – 5.04 (m, 3H), 4.85 (d, J = 10.8 Hz, 2H), 4.80 – 4.23 (m, 31H), 4.18 – 4.09 (m, 2H), 
4.05 – 3.85 (m, 5H), 3.85 – 3.26 (m, 20H), 3.08 (s, 1H), 2.89 – 2.74 (m, 2H), 2.44 (s, 1H), 
1.28 – 1.15 (m, 4H), 1.09 – 0.95 (m, 2H); 13C NMR (101 MHz, Chloroform-d) δ 164.98, 
156.26, 138.61, 137.97, 137.82, 136.76, 133.04, 130.40, 129.95, 129.67, 128.79, 128.49, 
128.39, 128.24, 128.15, 128.09, 128.02, 127.96, 127.83, 127.75, 127.56, 127.16, 101.87, 
100.90, 98.05, 83.03, 82.53, 82.11, 75.65, 75.15, 74.80, 74.47, 74.05, 73.66, 70.98, 70.67, 
69.07, 68.38, 66.45, 65.92, 61.55, 40.80, 29.34, 28.76, 23.08; m/z (HRMS+) 2937.180 [M + 
Na]+ (C175H175NO39Na requires 2937.163). 
 
Deprotection of 56a (12.2 mg, 4.1 µmol) as reported is Section 3.5 (Module F and G) 
followed by purification using preparative HPLC afforded the compound d-56a (2.5 mg, 
55%). 
Analytical data for d-56a: 1H NMR (600 MHz, Deuterium Oxide) δ 4.76 (d, J = 1.7 
Hz, 1H), 4.39 (dt, J = 9.0, 7.3 Hz, 4H), 4.33 (d, J = 8.1 Hz, 1H), 4.11 – 4.02 (m, 4H), 3.87 – 
3.43 (m, 19H), 3.40 – 3.31 (m, 9H), 3.31 – 3.23 (m, 1H), 3.23 – 3.16 (m, 4H), 3.13 (dd, J = 
9.1, 8.0 Hz, 1H), 2.85 (t, J = 7.5 Hz, 2H), 1.54 (h, J = 7.5, 7.1 Hz, 4H), 1.32 (p, J = 7.7, 7.3 
Hz, 2H); 13C NMR (151 MHz, Deuterium Oxide) δ 102.90, 102.81, 102.61, 102.16, 99.55, 
75.84, 75.59, 74.88, 73.01, 69.80, 69.42, 66.24, 60.66, 39.35, 28.15, 26.58, 22.06; m/z 









 Module Conditions 
 A: Resin Preparation for Synthesis   
5 { 
B: Acidic Wash with TMSOTf Solution  
C: Thioglycoside Glycosylation BB 41b, 6.5 eq (-20° for 5 min, 0° for 20 min) 
D: Fmoc Deprotection  
 B: Acidic Wash with TMSOTf Solution  
 C: Thioglycoside Glycosylation BB 37, 6.5 eq (-20° for 5 min, 0° for 20 min) 
 D: Fmoc Deprotection  
 
Cleavage from the solid support as described in Post-synthesizer manipulation 
followed by purification using preparative HPLC afforded 57a (16.8 mg, 47%). 
Analytical data for 57a: 1H NMR (600 MHz, Chloroform-d) δ 8.11 – 7.85 (m, 14H), 
7.59 – 6.87 (m, 81H), 5.66 (s, 1H), 5.40 (t, J = 8.7 Hz, 1H), 5.25 (dq, J = 18.1, 8.5 Hz, 3H), 
5.15 (t, J = 8.7 Hz, 1H), 5.05 (s, 3H), 4.89 (d, J = 11.2 Hz, 1H), 4.79 (d, J = 11.3 Hz, 1H), 
4.74 – 4.17 (m, 29H), 4.10 – 3.89 (m, 4H), 3.89 – 3.31 (m, 25H), 3.18 (d, J = 8.8 Hz, 1H), 
2.80 (q, J = 6.8 Hz, 2H), 1.33 – 1.11 (m, 4H), 1.03 (dq, J = 29.5, 7.4, 7.0 Hz, 2H); 13C NMR 
(101 MHz, Chloroform-d) δ 165.38, 165.11, 164.95, 164.88, 156.24, 138.40, 137.93, 137.83, 
137.78, 137.67, 136.80, 133.22, 133.10, 133.02, 132.92, 130.00, 129.92, 129.84, 129.69, 
129.64, 128.51, 128.44, 128.40, 128.35, 128.28, 128.25, 128.23, 128.10, 128.07, 128.01, 
127.95, 127.92, 127.88, 127.80, 127.76, 127.70, 127.67, 127.60, 127.54, 127.43, 127.37, 




75.10, 74.81, 74.67, 74.41, 74.27, 73.87, 73.61, 72.26, 71.22, 69.08, 68.71, 68.59, 68.05, 
66.37, 66.00, 61.84, 40.80, 29.27, 28.68, 23.07; m/z (HRMS+) 2937.180 [M + Na]+ 




Deprotection of 57a (15.1 mg, 5.2 µmol) as reported is Section 3.5 (Module F and G) 
followed by purification using preparative HPLC afforded the compound d-57a (2.8 mg, 
51%). 
Analytical data for d-57a: 1H NMR (600 MHz, Deuterium Oxide) δ 4.76 (d, J = 1.7 
Hz, 1H), 4.39 (dt, J = 7.6, 3.6 Hz, 4H), 4.33 (d, J = 8.0 Hz, 1H), 4.12 – 4.02 (m, 4H), 3.85 
(dd, J = 3.5, 1.7 Hz, 1H), 3.83 – 3.60 (m, 10H), 3.58 – 3.43 (m, 8H), 3.34 (td, J = 9.2, 3.4 Hz, 
10H), 3.18 (t, J = 8.5 Hz, 4H), 3.13 (t, J = 8.5 Hz, 1H), 2.87 (t, J = 7.6 Hz, 2H), 1.54 (dq, J = 
14.1, 7.3, 6.8 Hz, 4H), 1.33 (q, J = 7.9 Hz, 2H); 13C NMR (151 MHz, Deuterium Oxide) δ 
102.93, 102.90, 102.83, 102.14, 99.44, 75.65, 75.50, 74.82, 72.95, 70.50, 70.11, 69.82, 69.37, 
68.69, 66.58, 65.34, 64.98, 64.55, 60.79, 39.29, 28.11, 26.34, 22.02; m/z (HRMS+) 1076.429 
[M + H]+ (C41H74NO31 requires 1076.424). 







 Module Conditions 
 A: Resin Preparation for Synthesis   
6 { 
B: Acidic Wash with TMSOTf Solution  
C: Thioglycoside Glycosylation BB 41b, 6.5 eq (-20° for 5 min, 0° for 20 min) 
D: Fmoc Deprotection  
6 { 
B: Acidic Wash with TMSOTf Solution  
C: Thioglycoside Glycosylation BB 37, 6.5 eq (-20° for 5 min, 0° for 20 min) 
D: Fmoc Deprotection  
 
Cleavage from the solid support as described in Post-synthesizer manipulation 
followed by purification using preparative HPLC afforded 57b (28.8 mg, 41%). 
Analytical data for 57b: 1H NMR (700 MHz, Chloroform-d) δ 8.29 (td, J = 6.7, 1.7 
Hz, 6H), 8.26 – 8.24 (m, 2H), 8.24 – 8.21 (m, 2H), 8.21 – 8.18 (m, 6H), 8.18 – 8.13 (m, 7H), 
8.13 – 8.08 (m, 2H), 8.02 – 7.99 (m, 2H), 7.99 – 7.94 (m, 4H), 7.94 – 7.92 (m, 2H), 7.90 (d, J 
= 7.8 Hz, 2H), 7.63 – 7.59 (m, 1H), 7.58 – 7.54 (m, 4H), 7.54 – 7.38 (m, 12H), 7.46 – 7.38 
(m, 3H), 7.38 – 7.24 (m, 33H), 7.24 – 7.02 (m, 57H), 7.02 – 6.90 (m, 9H), 6.89 – 6.86 (m, 
2H), 6.86 – 6.82 (m, 1H), 6.75 (t, J = 7.7 Hz, 3H), 6.73 – 6.71 (m, 2H), 6.70 – 6.65 (m, 3H), 
6.59 (t, J = 7.5 Hz, 2H), 6.56 – 6.52 (m, 4H), 6.49 (dt, J = 15.2, 7.5 Hz, 3H), 6.08 (dt, J = 
18.8, 9.6 Hz, 2H), 6.00 (t, J = 9.2 Hz, 2H), 5.97 – 5.90 (m, 2H), 5.90 – 5.77 (m, 8H), 5.74 – 
5.61 (m, 4H), 5.58 (d, J = 8.1 Hz, 1H), 5.56 – 5.49 (m, 2H), 5.33 (dd, J = 13.1, 8.0 Hz, 2H), 
5.16 (d, J = 1.7 Hz, 1H), 5.09 – 5.00 (m, 7H), 4.97 (d, J = 1.8 Hz, 1H), 4.94 – 4.86 (m, 6H), 
4.86 – 4.77 (m, 7H), 4.76 – 4.70 (m, 2H), 4.70 – 4.65 (m, 2H), 4.62 (d, J = 11.1 Hz, 1H), 4.59 
(d, J = 8.0 Hz, 1H), 4.54 – 4.50 (m, 2H), 4.50 – 4.37 (m, 11H), 4.37 – 4.27 (m, 9H), 4.27 – 
3.82 (m, 25H), 3.79 – 3.63 (m, 12H), 3.56 (dtt, J = 12.8, 6.8, 3.2 Hz, 8H), 3.49 (dd, J = 11.4, 
3.4 Hz, 1H), 3.45 (dd, J = 11.7, 1.7 Hz, 1H), 3.43 – 3.37 (m, 2H), 3.32 – 3.24 (m, 2H), 3.03 – 
2.87 (m, 2H), 1.75 – 1.63 (m, 2H), 1.50 – 1.39 (m, 2H), 1.34 (dd, J = 14.1, 7.4 Hz, 2H), 13C 
NMR (176 MHz, CDCl3) δ 165.86, 165.80, 165.78, 165.74, 165.70, 165.67, 165.57, 165.53, 
165.50, 165.47, 165.42, 165.39, 165.30, 165.02, 164.85, 164.81, 164.35, 156.40, 138.90, 
138.68, 138.63, 138.55, 138.49, 138.32, 138.18, 137.95, 137.89, 137.69, 137.58, 137.55, 
137.52, 137.48, 137.44, 137.41, 137.05, 136.88, 136.57, 133.29, 133.25, 133.05, 132.96, 
132.86, 132.80, 132.65, 132.50, 132.40, 132.26, 130.46, 130.30, 130.28, 130.20, 130.14, 
130.06, 130.04, 130.01, 129.99, 129.96, 129.91, 129.88, 129.86, 129.84, 129.81, 129.79, 




128.65, 128.59, 128.50, 128.46, 128.43, 128.41, 128.38, 128.37, 128.33, 128.29, 128.25, 
128.23, 128.21, 128.18, 128.13, 128.08, 128.07, 128.05, 128.01, 127.99, 127.96, 127.94, 
127.88, 127.85, 127.81, 127.78, 127.69, 127.65, 127.62, 127.60, 127.55, 127.50, 127.41, 
127.36, 127.34, 127.20, 127.15, 127.10, 127.05, 126.96, 126.92, 126.87, 104.08, 103.66, 
103.34, 102.59, 101.86, 100.44, 98.64, 98.55, 98.52, 98.20, 97.69, 79.86, 79.41, 79.35, 78.99, 
78.80, 78.70, 78.29, 78.20, 78.19, 78.15, 77.70, 76.32, 76.25, 75.92, 75.75, 75.38, 75.18, 
75.12, 75.10, 75.05, 74.99, 74.96, 74.93, 74.89, 74.85, 74.10, 73.91, 73.80, 73.73, 73.68, 
73.66, 73.61, 73.47, 73.11, 73.06, 73.02, 72.76, 72.53, 72.45, 72.36, 72.11, 71.62, 71.33, 
71.26, 71.23, 71.20, 71.17, 70.95, 70.89, 70.82, 70.79, 69.86, 68.57, 68.46, 68.37, 68.32, 
68.25, 66.32, 66.18, 66.11, 65.80, 65.65, 65.42, 61.85, 41.10, 29.12, 28.77, 23.14; m/z 
(HRMS+) 2862.556 [M + 2Na]2+ (C337H319NO81Na2 requires 2862.538). 
 
 
Deprotection of 57b (19.2 mg, 3.4 µmol) as reported is Section 3.5 (Module F and G) 
followed by purification using preparative HPLC afforded the d-57b (3.5 mg, 52%). 
Analytical data for d-57b: 1H NMR (700 MHz, Deuterium Oxide) δ 4.86 – 4.80 (m, 
6H), 4.45 (td, J = 6.9, 3.6 Hz, 5H), 4.40 (d, J = 8.0 Hz, 1H), 4.18 – 4.11 (m, 6H), 3.92 (pd, J = 
4.7, 3.8, 1.8 Hz, 6H), 3.86 (dt, J = 9.5, 3.4 Hz, 6H), 3.82 (dd, J = 12.2, 2.1 Hz, 1H), 3.77 (dtd, 
J = 17.1, 8.7, 8.2, 4.4 Hz, 14H), 3.73 – 3.68 (m, 7H), 3.65 (dddd, J = 18.2, 8.5, 6.9, 3.9 Hz, 
6H), 3.59 (d, J = 9.8 Hz, 1H), 3.58 – 3.51 (m, 7H), 3.45 – 3.36 (m, 13H), 3.25 (td, J = 8.6, 
7.9, 2.2 Hz, 6H), 3.19 (t, J = 8.6 Hz, 1H), 2.94 (t, J = 7.6 Hz, 2H), 1.61 (dt, J = 16.0, 7.8 Hz, 
4H), 1.39 (p, J = 7.7 Hz, 2H); 13C NMR (176 MHz, Deuterium Oxide) δ 103.01, 102.91, 
102.23, 99.54, 99.41, 99.28, 75.90, 75.74, 75.59, 75.01, 74.90, 73.91, 73.04, 72.72, 70.84, 
70.78, 70.70, 70.55, 70.19, 69.99, 69.47, 68.80, 68.66, 66.76, 66.61, 65.62, 65.52, 65.24, 
60.94, 39.37, 28.19, 26.42, 22.10; m/z (HRMS+) 2048.743 [M + H]+ (C77H134NO61 requires 
2048.741). 







 Module Conditions 
 A: Resin Preparation for Synthesis   
6 { 
B: Acidic Wash with TMSOTf Solution  
C: Thioglycoside Glycosylation BB 41b, 6.5 eq (-20° for 5 min, 0° for 20 min) 
D: Fmoc Deprotection  
 B: Acidic Wash with TMSOTf Solution  
 C: Thioglycoside Glycosylation BB 37, 6.5 eq (-20° for 5 min, 0° for 20 min) 
 D: Fmoc Deprotection  
5 { 
B: Acidic Wash with TMSOTf Solution  
C: Thioglycoside Glycosylation BB 41b, 6.5 eq (-20° for 5 min, 0° for 20 min) 
D: Fmoc Deprotection  
 
Cleavage from the solid support as described in Post-synthesizer manipulation 
followed by purification using preparative HPLC afforded 56b (21 mg, 29%).  
Analytical data for 56b: 1H NMR (600 MHz, Chloroform-d) δ 8.35 – 8.26 (m, 2H), 
8.21 (dd, J = 19.2, 7.7 Hz, 12H), 8.17 – 7.95 (m, 28H), 7.96 – 7.82 (m, 7H), 7.74 (q, J = 10.0, 
9.6 Hz, 9H), 7.57 (q, J = 5.0 Hz, 2H), 7.55 – 7.27 (m, 39H), 7.22 – 6.34 (m, 86H), 6.16 – 6.00 
(m, 4H), 6.00 – 5.73 (m, 10H), 5.73 – 5.15 (m, 16H), 5.01 (d, J = 9.0 Hz, 8H), 4.90 (t, J = 
10.3 Hz, 3H), 4.84 – 4.43 (m, 16H), 4.43 – 3.42 (m, 49H), 3.39 – 3.18 (m, 6H), 2.91 (br, 4H), 
1.64 – 1.59 (m, 2H), 1.46 – 1.34 (m, 2H), 1.33 – 1.26 (m, 2H); 13C NMR (151 MHz, 
Chloroform-d) δ 166.14, 165.83, 165.74, 165.66, 165.49, 165.47, 165.44, 165.12, 165.05, 
164.86, 164.60, 164.56, 164.45, 138.94, 138.64, 138.13, 138.00, 137.90, 137.55, 137.50, 




130.51, 130.39, 130.19, 130.14, 130.06, 130.00, 129.92, 129.89, 129.85, 129.80, 129.79, 
129.74, 129.66, 129.57, 129.53, 129.07, 128.80, 128.76, 128.64, 128.58, 128.51, 128.37, 
128.34, 128.30, 128.22, 128.19, 128.17, 128.14, 128.12, 128.02, 127.99, 127.96, 127.92, 
127.88, 127.84, 127.80, 127.75, 127.73, 127.67, 127.61, 127.60, 127.57, 127.40, 127.31, 
126.95, 126.79, 126.58, 104.83, 103.62, 102.40, 102.15, 101.73, 100.42, 79.20, 79.14, 79.06, 
78.36, 76.27, 76.13, 75.97, 75.81, 75.66, 75.53, 75.36, 75.18, 75.13, 74.98, 74.77, 74.13, 
73.74, 73.65, 73.31, 73.19, 73.02, 72.91, 72.77, 72.47, 72.28, 72.05, 71.36, 69.78, 66.14, 





Deprotection of 56b (11.0 mg, 1.9 µmol) as reported is Section 3.5 (Module F and G) 
followed by purification using preparative HPLC afforded the compound d-56b (2.7 mg, 
68%). 
Analytical data for d-56b: 1H NMR (600 MHz, Deuterium Oxide) δ 4.77 (d, J = 1.7 
Hz, 1H), 4.44 – 4.37 (m, 10H), 4.34 (d, J = 8.0 Hz, 1H), 4.08 (td, J = 11.4, 7.7 Hz, 11H), 3.91 
– 3.64 (m, 16H), 3.63 – 3.53 (m, 2H), 3.49 (q, J = 7.1 Hz, 11H), 3.41 – 3.30 (m, 22H), 3.27 
(q, J = 10.4, 9.5 Hz, 1H), 3.20 (ddt, J = 10.5, 8.5, 3.5 Hz, 10H), 3.13 (t, J = 8.5 Hz, 1H), 2.88 
(t, J = 7.6 Hz, 2H), 1.55 (dt, J = 14.8, 7.5 Hz, 4H), 1.32 (p, J = 7.8 Hz, 2H); 13C NMR (151 
MHz, Deuterium Oxide) δ 102.99, 102.94, 102.90, 102.82, 102.61, 102.15, 99.54, 75.84, 
75.80, 75.66, 75.59, 75.51, 75.40, 74.86, 74.82, 73.88, 73.01, 72.97, 71.60, 70.42, 70.12, 
69.55, 69.39, 69.28, 68.72, 68.41, 66.27, 65.32, 60.66, 39.30, 28.12, 26.35, 22.03; m/z 
(HRMS+) 2048.738 [M + H]+ (C77H134NO61 requires 2048.741). 
 
 






 Module Conditions 
 A: Resin Preparation for Synthesis   
6 { 
B: Acidic Wash with TMSOTf Solution  
C: Thioglycoside Glycosylation BB 37, 6.5 eq (-20° for 5 min, 0° for 20 min) 
D: Fmoc Deprotection  
 B: Acidic Wash with TMSOTf Solution  
 C: Thioglycoside Glycosylation BB 44, 6.5 eq (-20° for 5 min, 0° for 20 min) 
 D: Fmoc Deprotection  
5 { 
B: Acidic Wash with TMSOTf Solution  
C: Thioglycoside Glycosylation BB 37, 6.5 eq (-20° for 5 min, 0° for 20 min) 
D: Fmoc Deprotection  
 
Cleavage from the solid support as described in Post-synthesizer manipulation 
followed by purification using preparative HPLC afforded 58 (25.5 mg, 37%). 
Analytical data for 58: 1H NMR (600 MHz, Chloroform-d) δ 8.19 – 8.02 (m, 28H), 
7.57 (t, J = 7.4 Hz, 1H), 7.53 – 7.39 (m, 34H), 7.39 – 6.94 (m, 117H), 5.87 – 5.72 (m, 10H), 
5.61 (t, J = 2.4 Hz, 1H), 5.17 (d, J = 1.8 Hz, 1H), 5.12 – 4.97 (m, 11H), 4.96 – 4.65 (m, 29H), 
4.62 – 4.26 (m, 27H), 4.12 – 3.33 (m, 57H), 3.16 (q, J = 7.0 Hz, 2H), 1.71 (s, 3H), 1.58 (tt, J 
= 14.1, 7.0 Hz, 2H), 1.52 – 1.43 (m, 2H), 1.34 (dt, J = 8.9, 3.5 Hz, 2H); 13C NMR (151 MHz, 
Chloroform-d) δ 170.61, 165.82, 165.58, 165.53, 165.50, 165.47, 165.43, 165.41, 165.37, 
138.52, 138.50, 138.46, 138.44, 138.42, 138.40, 138.34, 138.28, 138.22, 137.97, 137.92, 
137.69, 137.63, 137.61, 137.58, 137.54, 137.51, 137.47, 137.44, 137.33, 133.25, 133.21, 




128.54, 128.48, 128.45, 128.41, 128.35, 128.34, 128.31, 128.29, 128.27, 128.26, 128.22, 
128.19, 128.14, 128.12, 128.10, 128.07, 128.05, 128.01, 127.99, 127.97, 127.75, 127.66, 
127.64, 127.60, 127.58, 127.39, 127.32, 127.29, 127.27, 127.23, 127.18, 127.15, 127.06, 
127.03, 127.01, 126.95, 99.59, 98.77, 98.50, 98.45, 98.40, 98.14, 98.10, 97.85, 79.49, 78.56, 
78.35, 78.26, 78.20, 78.17, 78.14, 78.10, 78.05, 77.65, 75.30, 75.14, 75.10, 75.05, 75.02, 
74.95, 74.92, 74.78, 74.18, 73.88, 73.84, 73.78, 73.68, 73.15, 72.06, 71.69, 71.61, 71.43, 
71.38, 71.29, 71.26, 71.22, 71.16, 71.13, 71.04, 70.99, 70.93, 70.90, 70.84, 70.71, 69.98, 
69.05, 68.76, 68.55, 68.52, 68.43, 68.36, 68.30, 67.74, 66.51, 66.42, 66.30, 66.07, 65.76, 
65.68, 65.62, 65.36, 64.34, 62.72, 61.80, 40.93, 29.75, 29.01, 23.41, 20.60;m/z (HRMS+) 
2789.100 [M + 2Na]2+ (C332H329NO75Na2 requires 2789.093). 
 
 
Deprotection of 58 (17.5 mg, 2.5 µmol) as reported is Section 3.5 (Module F and G) 
followed by purification using preparative HPLC afforded the compound d-58 (3.4 mg, 64%). 
Analytical data for d-58: 1H NMR (600 MHz, Deuterium Oxide) δ 4.97 – 4.93 (m, 
1H), 4.90 (d, J = 1.7 Hz, 1H), 4.77 (qd, J = 6.1, 5.7, 1.4 Hz, 9H), 4.72 (d, J = 1.6 Hz, 1H), 
3.94 (dd, J = 3.5, 1.7 Hz, 1H), 3.91 – 3.75 (m, 30H), 3.75 – 3.48 (m, 42H), 3.43 (dt, J = 9.9, 
6.1 Hz, 1H), 2.87 (t, J = 7.7 Hz, 2H), 1.55 (dp, J = 21.6, 7.5 Hz, 4H), 1.32 (dq, J = 15.2, 7.4, 
6.9 Hz, 2H); 13C NMR (151 MHz, Deuterium Oxide) δ 102.11, 99.82, 99.23, 97.92, 78.79, 
72.78, 72.78, 72.65, 70.99, 70.85, 70.76, 70.61, 70.47, 70.40, 70.14, 69.91, 67.55, 66.68, 
66.52, 65.83, 65.45, 60.87, 39.30, 27.97, 26.50, 22.47; m/z (HRMS+) 2048.742 [M + H]+ 
(C77H134NO61 requires 2048.741). 







 Module Conditions 
 A: Resin Preparation for Synthesis   
5 { 
B: Acidic Wash with TMSOTf Solution  
C: Thioglycoside Glycosylation BB 37, 6.5 eq (-20° for 5 min, 0° for 20 min) 
D: Fmoc Deprotection  
 B: Acidic Wash with TMSOTf Solution  
C: Thioglycoside Glycosylation BB 45, 6.5 eq (-20° for 5 min, 0° for 20 min) 
D: Fmoc Deprotection  
 
Cleavage from the solid support as described in Post-synthesizer manipulation 
followed by purification using preparative HPLC afforded 59a (23.5 mg, 63%). 
Analytical data for 59a: 1H NMR (600 MHz, Chloroform-d) δ 8.16 – 8.08 (m, 12H), 
7.59 – 7.53 (m, 1H), 7.51 – 7.41 (m, 18H), 7.33 – 7.01 (m, 64H), 5.83 – 5.74 (m, 5H), 5.61 
(dd, J = 3.3, 1.8 Hz, 1H), 5.10 – 4.99 (m, 7H), 4.89 – 4.83 (m, 6H), 4.81 (dd, J = 11.3, 2.6 Hz, 
3H), 4.77 (d, J = 11.0 Hz, 4H), 4.70 (d, J = 11.4 Hz, 1H), 4.63 (d, J = 11.1 Hz, 1H), 4.54 (d, J 
= 11.0 Hz, 1H), 4.45 (dd, J = 11.1, 4.8 Hz, 2H), 4.43 – 4.38 (m, 5H), 4.37 (d, J = 11.5 Hz, 
1H), 4.35 – 4.29 (m, 2H), 4.18 (d, J = 16.4 Hz, 1H), 4.06 (ddd, J = 9.5, 6.3, 3.3 Hz, 2H), 4.03 
– 3.92 (m, 12H), 3.89 – 3.68 (m, 9H), 3.67 (s, 3H), 3.66 – 3.53 (m, 5H), 3.51 – 3.41 (m, 3H), 
3.39 (d, J = 9.2 Hz, 1H), 3.14 (t, J = 7.3 Hz, 2H), 1.57 – 1.45 (m, 4H), 1.38 – 1.28 (m, 2H); 
13C NMR (151  MHz, Chloroform-d) δ 170.56, 165.81, 165.57, 165.49, 156.33, 138.55, 
138.50, 138.47, 138.41, 138.22, 137.90, 137.61, 137.59, 137.55, 137.53, 137.51, 136.64, 
133.25, 133.11, 130.00, 129.96, 129.91, 129.82, 129.79, 128.60, 128.53, 128.45, 128.39, 
128.31, 128.29, 128.26, 128.24, 128.22, 128.18, 128.15, 128.13, 128.11, 128.09, 128.07, 




127.10, 127.08, 98.44, 98.37, 98.22, 98.10, 97.84, 78.56, 78.27, 78.22, 78.18, 78.13, 77.70, 
75.14, 75.01, 74.97, 74.17, 73.88, 73.79, 73.71, 73.67, 71.86, 71.60, 71.38, 71.30, 71.26, 
71.13, 70.94, 70.71, 69.95, 69.04, 68.82, 68.54, 68.46, 68.41, 68.35, 67.74, 66.51, 66.07, 
65.78, 65.72, 65.66, 65.61, 51.63, 40.92, 29.74, 29.00, 23.40; m/z (HRMS+) 3009.184 [M + 
Na]+ (C178H179NO41Na requires 3009.185). 
 
Deprotection of 59a (17.3 mg, 5.7 µmol) as reported is Section 3.5 (Module F and G 
and H) followed by purification using preparative HPLC afforded the compound p-59a (4.3 
mg, 57%).  
Analytical data for p-59a: 1H NMR (400 MHz, Deuterium Oxide) δ 7.28 – 7.10 (m, 
5H), 4.90 (s, 2H), 4.67 (t, J = 3.7 Hz, 6H), 3.91 (s, 2H), 3.79 – 3.68 (m, 12H), 3.68 – 3.42 (m, 
25H), 3.36 - 3.28 (m, 1H), 2.92 (d t, J = 7.6 Hz, 2H, 2H), 1.44 – 1.35 (m, 2H), 1.29 (q, J = 7.1 
Hz, 2H), 1.19 – 1.10 (m, 2H); 13C NMR (101 MHz, Deuterium Oxide) δ 128.62, 128.16, 
127.43, 99.72, 99.23, 99.15, 71.08, 70.74, 70.67, 70.50, 70.24, 69.93, 69.79, 69.67, 67.66, 
66.59, 66.39, 65.29, 40.12, 28.40, 27.96, 22.52; m/z (HRMS+)1268.476 [M + H]+ 
(C51H82NO35 requires 1268.466). 







Deprotection of p-59a (20.1 mg, 7.0 µmol) as reported is Section 3.5 (Module F and 
G) followed by purification using preparative HPLC afforded the d-59a (3.7 mg, 46%).  
Analytical data for d-59a: 1H NMR (400 MHz, Deuterium Oxide) δ 4.81 – 4.73 (m, 
6H), 4.16 (s, 2H), 3.90 – 3.77 (m, 12H), 3.75 – 3.51 (m, 25H), 3.65 (s, 3H), 3.44 (dt, J = 9.8, 
6.0 Hz, 1H), 2.87 (t, J = 7.6 Hz, 2H), 1.54 (dq, J = 9.5, 7.4, 6.8 Hz, 4H), 1.41 – 1.23 (m, 2H); 
13C NMR (101 MHz, Deuterium Oxide) δ 172.84, 99.82, 99.22, 70.67, 70.57, 69.87, 67.89, 
67.53, 66.47, 65.38, 52.32, 39.26, 27.95, 26.49, 22.46; m/z (HRMS+) 1148.447 [M + H]+ 
(C44H78NO33 requires 1148.445). 
 




 Module Conditions 
 A: Resin Preparation for Synthesis   
11 { 
B: Acidic Wash with TMSOTf Solution  
C: Thioglycoside Glycosylation BB 37, 6.5 eq (-20° for 5 min, 0° for 20 min) 
D: Fmoc Deprotection  
 B: Acidic Wash with TMSOTf Solution  
C: Thioglycoside Glycosylation BB 45, 6.5 eq (-20° for 5 min, 0° for 20 min) 
D: Fmoc Deprotection  
 
Cleavage from the solid support as described in Post-synthesizer manipulation 




Analytical data for 59b: 1H NMR (700 MHz, Chloroform-d) δ 8.22 – 8.11 (m, 25H), 
7.60 (t, J = 7.5 Hz, 1H), 7.56 – 7.46 (m, 38H), 7.37 – 7.30 (m, 7H), 7.26 (ddd, J = 8.0, 6.4, 4.5 
Hz, 9H), 7.24 – 7.05 (m, 105H), 5.89 – 5.77 (m, 11H), 5.69 – 5.60 (m, 1H), 5.10 (td, J = 13.9, 
12.5, 1.7 Hz, 5H), 5.08 – 5.04 (m, 8H), 4.90 (td, J = 10.9, 4.3 Hz, 12H), 4.87 – 4.83 (m, 3H), 
4.81 (dt, J = 10.9, 3.6 Hz, 11H), 4.75 (d, J = 11.4 Hz, 1H), 4.68 (d, J = 11.0 Hz, 1H), 4.58 (d, 
J = 11.0 Hz, 1H), 4.49 (dd, J = 11.1, 4.7 Hz, 2H), 4.47 – 4.41 (m, 12H), 4.39 (s, 1H), 4.36 
(dd, J = 11.9, 4.8 Hz, 8H), 4.22 (d, J = 16.4 Hz, 1H), 4.12 – 4.07 (m, 3H), 4.07 – 4.02  (m, 
12H), 3.99 – 3.92 (m, 10H), 3.95 – 3.83 (m, 4H), 3.83 – 3.73 (m, 11H), 3.71 (s, 3H), 3.68 – 
3.56 (m, 10H), 3.55 – 3.41 (m, 10H), 3.22 – 3.14 (m, 2H), 1.61 – 1.48 (m, 4H), 1.44 – 1.32 
(m, 2H); 13C NMR (151 MHz, Chloroform-d) δ 170.58, 165.85, 165.62, 165.52, 156.37, 
138.60, 138.56, 138.54, 138.53, 138.49, 138.45, 138.27, 137.96, 137.67, 137.64, 137.61, 
137.58, 137.56, 137.54, 136.71, 133.30, 133.27, 133.24, 133.14, 130.03, 129.97, 129.86, 
129.83, 128.64, 128.62, 128.56, 128.50, 128.48, 128.42, 128.35, 128.32, 128.28, 128.25, 
128.21, 128.18, 128.14, 128.10, 128.08, 128.06, 128.04, 128.02, 127.91, 127.77, 127.67, 
127.63, 127.56, 127.46, 127.42, 127.36, 127.34, 127.32, 127.30, 127.28, 127.25, 127.20, 
127.12, 127.08, 127.05, 98.56, 98.51, 98.42, 98.28, 98.14, 97.88, 78.60, 78.31, 78.25, 78.23, 
78.20, 77.75, 75.17, 75.05, 75.01, 74.23, 73.93, 73.83, 73.77, 73.75, 73.71, 71.92, 71.65, 
71.42, 71.34, 71.30, 71.18, 71.01, 70.98, 70.93, 70.76, 70.63, 70.01, 69.10, 68.87, 68.60, 
68.52, 68.48, 68.44, 68.40, 67.78, 66.54, 66.13, 65.83, 65.75, 65.70, 65.65, 64.36, 60.39, 




Deprotection of 59b (10.3 mg, 1.8 µmol) as reported is Section 3.5 (Module F and G 
and H) followed by purification using preparative HPLC afforded the d-59b (1.4 mg, 35%).  
Analytical data for d-59b: 1H NMR (600 MHz, Deuterium Oxide) δ 7.32 – 7.18 (m, 




3.36 (m, 1H), 2.99 (t, J = 6.7 Hz, 2H), 1.54 – 1.41 (m, 2H), 1.37 (t, J = 7.2 Hz, 2H), 1.28 – 
1.17 (m, 2H); 13C NMR (151 MHz, Deuterium Oxide) δ 128.72, 99.27, 71.24, 70.77, 70.62, 







4 Synthesis of Glycosaminoglycans 
4.1 Introduction 
Glycosaminoglycans (GAGs) are involved in many fundamental biological processes, 
such as cell recognition, cell proliferation and differentiation.141-144 They are linear polymers 
comprised of disaccharide repeating units consisting of a hexuronic acid (generally, 
glucuronic or iduronic) linked to hexosamine (galactosamine or glucosamine).141 Depending 
on the nature of disaccharide repeating units, GAGs are classified into several major types: 
keratan sulfate, chondroitin sulfate, dermatan sulfate, hyaluronic acid and heparan sulfate 
(Figure 11).  
 
 
Figure 12. Types of glycosaminoglycans 141 
Heterogeneity in GAGs results from various possible degrees of O-sulfation and, in 
some cases, from the presence of two types of hexuronic acid residues. This 
microheterogeneity complicates biological studies of these polysaccharides and causes 
difficulties in their applications in biology and medicine.145 In order to investigate the mode of 
action of GAGs and determine the structural fragments that are responsible for the 





Several approaches to synthesize GAG oligosaccharides have been described. 
Chemoenzymatic synthesis enables an access to heparin, chondroitin and dermatan sulfate, as 
well as sulfated hyaluron.146 But the number of possible repeating units that can be 
synthesized using this method is limited by the types of available enzymes.   
To date, many methods of solution phase synthesis of GAG oligosaccharides have 
been reported. But most of these methods rely on many manual operations and do not allow 
for rapid access the desired compounds. Recently, automated glycan assembly was employed 
for the synthesis of dermatan, chondroitin and keratan sulfate repeating units.91, 131, 147 
However, most of the methods access only fully-protected oligosaccharides: the global 
deprotection of them remains challenging. The main challenge is the fact that sulfated 
molecules are not stable in highly acidic and basic media, requiring very mild conditions for 
their synthesis. Therefore, new synthetic strategies that would enable the access to fully-
deprotected GAG-oligosaccharide have to be developed.  
Dermatan and chondroitin sulfate repeating units are an interesting target for 
automated glycan assembly. AGA modularity makes it possible to synthesize large collections 
of oligosaccharides. Several chondroitin and dermatan sulfate repeating units have been 
chosen as a synthetic target (Figure 13).  
4.2 Synthetic Strategies to Access GAGs 
In order to access different repeating units comprising dermatan and chondroitin 
sulfates, several building blocks been designed (Figure 13): two galactosamine BBs 62a and 
62b, two iduronic BBs 63 and 64, and one glucuronic acid BB 65. Benzyl ethers (Bn) serve as 
permanent protecting groups. Levulinic ester protecting groups will be selectively cleaved 
before sulfation of the corresponding hydroxides. The fluorenylmethyloxycarbonyl (Fmoc) 







Figure 13. Building blocks required for the synthesis of dermatan and chondroitin 
sulfate repeating units.  
For C-2 position of galactosamine BBs acetyl-protecting group would be a desirable 
option, because it will minimize protecting-group manipulations. But it has been previously 
shown, that for N-acetylaminosugars oxocarbenium ion undergoes rearrangement (Scheme 
37) leading to stabile oxazoline intermediate.148 In order to avoid oxazoline formation, the 
trichloroacetyl (TCA) protecting group should be used. 
 
 





Iduronic acid building blocks have benzoyl ester as a neighboring participating group 
that ensures selective trans-glycoside formation. BB 64 will be the last to install in 
oligosaccharide chain, therefore its C-4 hydroxyl group should be protected in order to avoid 
the sulfation of this position. The protecting group has to be stable in the conditions of 
deprotection of levulinic and benzoyl esters and should be easily cleaved in hydrogenolysis 
process. Therefore, naphtyl ether was chosen as the protecting group for this position. 
Two potential strategies for GAGs synthesis were considered (Scheme 38 and 39). 
The key synthetic step in both of them is radical reduction of trichloroacetyl protecting group 
by tributyltin hydride (Bu3SnH) in the presence of azobisisobutyronitrile (AIBN). In the 
strategy I (Scheme 38) a sulfated glycan is assembled via AGA, and then subjected to 
reduction by Bu3SnH and further global deprotection. The advantage of this strategy is the 
possibility to perform most of the synthetic steps in a glycan synthesizer. 
Strategy II (Scheme 39) implies the assembly of a fully-protected oligosaccharide via 
AGA and further reduction of trichloroacetyl protecting groups by Bu3SnH. Then, 
deprotection and sulfation steps could lead to target oligosaccharides, while all the reactions 

















4.3 Synthesis of Building Blocks 
4.3.1 Synthesis of galactosamine building blocks 
 
Scheme 40. Galactosamine BBs: retrosynthetic analysis. 
Galactosamine building (62a) block was synthesized from glucosamine (Scheme 40) 
via an established protocol.147 First, glucosamine 66 was coupled with p-
methoxybenzaldehyde giving compound 67. Then, after acetylation of all the hydroxyl groups 
and hydrolysis of the imine, the compound was subjected to acetylation by trichloroacetyl 
chloride, resulting in compound 70. The reaction with ethylthiol produces compound 71, basic 
hydrolysis of acetic groups results in compound 72. Then, 72 reacted with benzaldehyde 
dimethyl acetal giving compound 73. Interaction of 73 with levulinic acid anhydrate enables 
to install levulinic ester protecting group on the position C3 of glucosamine. The further 





Scheme 41. Synthesis of glucosamine derivative 75 
The key step in the synthesis of galactosamine derivatives from glucosamine is the 
reaction of levulinic ester migration of from position C3 to C4, accompanied by the inversion 
of configuration of the C4 center. In this reaction compound 75 is firstly treated by Tf2O/Py, 
giving the corresponding triflate. Treatment of xx with water und conditions this triflate 
undergoes the reaction analogous to intramolecular nucleophilic substitution, resulting in 
galactosamine derivative 76. In order to place a Fmoc-protecting group on the position C3, 
compound 76 was treated by FmocCl/Py. The further reaction with (HO)P(O)(OBu)2 results 
in building block 62a in excellent yield.  
 
 





The other galactosamine building block 62b was synthesized via a described protocol 
from  galactose derivative 78.91 Azide 78 was reduced by PPh3, resulting in galactosamine 
derivative 79, that was then treated by trichloroactyl chloride giving 80. Subsequent removal 
of acetyl protecting groups and reaction with benzaldehyde dimethyl acetal yielded 82. 
Installation of a Fmoc-protecting group, selective opening of the benzylidene ring, followed 
by treatment with levulinic acid anhydride gave 85, that was reacted with (HO)P(O)(OBu)2 to 
give final building block 62.  
 
Scheme 43. Synthesis of galactosamine building block 62b 
 
4.3.2 Synthesis of iduronic acid building blocks 
The building blocks 63 and 64 could be synthesized from the protected D-xylose (17) 
(scheme 4). 
 





Compound 86x is oxidized, using Parikh-Doering oxidation conditions149, giving 
aldehyde 87. Further chelate-control diastereoselective cyanation of compound 87 results in 
compound 88 with a moderate yield. In this reaction, MgBr2 is used as a chelating activator 
that furnishes only one diastereomer of 88. Nitrile 88 was then treated by MeOH and 
anhydrous HCl that was generated directly in the reaction mixture from methanol and acetyl 
chloride. As a result of this reaction, ester 89 was obtained. The reaction of this compound 
with NIS results in the mixture of 90a and 90b.  
 
Scheme 45. Synthesis of iduronic acid building blocks. 
 
Scheme 46. Synthesis of iduronic acid building blocks 
The reaction of 90 with a barbituric acid derivative and Pd(PPh3)4 enables the cleavage 
of the allyl group, and the subsequent treatment my BzCl/Py results in the placement of 
benzoyl protecting group on C2 position of iduronic acid, giving compound 92. The reaction 
of this compound with (HO)P(O)(OBu)2 furnishes building block 64 in good yield. Treatment 
of 92 with DDQ enables the selective deprotection of the naphtyl protecting group, giving 
                                                 




compound 93. The further reaction of 93 with FmocCl/Py and subsequent treatment with 
dibutyl phosphate gives building block 63 in good yield.  
4.3.3 Synthesis of glucuronic acid building block 
Glucuronic acid building block was synthesized from compound xxxi using procedure, 
analogous to the one previously described.91 Benzylation of C-2 hydroxide of compound 95, 
followed by removing the benzylidene protecting group resulted in 97. TEMPO-mediated 
oxidation of the C6 hydroxide and esterification of the resulting carboxylic acid gave 98. 
Compound 98 was treated by FmocCl giving 99, the reaction of which with dibutyl phosphate 
gave phosphate glycoside 65. 
 
Scheme 47. Synthesis of glucuronic acid building block 65 
4.4 Testing synthetic strategies to access dermatan sulfate 
With the necessary building blocks in hand, testing of the synthetic strategies were 
tested. Initially, disaccharide 103 was synthesized in solution-phase (Scheme 48). 
 
Scheme 48. Synthesis of disaccharide 103 
                                                 




In order to test the potential applicability Strategy I, disaccharide 103 was first sulfated 
by sulfur trioxide pyridine complex, giving compound 104. Then, it was subjected to 
reduction by Bu3SnH. This reaction lead to the mixture of products: partial desulfation was 
observed. This means that sulfated oligosaccharides are not stabile under radical conditions 
and this synthetic strategy cannot be applied for the synthesis of sulfated glycosaminoglycans. 
These findings lead me to the investigation of synthetic strategy II. In this case, the 
reduction selectivity had to be tested. For this purpose, disaccharide 103 was subjected to 
reduction by Bu3SnH that lead selectively to formation of disaccharide 105. Levulinic ester 
protecting group of this oligosaccharide can be further removed and this disaccharide can be 
sulfated. The global deprotection of the resulting molecule will not lead to the formation of 
HCl in the reaction mixture and, therefore, sulfate groups should stay intact. 
 
Scheme 49. Investigation of synthetic strategies on dermatan sulfate disaccharide 
Strategy II, though, is not the best way for the synthesis of sulfated GAGs via AGA. In 
this strategy, sulfation has to take place after the reduction of the trichloroacetyl-protecting 
group. As long as this reaction requires very aggressive reagents (Bu3SnH), it is not advisable 
to perform this step in the automated synthesizer. Also, the photocleavable linker may not be 
stable in the presence of active radicals, generated during the reduction reaction. All these 
considerations lead to the fact that most of the synthetic steps in this strategy have to be 
performed in via solution-phase synthesis. 
Another potential strategy that can be explored is the usage 2,2,2-trichloroethyl sulfate 
for sulfation (Scheme 50).150 In this case, the sulfate group is “protected” and therefore is 
more stable during the synthetic manipulations. Although, the conditions for sulfation in an 





Scheme 50. Potential sulfation method 
4.5 Automated synthesis of dermatan sulfate oligosaccharides 
 
Scheme 51. AGA of dermatan sulfate oligosaccharides  
Building blocks 61a, 63 and 64 were utilized for the assembly of dermatan sulfate 
oligosaccharides via AGA (Scheme 51). TMSOTf solution (0.125 mM in DCM) was used as 
an activator and Et3N (20% in DMF) was used for Fmoc-protecting group removal. 
Galactosamine and iduronic acid building blocks were assembled alternately, and building 
block 64 was installed at the end of the chain. Because of low reactivity of the iduronic acid 
building blocks, two glycosylation cycles (each one using 5 eq. of building block) were used 
for one elongation reaction. As a result, di-, tetra- and hexasaccharide of dermatan sulfate 
were obtained. These oligosaccharides can be used for further investigation of deprotection 
strategies.  
4.6 Synthesis of disulfated iduronic acid 
Identification of glycosaminoglycan sequences that determine the affinity to specific 
chemokines is a critical step for strategies to interfere with chemokine-mediated leukocyte 
trafficking. Disulfated iduronic acid derivative 113 was synthesized as a part of a heparin-like 




The synthesis of compound 113 was performed from iduronic acid building block 64 
(Scheme 52).  Building block 64 was coupled to C-5 linker, followed by Fmoc-deprotection. 
Further basic hydrolysis led to compound 111, that was sulfated to give derivative 112, before 
global deprotection resulted in target compound 113. Non-sulfated iduronic acid derivative 
(114) was synthesized as a control compound.  
 
 
Scheme 52. Synthesis of iduronic acid derivatives 
Interestingly, the data from surface plasmon resonance (SPR) showed that CCL20 
binds to immobilized Di-S-IdoA in the micromolar range (KD=2.9×10−6M).xii In Cultured F2 
cells, that are known to express endogenous heparin sulfate, Di-S-IdoA also interfered with 
the CCL20–heparin sulfate interactions in a dose-dependent manner. These results suggest 
that Di-S-IdoA is an effective as a functional inhibitor of CCL20 chemokine activity. To 
study the specificity of Di-S-IdoA, the inhibitory effect of Di-S-IdoA on the bindings between 
the various proteins and endothelial cells was assayed. It is known that CCL21, IL-8, L-
selectin and complement component 5a (C5a) are involved both in the binding to 
heparin/heparan sulfate in vitro and in the asthma pathogenesis. The result showed that Di-S-
IdoA did not block the attachment of CCL21 to mouse endothelial F2 cells, whereas heparin 
efficiently blocked. Di-S-IdoA significantly blocked the binding of L-selectin to F2 cells. 
However, Di-S-IdoA showed even higher inhibitory effect than heparin in IL-8 binding. In 
                                                 




this experimental model, C5a did not show any bindings to F2 cells. Those results indicate Di-
S-IdoA has unique binding preferences distinct from heparin. 
  
4.7 Conclusions and perspectives 
Building blocks required for the synthesis of chondroitin and dermatan sulfate 
oligosaccharides were prepared. Synthetic strategies for dermatan sulfate oligosaccharides 
were investigated. It was found that sulfated dermatan sulfate oligosaccharides are not stable 
in radical conditions. Several dermatan sulfate oligosaccharides were assembled via 
automated solid-phase synthesis.  
The synthesis of disulfated iduronic acid that is a potential inhibitor of heparin sulfate-
CCL20 interaction was optimized. Non-sulfated iduronic acid analogue was synthesized.  In 
order to enable the access to fully-deprotected sulfated GAG oligosaccharides, new sulfation 
methods in automated synthesis have to be explored.  Further biological investigations of 
disulfated iduronic acid have to be performed.  
 
4.8 Experimental Part 
4.8.1  Synthesis of galactosamine building blocks 
Synthesis of 2-p-Methoxybenzylidenamino-D-glucopyranose 67 
 
D-Glucosamine hydrochloride (50.0 g, 0.232 mol) was dissolved in 240 mL of 1 M 
aqueous sodium hydroxide, forming a colorless solution. Anisaldehyde (28.5 mL, 0.235 mol) 
was added using a syringe while stirring the mixture intensely, and a turbid solution formed. 
After several minutes of agitation, a white precipitate was formed. The system was kept in an 




filtration and washed with water (2 × 200 mL) and a 1:1 mixture of methanol and ether (2 × 
200 mL).  
Analytical data for 67  1H NMR (400 MHz, DMSO-d6): δ = 8.09 (s, 1H), 7.67 (d, J = 
9.6 Hz, 2H), 6.96 (d, J = 9.6 Hz, 2H), 6.53 (d, J = 6.8 Hz, 2H), 4.93 (d, J = 5.3 Hz, 1H), 4.82 
(d, J = 5.6 Hz, 1H), 4.67 (t, J = 9.6 Hz, 1H), 4.55 (t, J = 9.6 Hz , 1H), 3.79 (s, 3H), 3.67-3.85 
(m, 1H), 3.35-3.50 (m, 2H), 3.17-3.23 (m, 1H), 3.09-3.16 (m, 1H), 2.77 (t, J = Hz, 1H). 
 
Synthesis of 2-p-Methoxybenzylidenamino-D-glucopyranose 68 
 
To the imide 67 (0.73 g) under cooling conditions (ice bath) acetic anhydrate (2.84 
mL), 5.2 mL of pyridine and 10 mg of DMAP were added. After 30 minutes, all the starting 
material was dissolved and the transparent solution formed. The mixture was stirred at 0˚C for 
90 minutes in total. Then, the mixture was allowed to warm up to room temperature and 
stirred overnight. Then, the reaction mixture was poured out in the 25 mL of ice. The white 
precipitate formed. The precipitate was washed by water (4x10 mL), then by Et2O (4x10 mL). 
The product was dried under vacuum. 
Analytical data for 68 1H NMR (400 MHz, cdcl3) δ 8.15 (s, 1H), 7.66 (d, J = 8.6 Hz, 
2H), 7.24 (d, J = 19.8 Hz, 1H), 6.92 (d, J = 8.7 Hz, 2H), 5.96 (t, J = 14.1 Hz, 1H), 5.43 (t, J = 
9.6 Hz, 1H), 5.14 (t, J = 9.8 Hz, 1H), 4.38 (dd, J = 12.4, 4.5 Hz, 1H), 4.13 (dd, J = 12.4, 1.9 
Hz, 1H), 3.97 (ddd, J = 10.0, 4.4, 1.9 Hz, 1H), 3.82 (d, J = 19.8 Hz, 3H), 3.51 – 3.39 (m, 1H), 
2.10 (s, 3H), 2.03 (d, J = 5.7 Hz, 5H), 1.88 (s, 3H). 
Synthesis of 2-p-Methoxybenzylidenamino-D-glucopyranose 69 
 
Compound 68 (9.7 g) was dissolved in refluxing acetone (50 mL). To the resulting 




was cooled to the room temperature, the precipitate was filtered and washed with acetone (25 
mL) and Et2O (2x50 mL) giving compound 69. 
Analytical data for 69 1H NMR (400 MHz, dmso) δ 8.65 (s, 3H), 5.86 (s, 1H), 5.32 (s, 
1H), 4.92 (s, 1H), 4.16 (s, 1H), 4.04 (s, 1H), 3.96 (s, 1H), 3.55 (s, 1H), 2.15 (s, 3H), 2.01 (t, J 
= 3.9 Hz, 3H), 1.98 (s, 3H), 1.96 (d, J = 0.6 Hz, 3H). 
Synthesis of 2-p-Methoxybenzylidenamino-D-glucopyranose 70 
 
Compound 69 was dispersed in 50 mL of DCM, the mixture was cooled down to 0ºC. 
Triethylamine (4.2 mL) and trichloroacetyl chloride (2.2 mL) was added to the mixture. The 
mixture was stirred for 2 hours. Then, the resulting solution was washed by water (3x25 mL), 
NaHCO3 (3x25 mL), dried over Na2SO4 and concentrated in vacuum. The resulting solid was 
washed by hexane, giving the product. 
Analytical data for 70 1H NMR (400 MHz, cdcl3) δ 6.96 (s, 1H), 5.79 (s, 1H), 5.31 (s, 
1H), 5.18 (s, 1H), 4.30 (dd, J = 5.4, 3.0 Hz, 1H), 4.27 (s, 1H), 4.16 (s, 1H), 3.87 (d, J = 2.1 
Hz, 1H), 2.12 (d, J = 0.8 Hz, 3H), 2.11 (s, 3H), 2.07 (d, J = 0.8 Hz, 3H), 2.05 (s, 3H). 
Synthesis of 2-p-Methoxybenzylidenamino-D-glucopyranose 71 
 
Compound 70 (15.4 g) was dissolved in DCM (Volume: 35 mL). To the resulting 
solution ethanethiol (2.31 mL) was added. The mixture was cooled to 0°C. Then BF3.OEt2 
(1.12 mL) was added dropwise. The mixture was stirred at this temperature for 30 minutes. 
Then it was allowed to warm up to r.t. The mixture was left stirring overnight. Then the 
mixture was diluted by DCM to the volume of 70 mL, washed by NaHCO3 (2x30mL), then 
by brine (2x30mL) and dried over Na2SO4.Volatile components were removed under the 
vacuum. Crude product was washed by hexane. Yield - 10.8 g (69%). 
Analytical data for 71  1H NMR (400 MHz, cdcl3) δ 6.75 (d, J = 9.2 Hz, 1H), 5.27 (q, J 




5.0 Hz, 1H), 4.15 (dd, J = 12.6, 2.4 Hz, 1H), 4.09 (d, J = 10.0 Hz, 1H), 3.73 (ddd, J = 10.0, 
5.0, 2.1 Hz, 1H), 2.81 – 2.66 (m, 2H), 2.11 – 2.07 (m, 3H), 2.05 (t, J = 2.6 Hz, 3H), 2.03 (d, J 
= 0.5 Hz, 3H), 1.60 (s, 1H), 1.32 – 1.23 (m, 3H). 
Synthesis of Ethyl 4,6-O-benzyliden-2-deoxy-2-N-trichloroacetamido-thio-β-D-
glucopyranoside 73 
 
Starting material was coevaporated with toluene, then was dried overnight under 
vacuum. Then, 1.3 g of it was dissolved in 17 mL of MeCN. Benzaldehyde dimethyl acetal 
(1.1 mL) was added. Then, 61 mg of TsOH was added. The mixture was stirred at r.t. for 24 
hours (control of the reaction by MS). The mixture was neutralized by triethylamine (0.1 mL). 
After it, volatile products were removed under vacuum. The crude product was dissolved in 
DCM (20 mL), washed with brine (2x10 mL), dried over Na2SO4. The volatiles were removed 
under the vacuum. Yield - 1.3g (81%) 
Analytical data for 73 1H NMR (400 MHz, cdcl3) δ 7.53 – 7.43 (m, 2H), 7.38 (dd, J = 
4.7, 2.4 Hz, 2H), 6.88 (d, J = 7.8 Hz, 1H), 5.56 (s, 1H), 4.96 (dd, J = 10.4, 2.2 Hz, 1H), 4.41 – 
4.31 (m, 1H), 4.24 (t, J = 8.1 Hz, 1H), 3.78 (dd, J = 17.9, 9.6 Hz, 1H), 3.73 – 3.65 (m, 1H), 




Thioglycoside (8.0 g, 21.7 mmol) and levulinic anhydride (Lev2O, 6.3 g, 29.6 mmol) 
were stirred in a mixture of dichloromethane (DCM) and pyridine (100 mL, 1:1) at room 
temperature and the progress was monitored by TLC. After completion (~ 18 h), the reaction 
mixture was diluted with DCM and washed with 0.1M HCl, saturated NaHCO3 and brine. 
The organic layer was then dried over MgSO4, concentrated and subjected to flash column 




Analytical data for 74 1H NMR (400 MHz, cdcl3) δ 7.48 (d, J = 2.3 Hz, 1H), 7.47 – 
7.42 (m, 2H), 7.37 – 7.28 (m, 3H), 5.51 (dd, J = 15.5, 5.7 Hz, 1H), 5.49 (s, 1H), 4.54 (d, J = 
10.4 Hz, 1H), 4.12 (dt, J = 7.1, 6.2 Hz, 1H), 4.00 (dd, J = 10.0, 4.7 Hz, 1H), 3.68 (t, J = 9.4 
Hz, 1H), 3.62 (t, J = 10.0 Hz, 1H), 3.57 – 3.50 (m, 1H), 2.76 – 2.68 (m, 2H), 2.64 – 2.49 (m, 
4H), 2.12 (s, 3H), 1.18 (t, J = 7.4 Hz, 3H). 
Synthesis of ethyl 6-O-benzyl-3-O-levulinoyl-2-deoxy-2-N-trichloroacetamido-thio-β-D-
glucopyranoside 75 
 
Thioglycoside 74 (8 g, 14.4 mmol), triethylsilane (9.21 mL, 57.7 mmol), and hot gun-
dried 4 Å molecular sieves (powdered, 2.5 g) were stirred in anhydrous DCM (25 mL) for 30 
minutes at room temperature and cooled down to 0ºC. Trifluoracetic acid (4.4 mL, 57.7 mL) 
was added dropwise and the reaction mixture was allowed to warm to room temperature. 
After complete conversion of the starting material the reaction mixture was neutralized with 
Et3N and diluted with DCM. Molecular sieves were filtered off and the filtrate was washed 
with H2O, saturated NaHCO3 and brine. The organic layer was then dried over MgSO4, 
concentrated and subjected to flash column chromatography (Silica, Hexane/EtOAc) to obtain 
thioglycoside 75 in 77% yield (6.2 g). The analytical data was in agreement with the literature 
data. 
Analytical data for 75 1H NMR (400 MHz, cdcl3) δ 7.00 – 6.95 (m, 1H), 5.22 (dd, J = 
10.4, 9.0 Hz, 1H), 4.61 – 4.52 (m, 3H), 4.04 (td, J = 10.3, 9.5 Hz, 1H), 3.81 – 3.74 (m, 3H), 
3.63 (dt, J = 9.5, 4.3 Hz, 1H), 3.31 (s, 1H), 2.79 – 2.64 (m, 4H), 2.62 – 2.52 (m, 1H), 2.52 – 
2.43 (m, 1H), 2.15 (s, 3H), 1.24 (t, J = 7.4 Hz, 3H). 






Thioglycoside 75 (5 g, 9.0 mmol) was stirred in a mixture of DCE and pyridine (30 
mL, 10:1) at -15°C. Tf2O (9.9 mL, 1M solution in DCM) was added dropwise to the reaction 
mixture and the progress was monitored by TLC. After complete conversion of the starting 
material, H2O (4 mL) was added and the mixture was stirred at ~80°C for 5h. The reaction 
mixture was then cooled down to room temperature, diluted with DCM, and washed with 
0.1M HCl, saturated NaHCO3 and brine. The organic layer was dried over MgSO4, 
concentrated and subjected to flash column chromatography to obtain title compound in 78% 
yield (3.9 g). 
Analytical data for 76  1H NMR (400 MHz, cdcl3) δ 7.32 (dt, J = 3.1, 1.5 Hz, 1H), 7.30 
(d, J = 1.9 Hz, 2H), 7.28 (dd, J = 2.8, 1.3 Hz, 1H), 7.27 – 7.24 (m, 1H), 6.89 (d, J = 8.1 Hz, 
1H), 5.46 (d, J = 2.7 Hz, 1H), 4.80 – 4.72 (m, 1H), 4.48 (q, J = 11.7 Hz, 2H), 4.10 – 4.03 (m, 
1H), 3.84 (ddd, J = 12.7, 10.1, 7.8 Hz, 2H), 3.58 (dd, J = 9.8, 6.0 Hz, 1H), 3.50 (dd, J = 9.8, 
6.5 Hz, 1H), 2.82 – 2.75 (m, 2H), 2.75 – 2.68 (m, 2H), 2.64 (ddd, J = 13.5, 8.3, 4.3 Hz, 1H), 
2.60 – 2.53 (m, 2H), 2.18 (s, 3H), 1.26 (dd, J = 9.3, 5.6 Hz, 3H). 
 
Synthesis of ethyl 6-O-benzyl-3-O-fluorenylmethoxycarbonyl-4-O-levulinoyl-2-deoxy-2-N-
trichloroacetamido-thio-β-D-galactopyranoside 77 
 
Thioglycoside 76 (3.9 g, 7.0 mmol) and FmocCl (3.6 g, 14.0 mmol) were stirred in 
DCM at 0oC and pyridine (2.5 mL) was added dropwise. After stirring for 4h at room 
temperature, the reaction mixture was concentrated and co-evaporated with toluene (twice) 
and subjected to S-5 flash column chromatography using Hexane/EtOAc to afford Fmoc-
protected thioglycoside 77 in 93% yield (5.1 g). 
Analytical data for 77  1H NMR (400 MHz, cdcl3) δ 7.73 (d, J = 7.6 Hz, 2H), 7.55 (dd, 
J = 10.2, 3.6 Hz, 2H), 7.42 – 7.34 (m, 2H), 7.34 – 7.31 (m, 1H), 7.31 – 7.29 (m, 3H), 7.29 – 
7.27 (m, 1H), 7.26 (dd, J = 4.2, 3.4 Hz, 1H), 6.78 (d, J = 8.7 Hz, 1H), 5.67 (d, J = 3.1 Hz, 
1H), 5.19 (dd, J = 10.8, 3.3 Hz, 1H), 4.88 – 4.81 (m, 1H), 4.48 (d, J = 5.0 Hz, 2H), 4.43 (dd, J 




3.87 (m, 1H), 3.61 (dt, J = 10.2, 5.1 Hz, 1H), 3.52 (dd, J = 9.6, 6.9 Hz, 1H), 2.82 – 2.58 (m, 
6H), 2.13 (d, J = 3.1 Hz, 3H), 1.27 (t, J = 7.4 Hz, 3H). 
 
Synthesis of di-O-butyl 6-O-benzyl-3-O-fluorenylmethoxycarbonyl-4-O-levulinoyl-2-deoxy-
2-N-trichloroacetamido-thio-β-D-galactopyranosylphosphate 62a 
 
Fmoc-protected thioglycoside (5.0 g, 6.5 mmol), dibutyl hydrogen phosphate (6.5 mL, 
32.7 mmol) and hot gun-dried 4 Å molecular sieves (3.0 g, powdered) were stirred in 
anhydrous DCM (15 mL) at room temperature. After for 30 minutes, N-iodosuccinimide 
(NIS, 1.76 g, 7.8 mmol) was added to the reaction mixture at once and cooled immediately to 
-5ºC. After 3 minutes, a catalytic amount of TfOH (0.1 mL) was added and stirred for 1h at 
the same temperature. After complete conversion of the starting material the reaction mixture 
was neutralized with pyridine and diluted with DCM. Molecular sieves were filtered off and 
the filtrate was washed with saturated Na2S2O3, NaHCO3 and brine. The organic phase was 
dried over MgSO4, concentrated and subjected for flash column chromatography (Silica; 
Hexane/EtOAc), to obtain phosphoglycoside 62a in 93% yield, 5.56 g. 
Analytical data for 62a  1H NMR (400 MHz, cdcl3) δ 7.74 (d, J = 7.5 Hz, 2H), 7.55 
(dd, J = 6.8, 5.9 Hz, 2H), 7.38 (dd, J = 10.7, 4.3 Hz, 2H), 7.34 – 7.31 (m, 1H), 7.31 – 7.29 (m, 
3H), 7.28 – 7.25 (m, 2H), 7.00 (d, J = 9.1 Hz, 1H), 5.81 (dt, J = 14.1, 7.0 Hz, 1H), 5.70 (d, J = 
3.0 Hz, 1H), 5.17 (dd, J = 11.3, 3.1 Hz, 1H), 4.63 (ddt, J = 12.1, 9.1, 3.1 Hz, 1H), 4.48 (s, 
2H), 4.46 – 4.42 (m, 1H), 4.42 – 4.37 (m, 1H), 4.27 (t, J = 4.8 Hz, 1H), 4.23 (dd, J = 12.1, 5.4 
Hz, 1H), 4.10 – 3.98 (m, 4H), 3.56 (ddd, J = 19.5, 9.7, 6.3 Hz, 2H), 2.88 – 2.59 (m, 5H), 2.14 
(s, 3H), 1.63 – 1.53 (m, 4H), 1.39 – 1.28 (m, 4H), 0.88 (td, J = 7.4, 1.7 Hz, 5H). 
4.8.2 Synthesis of iduronic acid building blocks 





Thioglycoside 92 (5.5 g, 9.37 mmol) was stirred in a mixture of dichloromethane 
(DCM) and methanol (50 mL, 4:1) at room temperature and 2,3-dichloro-5,6-dicyano-1,4-
benzoquinone (DDQ) (4.26 g, 18.75 mmol) was added at once and the progress was 
monitored by TLC. After completion (~ 8 h), the reaction mixture was diluted with DCM and 
washed with saturated NaHCO3, and brine. The organic layer was then dried over MgSO4, 
concentrated and subjected to flash column chromatography (Silica, Hexane/EtOAc) to obtain 
thioglycoside 93 in 88% yield (3.7 g). 
Analytical data for 93: 1H NMR (400 MHz, cdcl3) δ 8.15 – 8.08 (m, 2H), 7.75 – 7.61 
(m, 2H), 7.49 – 7.38 (m, 4H), 7.34 – 7.25 (m, 2H), 5.43 (d, J = 2.2 Hz, 1H), 5.35 – 5.28 (m, 
1H), 5.19 – 5.16 (m, 1H), 4.34 – 4.24 (m, 2H), 4.13 (dd, J = 14.2, 7.1 Hz, 1H), 4.04 – 3.99 
(m, 1H), 3.77 (s, 3H), 2.82 – 2.64 (m, 2H), 1.38 – 1.29 (m, 3H). 
 
 
Synthesis of methyl(ethyl 2-O-benzoyl-3-O-benzyl-4-O-fluorenylmethoxycarbonyl-1-thio-α-
L-idopyranosyl)urinate 94 
 
Thioglycoside 93 (3.7 g, 8.30 mmol) and FmocCl (4.29 g, 16.6 mmol) were stirred in 
DCM (50 mL) at 0ºC and pyridine (4 mL) was added dropwise. After stirring for 4h at room 
temperature, the reaction mixture was concentrated, co-evaporated with toluene (twice) and 
subjected to column chromatography (Silica, Hexane/EtOAc) to afford thioglycoside 94 in 
94% yield (5.2 g). 
Analytical data for 94: 1H NMR (400 MHz, cdcl3) δ 8.16 – 8.11 (m, 2H), 7.74 (dd, J = 
7.6, 0.7 Hz, 2H), 7.58 (dt, J = 7.7, 3.9 Hz, 1H), 7.46 – 7.43 (m, 2H), 7.43 – 7.38 (m, 3H), 7.38 
– 7.34 (m, 3H), 7.34 – 7.30 (m, 1H), 7.28 (dt, J = 3.9, 1.5 Hz, 2H), 7.26 (dd, J = 3.5, 0.7 Hz, 
1H), 7.22 – 7.17 (m, 1H), 5.59 (s, 1H), 5.39 (d, J = 2.0 Hz, 1H), 5.31 (dt, J = 2.5, 1.1 Hz, 1H), 
5.18 – 5.14 (m, 1H), 4.85 (d, J = 11.8 Hz, 1H), 4.75 – 4.70 (m, 1H), 4.36 – 4.28 (m, 1H), 4.22 
(dd, J = 10.3, 7.3 Hz, 1H), 4.09 (dd, J = 14.5, 6.9 Hz, 1H), 4.00 (td, J = 2.9, 1.1 Hz, 1H), 3.79 





Synthesis of methyl 2-O-benzoyl-3-O-benzyl-4-O-fluorenylmethoxycarbonyl-1-di-O-
butylphosphatidyl-α-L-idopyranosyluronate 64 
 
Thioglycoside 92 (4.32 g, 7.82 mmol), dibutyl hydrogen phosphate (7.03 mL, 35.5 
mmol), and hot gun-dried 4 Å molecular sieves (powdered, 3.2 g) were stirred in anhydrous 
DCM (15 mL) at room temperature. After 30 minutes, NIS (2.1 g, 9.36 mmol) was added to 
the reaction mixture at once and immediately cooled to -5ºC. After 3 minutes, a catalytic 
amount of TfOH (0.1 mL) was added to the reaction and stirred for 1h at the same 
temperature and monitored by TLC. After complete conversion of the starting material the 
reaction mixture was neutralized with pyridine and diluted with DCM. Molecular sieves were 
filtered off and the filtrate was washed with saturated Na2S2O3, NaHCO3, and brine. The 
organic phase was dried over MgSO4, concentrated and subjected for column chromatography 
(Silica; Hexane/Ethyl acetate) to obtain phosphoglycoside 64 in 92% yield (4.88 g). 
Analytical data for 64: 1H NMR (400 MHz, cdcl3) δ 8.15 – 8.09 (m, 2H), 7.74 (d, J = 
7.6 Hz, 2H), 7.56 (d, J = 7.5 Hz, 1H), 7.50 – 7.44 (m, 1H), 7.43 – 7.39 (m, 3H), 7.38 (s, 2H), 
7.36 – 7.30 (m, 4H), 7.28 (dd, J = 9.8, 2.3 Hz, 2H), 7.19 (td, J = 7.5, 1.0 Hz, 1H), 5.95 (d, J = 
6.8 Hz, 1H), 5.33 (d, J = 1.1 Hz, 1H), 5.25 – 5.19 (m, 1H), 5.16 (d, J = 1.9 Hz, 1H), 4.86 (d, J 
= 11.6 Hz, 1H), 4.77 (d, J = 11.6 Hz, 1H), 4.31 (dd, J = 10.3, 8.0 Hz, 1H), 4.22 – 4.14 (m, 
1H), 4.13 – 3.99 (m, 6H), 3.81 (d, J = 5.5 Hz, 3H), 1.68 – 1.56 (m, 4H), 1.44 – 1.29 (m, 4H), 
0.89 (tt, J = 4.8, 3.9 Hz, 6H). 
 
Synthesis of methyl 2-O-benzoyl-3-O-benzyl-4-O-(2-naphthyl)methyl-1-di-O-
butylphosphatidyl-α-L-idopyranosyluronate 63 
 
Thioglycoside 94 (5.30 g, 8.44 mmol), dibutyl hydrogen phosphate (8.38 mL, 42.3 
mmol), and hot gun-dried 4 Å molecular sieves (powdered, 3.5 g) were stirred in anhydrous 
DCM (15 mL) at room temperature. After 30 minutes, NIS (2.27 g, 10.1 mmol) was added to 




amount of TfOH (0.1 mL) was added to the reaction and stirred for 1h at the same 
temperature and monitored by TLC. After complete conversion of the starting material the 
reaction mixture was neutralized with pyridine and diluted with DCM. Molecular sieves were 
filtered off and the filtrate was washed with saturated Na2S2O3, NaHCO3, and brine. The 
organic phase was dried over MgSO4, concentrated and subjected for column chromatography 
(Silica; Hexane/Ethyl acetate) to obtain phosphoglycoside 63. Yield 85% (5.45 g). 
Analytical data for 63: 1H NMR (400 MHz, cdcl3) δ 7.98 – 7.93 (m, 2H), 7.79 – 7.74 
(m, 1H), 7.67 – 7.62 (m, 2H), 7.51 (s, 1H), 7.44 (dt, J = 5.6, 2.0 Hz, 2H), 7.42 – 7.39 (m, 1H), 
7.31 (dd, J = 3.5, 2.3 Hz, 1H), 7.29 – 7.23 (m, 2H), 7.22 – 7.14 (m, 3H), 5.94 (d, J = 6.8 Hz, 
1H), 5.28 (t, J = 2.8 Hz, 1H), 5.00 (d, J = 2.1 Hz, 1H), 4.79 (d, J = 11.7 Hz, 1H), 4.62 (d, J = 
11.8 Hz, 1H), 4.60 – 4.50 (m, 2H), 4.09 – 4.02 (m, 2H), 4.02 – 3.94 (m, 4H), 3.74 (s, 3H), 
1.63 – 1.51 (m, 4H), 1.40 – 1.23 (m, 4H), 0.88 (t, J = 5.8 Hz, 3H), 0.85 (t, J = 5.8 Hz, 3H). 
 
4.8.3 Synthetic strategies for dermatan sulfate 
Synthesis of compound 110 
 
Phosphate 62a (1.35 g, 1.8 mmol) and linker (0.66 g, 2.0 mmol) were dissolved in anhydrous 
DCM (15 mL) the solution was cooled to -10ºC before TMSOTf (0.36 mL, 2.0 mmol) was 
added to the reaction mixture. The reaction mixture was allowed to warm up to 0ºC. After 
stirring for 1 hour, the reaction mixture was neutralized with pyridine and diluted with DCM, 
washed with saturated NaHCO3, and brine. The organic phase was dried over MgSO4, 
concentrated and subjected for column chromatography (Silica; Hexane/Ethyl acetate) to 
obtain compound 100 (1.49 g, 82% yield). 
Analytical data for 100: 1H NMR (400 MHz, cdcl3) 7.73 (d, J = 7.4 Hz, 2H), 7.58 – 
7.53 (m, 4H), 7.41 – 7.24 (m, 12H), 7.03 (d, J = 8.9 Hz, 1H), 5.36 (d, J = 3.1 Hz, 1H), 5.12 (s, 




4.25 (d, J = 7.2 Hz, 1H), 4.18 – 4.10 (m, 1H), 3.93 – 3.87 (m, 1H), 3.70 – 3.62 (m, 1H), 3.55 
– 3.51 (m, 1H), 2.84 – 2.63 (m, 6H), 2.15 – 2.10 (m, 3H), 1.29 (t, J = 7.2 Hz, 3H).  




Compound 100 (1.49 g, 1.63 mmol) was dissolved in anhydrous DCM (20 mL) the solution 
was cooled to 0ºC before NEt3 (1.1 mL, 8.2 mmol) was added to the reaction mixture. The 
reaction mixture was warmed up to room temperature.  After stirring for 4 hours, the reaction 
mixture was washed with 1M HCl and brine. The organic phase was dried over MgSO4, 
concentrated and subjected for column chromatography (Silica; Hexane/Ethyl acetate) to give 
101. Yield 94% (1.05 g). 
 
Analytical data for 101: 1H NMR (400 MHz, cdcl3) 
1H NMR (400 MHz, cdcl3) 7.55 – 7.50 
(m, 2H), 7.43 – 7.26 (m, 8H), 7.06 (d, J = 9.1 Hz, 1H), 5.34 (d, J = 3.2 Hz, 1H), 5.10 (s, 2H), 
4.93 – 4.80 (m, 4H), 4.55 (d, J = 5.4 Hz, 2H), 4.41 – 4.38 (m, 1H), 4.30 – 4.24 (m, 2H), 4.16 
– 4.10 (m, 1H), 3.95 – 3.88 (m, 1H), 3.71 – 3.65 (m, 1H), 3.56 – 3.53 (m, 1H), 2.88 – 2.66 (m, 
6H), 2.17 – 2.10 (m, 3H), 1.33 – 1.26 (m, 3H). 
 






Compound 101 (1.05 g, 1.54 mmol) and building block 64 (1.10 mg, 1.62 mmol) were 
dissolved in anhydrous DCM (30 mL) the solution was cooled to -10ºC before TMSOTf (0.32 
mL) was added to the reaction mixture.  After stirring for 1 hour, the reaction mixture was 
neutralized with pyridine and diluted with DCM, washed with saturated NaHCO3, and brine. 
The organic phase was dried over MgSO4, concentrated and subjected for column 
chromatography (Silica; Hexane/Ethyl acetate) to obtain 102. Yield 72% (1.30 g). 
 
Analytical data for 102: 1H NMR (400 MHz, cdcl3) 8.12 – 8.06 (m, 2H), 7.78 – 7.70 (m, 2H), 
7.57 (d, J = 7.8 Hz, 1H), 7.52 – 7.43 (m, 3H), 7.41 – 7.22 (m, 19H), 7.17 – 7.10 (m, 2H), 5.97 
(d, J = 6.6 Hz, 1H), 5.38 (d, J = 3.0 Hz, 1H), 5.31 (d, J = 1.3 Hz, 1H), 5.28 – 5.22 (m, 1H), 
5.12 (d, J = 1.7 Hz, 1H), 5.02 (s, 2H), 4.96 – 4.84 (m, 5H), 4.75 (d, J = 11.0 Hz, 1H),   4.58 
(d, J = 5.6 Hz, 2H), 4.43 – 4.39 (m, 1H), 4.33 – 4.25 (m, 3H), 4.22 – 4.10 (m, 2H), 4.10 – 
3.97 (m, 2H), 3.97 – 3.90 (m, 1H), 3.83 (s, 3H), 3.73 – 3.68 (m, 1H), 3.55 – 3.52 (m, 1H), 
2.88 – 2.70 (m, 6H), 2.15 – 2.10 (m, 3H), 1.35 – 1.25 (m, 3H). 
Synthesis of compound 103 
 
 
To a solution of 102 (0.61 g, 0.52 mmol) in pyridine (15 mL) a 1M solution of hydrazine 
hydrate (10 µL) in pyridine/acetic acid (3:2) was added at 0ºC. The reaction was allowed to 
warm up to room temperature and stirred for 5 hours. Then, 5 mL of acetone was added, all 
the volatiles were removed under vacuum. The residue was diluted with DCM, washed with 
NaHCO3, brine, dried over MgSO4, concentrated and subjected for column chromatography 





Analytical data for 103: 1H NMR (400 MHz, cdcl3) 8.14 – 8.07 (m, 2H), 7.80 – 7.70 (m, 2H), 
7.55 – 7.41 (m, 4H), 7.39 – 7.19 (m, 21H), 5.94 (d, J = 6.0 Hz, 1H), 5.34 (d, J = 3.2 Hz, 1H), 
5.31 (d, J = 1.5 Hz, 1H), 5.27 – 5.21 (m, 1H), 5.15 (d, J = 2.0 Hz, 1H), 5.00 (s, 2H), 4.94 – 
4.80 (m, 5H), 4.73 (d, J = 11.4 Hz, 1H),   4.56 (d, J = 5.8 Hz, 2H), 4.42 – 4.37 (m, 1H), 4.35 – 
4.25 (m, 3H), 4.22 – 4.00 (m, 4H), 3.95 – 3.90 (m, 1H), 3.80 (s, 3H), 3.75 – 3.69 (m, 1H), 
3.58 – 3.54 (m, 1H), 2.88 – 2.78 (m, 2H), 1.35 – 1.27 (m, 3H). 
 
 
Synthesis of compound 104 
 
 
To a solution of 103 (25.0 mg, 0.023 mmol) in anhydrous pyridine (5.0 mL), was 
added SO3·pyridine (0.12 g). The reaction mixture was stirred at RT for 24 h, quenched by the 
addition of MeOH (1.5 mL) and triethylamine (0.2 mL), and concentrated. The residue was 
purified by a Sephadex LH-20 chromatography (MeOH–CH2Cl2, 1:1, vol/vol). The obtained 
product was converted into the Na salt by passing through a column of Dowex 50WX8 (Na+) 
in MeOH–H2O (9:1, vol/vol) to give 104 (22 mg, 82%).  
 
Analytical data for 104: 1H NMR (400 MHz, cdcl3) 8.13 – 8.07 (m, 2H), 7.82 – 7.71 (m, 2H), 
7.56 – 7.42 (m, 4H), 7.40 – 7.19 (m, 21H), 5.97 – 5.92 (dm, 1H), 5.37 (d, J = 3.1 Hz, 1H), 
5.30 (d, J = 1.3 Hz, 1H), 5.27 – 5.19 (m, 2H), 5.14 (d, J = 1.8 Hz, 1H), 5.03 (s, 2H), 4.945 – 
4.85 (m, 4H), 4.74 (d, J = 11.2 Hz, 1H),   4.54 (d, J = 5.6 Hz, 2H), 4.44 – 4.38 (m, 1H), 4.36 – 
4.22 (m, 4H), 4.19 – 4.05 (m, 3H), 3.97 – 3.91 (m, 1H), 3.82 (s, 3H), 3.77 – 3.72 (m, 1H), 






4.8.4 Automated synthesis of dermatan sulfate oligosaccharides 
4.8.4.1 General materials and methods 
All solvents used were HPLC-grade. The solvents used for the building block, 
activator, TMSOTf and capping solutions were taken from an anhydrous solvent system 
(jcmeyer-solvent systems). The building blocks were co-evaporated three times with 
chloroform and dried for 1 h on high vacuum before use. Activator, deprotection, acidic wash 
and building block solutions were freshly prepared and kept under argon during the 
automation run. All yields of products obtained by AGA were calculated on the basis of resin 
loading. Resin loading was determined by Method 2 (described in Chapter 2). 
4.8.4.2  Preparation of stock solutions 
 
• Building Block: 0.0625 mmol of building block was dissolved in 1 mL of DCM. 
• Fmoc deprotection solution: A solution of 20% Et3N in DMF (v/v) was prepared. 
• TMSOTf Solution: TMSOTf (0.45 mL) was added to DCM (40 mL). 
4.8.4.3 Modules for automated synthesis 
 
Module A: Resin Preparation for Synthesis (20 min) 
All automated syntheses were performed on 0.0125 mmol scale. Resin was placed in 
the reaction vessel and swollen in DCM for 20 min at room temperature prior to synthesis. 
During this time, all reagent lines needed for the synthesis were washed and primed. Before 
the first glycosylation, the resin was washed with the DMF, THF, and DCM (three times each 
with 2 mL for 25 s).  
Module B: Acidic Wash with TMSOTf Solution (20 min) 
The resin was swollen in 2 mL DCM and the temperature of the reaction vessel was 
adjusted to -20°C. Upon reaching the low temperature, TMSOTf solution (1 mL) was added 
drop wise to the reaction vessel. After bubbling for 3 min, the acidic solution was drained and 
the resin was washed with 2 mL DCM for 25 s. 
Action Cycles Solution Amount T (°C) 
Incubation 
time 
Cooling - - - -20 (15 min) 
Deliver 1 DCM 2 mL -20 - 




Wash 1 DCM 2 mL -20 25 s 
 
Module C: Phosphate Glycosylation (35 min) 
The building block solution (0.0625 mmol of BB in 1 mL of DCM per glycosylation) 
was delivered to the reaction vessel. After the set temperature was reached, the reaction was 
started by drop wise addition of the activator solution (1.0 mL, excess). The glycosylation 
conditions are building block dependent (we report the most common set of conditions). After 
completion of the reaction, the solution is drained and the resin was washed with DCM (three 
times, each with 2 mL for 25 s). The procedure is repeated twice. Afterwards the temperature 
of the reaction vessel is increased to 25 °C for the next module. 
 




Cooling - - - -20 - 














Wash 3 DCM 2 mL 0 5 s 
Heating - - - 25 - 
Wash 2 DCM 2 mL > 0 25 s 
 
Module D: Fmoc Deprotection (14 min) 
The resin was washed with DMF (three times with 2 mL for 25 s) and the temperature 
of the reaction vessel was adjusted to 25 °C. 2 mL of Fmoc deprotection solution was 
delivered into the reaction vessel. After 15 min, the reaction solution was drained and the 
resin washed with DMF (three times with 3 mL for 25 s) and DCM (five times each with 2 
mL for 25 s). The procedure is repeated three times. The temperature of the reaction vessel is 
decreased to -20 °C for the next module. 
Action Cycles Solution Amount T (°C) 
Incubation 
time 




Wash 3 DMF 2 mL 25 25 s 
Deliver 1 Fmoc depr. solution 2 mL 25 5 min 
Wash 1 DMF 2 mL   
Cooling - - - -20 - 
Wash 3 DMF 2 mL < 25 25 s 
Wash 5 DCM 2 mL < 25 25 s 
 
4.8.4.4  Post-synthesizer manipulations 
Cleavage from Solid Support  
After automated synthesis, the oligosaccharides were cleaved from the solid support 
using a continuous-flow photoreactor as described previously.91  
Purification 
Solvent is evaporated in vacuo and the crude products were analyzed and purified 
using analytical and preparative HPLC (Agilent 1200 Series spectrometer). 




 Module Conditions 
 A: Resin Preparation for Synthesis   
 
B: Acidic Wash with TMSOTf Solution  
C: Phosphate Glycosylation 2x62a 5 eq (-20°C for 5 min, 0°C for 
20 min) 
D: Fmoc Deprotection  
 
B: Acidic Wash with TMSOTf Solution  






Cleavage from the solid support as described in Post-synthesizer manipulation 
followed by purification using preparative HPLC afforded compound 106 (28.3 mg, 66%). 
Analytical data for 106: 1H NMR (400 MHz, Chloroform-d) δ 8.13 (d, J = 8.6 Hz, 
1H), 8.03  (m, J = 2H), 7.91–7.87 (m, 1H), 7.85 (d, J = 8.3 Hz, 1H), 7.63 – 7.49 (m, 4H), 7.45 
– 7.41 (m, 3H), 7.39 – 7.27 (m, 15H), 6.97 (d, J = 7.2 Hz, 1H), 5.52 (d, J = 3.2 Hz, 1H), 5.27 
(d, J = 2.5 Hz, 1H), 5.20 (s, 1H), 5.18 – 5.14 (m, 1H), 5.09 (d, J = 4.6 Hz, 1H), 5.02 (s, 2H), 
4.99 (d, J = 2.0 Hz, 1H), 4.90 (d, J = 8.3 Hz, 1H), 4.79 – 4.64 (m, 2H), 4.54 (d, J = 10.8 Hz, 
1H), 4.48 (d, J = 2.1 Hz, 2H), 3.93 – 3.87 (m, 1H), 3.82 (d, J = 10.8 Hz, 2H), 3.78 (s, 3H), 
3.72 – 3.61 (m, 1H), 3.58 – 3.54 (m, 1H), 3.53 – 3.41 (m, 2H), 3.18 – 3.14 (m, 2H), 2.57 – 
2.54 (m, 1H), 2.46 – 2.42 (m, 1H), 2.32 – 2.29 (m, 1H), 2.19 – 2.09 (m, 1H), 2.08 (s, 3H),  
1.65 – 1.56 (m, 2H), 1.56 – 1.45 (m, 2H), 1.43 – 1.32 (m, 2H); 13C NMR (101 MHz, 
Chloroform-d) δ 205.3, 172.7, 169.9, 169.8, 168.7, 164.9, 163.2, 157.2, 138.2, 137.4, 136.3, 
134.0, 133.6, 133.3, 131.1, 129.8, 129.7, 129.0, 128.8, 128.5, 128.4, 128.4, 128.1, 127.9, 
127.8, 127.7,127.6, 126.8, 126.4, 125.6, 123.8, 100.8, 99.2, 75.3, 73.8, 72.2, 72.0, 71.8, 69.8, 
69.3, 68.2, 67.9, 67.2, 66.3, 66.1, 56.2, 52.9, 42.7, 36.4, 31.6, 28.5, 27.4, 27.0, 23.1, 20.3.  MS 
(ESI) m/z calcd for C65H69Cl3N2O17 [M+Na]
+ 1289.6. Found 1289.3. 
Synthesis of tetrasaccharide 107 
 
 Module Conditions 
 A: Resin Preparation for Synthesis   
 




C: Phosphate Glycosylation 2x62a 5 eq (-20° for 5 min, 0° for 20 
min) 
D: Fmoc Deprotection  
 B: Acidic Wash with TMSOTf Solution  
 C: Phosphate Glycosylation 2x63 5 eq (-20° for 5 min, 0° for 20 
min) 
 D: Fmoc Deprotection  
 
B: Acidic Wash with TMSOTf Solution  
C: Phosphate Glycosylation 2x62a 5 eq (-20° for 5 min, 0° for 20 
min) 
D: Fmoc Deprotection  
 B: Acidic Wash with TMSOTf Solution  
 C: Phosphate Glycosylation 2x64 5 eq (-20° for 5 min, 0° for 20 
min) 
 
Cleavage from the solid support as described in Post-synthesizer manipulation 
followed by purification using preparative HPLC afforded compound 107 (36 mg, 42%). 
Analytical data for 107: 1H NMR (400 MHz, CDCl3) δ: 8.20–7.85 (m, 4H), 7.66 – 
7.56 (m, 1H,), 7.54 – 7.20 (m, 35H), 7.06 (d, J = 7.4 Hz, 1H), 6.86 (d, J = 7.8 Hz, 1H), 5.52 
(d, J = 3.0 Hz, 1H), 5.34 (d, J = 3.0 Hz, 1H), 5.23 – 5.17 (m, 2H), 5.13 – 5.04 (m, 4H), 5.01 
(s, 2H), 4.96–4.79 (m, 4H), 4.79 – 4.61 (m, 4H), 4.55 – 4.40 (m, 3H), 4.36 (q, J = 11.8 Hz, 
3H), 4.24 (dd, J = 10.2, 3.5 Hz, 1H), 4.06 (dd, J = 9.6, 5.2 Hz, 2H), 3.91 (dd, J = 9.2, 5.9 Hz, 
1H), 3.83 – 3.74 (m, 2H), 3.71 (s, 3H), 3.73 – 3.61 (m, 8H), 3.56 (dd, J = 10.0, 6.0 Hz, 1H), 
3.48 (dd, J = 10.0, 6.2 Hz, 2H), 3.18 (m, 3H), 2.38–2.16 (m, 2H), 2.12 – 2.04 (m, 2H), 2.00 (s, 
3H), 1.98 (s, 3H), 1.85 - 1.72 (m, 3H), 1.58 – 1.52 (m, 3H), 1.50 – 1.42 (m, 2H), 1.33 – 1.26 
(m, 2H). 13C NMR (101 MHz, CDCl3) δ 206.2, 206.0, 171.9, 171.8, 169.7, 169.6, 168.7, 
165.0, 164.6, 162.1, 162.0, 156.3, 137.9, 137.9, 137.7, 137.6, 136.5, 134.0, 133.5, 133.3, 
133.1, 129.9, 129.8, 129.7, 129.6, 129.0, 128.5, 128.4, 128.4, 128.3, 128.3, 128.2, 128.2, 
128.0, 127.8, 127.8, 127.8, 127.7, 127.7, 127.7, 127.5, 126.6, 126.2, 125.4, 123.7,  101.0, 
101.0, 100.7, 99.2, 92.2, 92.2, 77.2, 76.3, 75.2, 74.1, 73.8, 73.5, 73.4, 72.8, 72.7, 72.5, 72.3, 
69.8, 69.4, 68.9, 68.3, 68.2, 67.8, 66.9, 66.8, 66.7, 66.5, 66.4, 56.1, 55.3, 54.3, 52.4, 52.3, 
40.8, 37.7, 37.5, 31.7, 29.6, 29.5, 28.8, 27.6, 27.2, 23.2, 20.5. m/z (MALDI-TOF) m/z calcd 
for C106H111Cl6N3O31 [M+Na]





Synthesis of hexasaccharide 108 
 
 Module Conditions 
 A: Resin Preparation for Synthesis   
 
B: Acidic Wash with TMSOTf Solution  
C: Phosphate Glycosylation 2x62a 5 eq (-20° for 5 min, 0° for 20 
min) 
D: Fmoc Deprotection  
 B: Acidic Wash with TMSOTf Solution  
 C: Phosphate Glycosylation 2x63 5 eq (-20° for 5 min, 0° for 20 
min) 
 D: Fmoc Deprotection  
 
B: Acidic Wash with TMSOTf Solution  
C: Phosphate Glycosylation 2x62a 5 eq (-20° for 5 min, 0° for 20 
min) 
D: Fmoc Deprotection  
 B: Acidic Wash with TMSOTf Solution  
 C: Phosphate Glycosylation 2x63 5 eq (-20° for 5 min, 0° for 20 
min) 




 B: Acidic Wash with TMSOTf Solution  
 C: Phosphate Glycosylation 2x62a 5 eq (-20° for 5 min, 0° for 20 
min) 
 D: Fmoc Deprotection  
 B: Acidic Wash with TMSOTf Solution  
 C: Phosphate Glycosylation 2xBB 5 eq (-20° for 5 min, 0° for 20 
min) 
 
Cleavage from the solid support as described in Post-synthesizer manipulation 
followed by purification using preparative HPLC afforded compound 108 (44 mg, 28%). 
Analytical data for 108: 1H NMR (400 MHz, CDCl3) δ: 8.19–7.81 (m, 4H), 7.63 – 
7.56 (m, 1H,), 7.54 – 7.22 (m, 50H), 7.12 (d, J = 7.4 Hz, 1H), 6.91 (d, J = 7.6 Hz, 1H), 5.50 
(d, J = 3.0 Hz, 1H), 5.34 (d, J = 3.0 Hz, 1H), 5.27 (d, J = 3.0 Hz, 1H), 5.25 – 5.16 (m, 3H), 
5.12 – 5.02 (m, 6H), 5.00 (s, 2H), 4.98–4.80 (m, 7H), 4.80 – 4.63 (m, 5H), 4.58 – 4.32 (m, 
10H), 4.26 – 4.08 (m, 4H), 3.91 – 3.61 (m, 16H), 3.58 – 3.42 (m, 6H), 3.22 – 3.16 (m, 5H), 
2.44–2.14 (m, 6H), 2.13 – 2.00 (m, 6H), 1.99 – 1.96 (m, 9H), 1.63 – 1.48 (m, 2H), 1.54 – 1.44 
(m, 2H), 1.38 – 1.23 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 207.3, 206.4, 171.9, 171.8, 
171.7, 170.2 169.6, 169.4, 168.8, 166.2, 165.4, 165.2, 163.8, 162.5, 162.3, 162.2, 158.9, 
137.9, 137.8, 137.7, 137.6, 137.4, 137.2, 134.9, 134.6, 133.8, 133.6, 133.2, 130.9, 129.9, 
129.8, 129.2, 129.1, 128.9, 128.0, 127.9, 127.6, 127.5, 127.3, 127.2, 127.1, 126.9, 126.8, 
126.5, 126.4, 125.2, 124.6,  101.9, 101.6, 101.4, 98.3, 94.4, 94.2, 78.5, 78.3, 78.2, 75.5, 74.4, 
73.9, 73.6, 73.5, 72.7, 72.6, 72.4, 70.6, 70.4, 69.9, 69.5, 69.3, 68.8, 68.6, 67.8, 66.6, 66.5, 
66.3, 66.2, 66.0, 65.8, 64.2, 56.6, 55.8, 55.3, 54.8, 54.3, 42.6, 36.9, 35.9, 34.8, 34.2, 29.8, 
28.9, 28.6, 28.5, 26.9, 22.4, 21.8. m/z (MALDI-TOF) m/z calcd for C147H153Cl9N4O45 





4.8.5  Synthesis of disulfated iduronic acid.   
Synthesis of Methyl N-benzyl-(benzyloxycarbonyl)-5-aminopentyl 2-O-benzoyl-3-O-benzyl-
4- fluorenylmethyloxycarbonyl-α-L-idopyranosyl urinate 109 
 
To a solution of 64 (110 mg, 0.16 mmol) and (HO)(CH2)5NBnCBz (269 mg, 0.82 
mmol) in anhydrous DCM (20 mL) molecular sieves (4 Å, powder) were added. The mixture 
was stirred for 10 minutes before NIS (56 mg, 0.25 mmol) was added. After stirring for 20 
minutes the reaction mixture was cooled down to -15°C before TfOH (0.015 mL, 0.16 mmol) 
was added dropwise to the reaction mixture. The reaction mixture was stirred for 20 minutes 
and allowed to warm to room temperature. The reaction was successively quenched by 
saturated NaHCO3 solution (15 mL) and saturated Na2S2O3 solution. The organic layer was 
washed with brine (3x 15 mL), dried over Na2SO4 and concentrated in vacuum. The crude 
product was purified by column chromatography (silica gel, hexane – EtOAc, 1:5 to 1:1), 
giving 109 (120 mg, 0.128 mmol, 78%) as white crystallizing syrup Rf = 0.82 (hexane – 
EtOAc, 1:1).  
Analytical data for 109: 1H NMR (400 MHz, CDCl3) δ 8.12 (d, J = 7.1 Hz, 2H), 7.74 
(d, J = 7.6 Hz, 1H), 7.72 – 7.68 (m, 1H), 7.59 (d, J = 7.5 Hz, 1H), 7.49 – 7.11 (m, 23H), 5.23 
– 4.98 (m, 5H), 4.83 (d, J = 11.6 Hz, 1H),  4.77 – 4.67 (m, 1H), 4.47 (d, J = 7.3 Hz, 2H), 4.34 
(dd, J = 10.3, 8.0 Hz, 1H), 4.22 (dd, J = 10.3, 7.3 Hz, 1H), 4.04 – 3.97 (m, 2H), 3.82 – 3.68 
(m, 1H), 3.79 (s, 3H), 3.49 (d, J = 20.1 Hz, 1H), 3.18 (d, J = 27.2 Hz, 2H), 1.65 – 1.45 (m, 
4H), 1.35 – 1.20 (m, 2H). MS (ESI) m/z calcd for C56H55NO12 [M+Na]+ 956.4. Found 956.2 
 
Synthesis of Methyl N-benzyl-(benzyloxycarbonyl)-5-aminopentyl 2-O-benzoyl-3-O-benzyl-





To a solution of 109 (68 mg, 0.073 mmol) in DCM (50 mL), Et3N (1 mL, 7.16 mmol) 
was added dropwise. The reaction mixture was stirred for 5 hours. Then, all the volatiles were 
evaporated in vacuum, the residue was dissolved in DCM (20 mL), washed with brine (3x 10 
mL), dried over Na2SO4 and concentrated in vacuum. The crude product was purified by 
column chromatography (silica gel, hexane – EtOAc, 1:3 to 1:1), giving S9 (45 mg, 0.063 
mmol, 87%) as yellow syrup. Rf = 0.61 (hexane – EtOAc, 1:1).  
Analytical data for 110: 1H NMR (400 MHz, CDCl3) δ 7.99 (dd, J = 8.4, 1.2 Hz, 2H), 
7.59 (t, J = 7.4 Hz, 1H), 7.47 – 7.42 (m, 2H), 7.39 – 7.13 (m, 15H), 5.24 – 5.13 (m, 3H), 5.11 
– 5.05 (m, 1H), 4.89 (s, 1H), 4.82 (d, J = 11.1 Hz, 1H), 4.63 (d, J = 11.7 Hz, 1H), 4.47 (d, J = 
9.8 Hz, 2H), 4.10 (d, J = 10.2 Hz, 1H), 3.82 (s, 3H), 3.77 (s, 1H), 3.46 (d, J = 14.7 Hz, 2H), 
3.26 – 3.11 (m, 2H), 1.67 – 1.43 (m, 4H), 1.37 – 1.22 (m, 2H). MS (ESI) m/z calcd for 
C41H45NO10 [M+Na]
+ 734.3. Found 734.0 
Synthesis of N-Benzyl-(benzyloxycarbonyl)-5-aminopentyl 3-O-benzyl-α-L-
idopyranosyluronate 111 
 
To a solution of 110 (45 mg, 0.063 mmol) MeOH/THF (15 mL, 1:4), LiOH (0.4 mL, 
0.4 mmol, 1 M in solvent) was added. The reaction was stirred for 30 minutes. Afterwards all 
volatiles were evaporated in vacuum yielding crude 111 (30 mg, 0.050 mmol, 78%) as a white 
powder. The compound was used in the next step without further purification.  
MS (ESI) m/z calcd for C33H39NO9 [M+Na]
+ 616.3. Found 616.0 
Synthesis of N,N-Dimethyl-5-aminopentyl α-L-idopyranosyluronate 114  
 
Argon was bubbled through a solution of 111 (20 mg, 0.033 mmol) in methanol (10 
mL) for 10 minutes. To this solution Pd/C (20 mg, 0.019 mmol, 10wt%) was added. Argon 
was bubbled through this slurry for 10 minutes, before hydrogen was bubbled through the 




atmosphere. The suspension was filtered over Celite®, concentrated in vacuum and purified 
by size-exclusion column chromatography (Sephadex® LH-20, water) giving compound 114 
(4.4 mg, 0.011 mmol, 33%) as slightly yellow solid after lyophilization.  
Analytical data for 114: 1H NMR (400 MHz, CD3OD) δ 4.73 – 4.64 (m, 1H), 4.32 – 
4.23 (m, 1H), 3.92 – 3.81 (m, 1H), 3.75 – 3.67 (m, 1H), 3.67 – 3.61 (m, 1H), 3.61 – 3.46 (m, 
2H), 3.36 – 3.34 (m, 1H), 3.28 – 3.20 (m, 1H), 2.72 (s, 6H), 1.77 – 1.59 (m, 4H), 1.55 – 1.40 
(m, 2H). 13C NMR (CD3OD) 175.72, 100.51, 72.93, 72.12, 71.16, 70.88, 67.97, 57.90, 42.43, 
28.31, 24.21, 22.68. MS (ESI) m/z calcd for C13H25NO7 [M+H]
+ 308.2. Found 308.2 
Synthesis of compound 112 
 
To a solution of 111 (60.0 mg) in anhydrous pyridine (4.0 mL), was added 
SO3·pyridine (0.16 g). The reaction mixture was stirred at RT for 24 h, quenched by the 
addition of MeOH (0.5 mL) and triethylamine (0.1 mL), and concentrated. The residue was 
purified by a Sephadex LH-20 chromatography (MeOH–CH2Cl2, 1:1, vol/vol). The obtained 
product was converted into the Na salt by passing through a column of Dowex 50WX8 (Na+) 
in MeOH–H2O (9:1, vol/vol) to give 112 (64 mg, 85%).  
Analytical data for 112: 1H NMR (CD3OD) δ 7.38–7.07 (m, 15H), 5.20–5.05 (m, 3H), 
4.87–4.64 (m, 4H), 4.50–4.35 (m, 4H), 3.61 (br, 1H), 3.44 (br, 1H), 3.13 (br, 4H), 1.08–1.66 
(m, 6H). MS (ESI) m/z calcd. [M3−+2H]− 616.3, found 616.3. 
Synthesis of compound 113 
 
 
A solution of 112 (39.0 mg) in MeOH–H2O (2:1, vol/vol, 3 mL) was bubbled by Ar 
for 10 min. To the solution, was added 10% Pd/C (16 mg). The mixture was bubbled by Ar 
for 10 min then by H2 for 15 min, and stirred at RT for 24 h. The suspension was filtered and 




 Analytical data for 113: 1H NMR (D2O) δ 4.98 (br s, 1H), 4.45 (br, 2H), 4.37 (br s, 
1H), 4.07 (br s, 1H), 3.61 (br, 1H), 3.53 (br, 1H), 2.87 (br, 2H), 1.55 (br, 4H), 1.33 (br, 2H). 
13C NMR (D2O) δ 174.8, 98.3, 74.6, 73.5, 68.2, 66.4, 66.3, 39.4, 27.8, 26.3, 22.2. [M3−+2H]− 
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